Towards personalized medicine in kidney transplantation: Unravelling the results of a large multi-centre clinical study by Blázquez Navarro, Arturo
 
Towards personalized medicine in kidney 
transplantation: Unravelling the results of a large 
multi-centre clinical study 
 
DISSERTATION 
zur Erlangung des akademischen Grades 
 
Doctor rerum naturalium 
(Dr. rer. nat.) 
 
eingereicht an der 
Lebenswissenschaftlichen Fakultät der Humboldt-Universität zu Berlin 
 
von 





der Humboldt-Universität zu Berlin 
 
Prof. Dr.-Ing. Dr. Sabine Kunst 
 
Dekan der Lebenswissenschaftlichen Fakultät 
der Humboldt-Universität zu Berlin 
 




1. Prof. Dr. Dr. h. c. Edda Klipp 
2. Prof. Dr. Hans-Dieter Volk 
3. Prof. Dr. Klemens Budde 
 






1. Table of contents 
1. Table of contents ............................................................................................................................ 3 
2. Summary ......................................................................................................................................... 9 
3. Zusammenfassung ........................................................................................................................ 10 
4. Acknowledgements / Danksagung / Agradecimientos ................................................................. 11 
5. Introduction .................................................................................................................................. 13 
5.1 Personalized medicine: Promise and challenges ................................................................. 13 
5.2 Personalized approaches to renal transplantation ............................................................. 13 
5.3 Basic concepts of data management .................................................................................. 16 
5.3.1 The stages of data management ..................................................................................... 16 
5.3.2 Defining and achieving quality data ................................................................................ 17 
5.3.3 Data pre-processing for data analysis ............................................................................. 18 
5.4 Data analysis methods for systems medicine ..................................................................... 18 
5.4.1 Statistical analysis of clinical studies ............................................................................... 19 
5.4.2 Machine learning approaches for disease biomarker discovery ..................................... 21 
5.4.3 Mathematical modelling as a tool for mechanistic understanding ................................ 23 
5.5 Scope and structure of this dissertation ............................................................................. 27 
6. Data management in the e:KID study ........................................................................................... 29 
6.1 Background: e:KID, a systems medicine study for kidney transplantation ......................... 29 
6.1.1 Design of the e:KID study: Patient cohort and selected markers ................................... 29 
6.1.2 Organizational aspects of the consortium ...................................................................... 30 
6.2 Database design and integration for the e:KID study ......................................................... 31 
6.2.1 Structure of the original Harmony database .................................................................. 32 
6.2.2 Design of the e:KID database .......................................................................................... 34 
6.2.3 Data integration in the e:KID study ................................................................................. 35 
6.3 Data cleaning in the e:KID study ......................................................................................... 36 
6.3.1 Improving conformance of the database ........................................................................ 36 
6.3.2 Management of missing data ......................................................................................... 37 
6.3.3 Evaluating the plausibility of data with biostatistical methods ...................................... 39 
6.4 Data pre-processing in the e:KID study ............................................................................... 42 
6.4.1 Generation of new variables for data analysis ................................................................ 42 
6.4.2 Statistical transformation and normalization of variables .............................................. 43 
6.4.3 Dealing with strong centre effects: The case of GFR ...................................................... 43 
6.4.4 Working with variables with missing values ................................................................... 44 
6.5 Lessons learned from data management at the e:KID study .............................................. 45 
7. BKV, CMV, and EBV interactions and their effect on graft function one year post-renal 
transplantation: Results from a large multi-centre study .................................................................... 47 
7.1 Main text ............................................................................................................................. 48 
7.2 Supplementary materials .................................................................................................... 57 
7.2.1 Figure S1 ......................................................................................................................... 57 
7.2.2 Figure S2 ......................................................................................................................... 57 
7.2.3 Figure S3 ......................................................................................................................... 58 
8. Sex-associated differences in cytomegalovirus prevention: Prophylactic strategy is associated 
with a strong kidney function impairment in female renal transplant patients ................................... 59 
8.1 Main text ............................................................................................................................. 60 
8.2 Supplementary materials .................................................................................................... 88 
8.2.1 Table S1 ........................................................................................................................... 88 
8.2.2 Table S2 ........................................................................................................................... 88 
8.2.3 Table S3 ........................................................................................................................... 93 
8.2.4 Figure S4 ....................................................................................................................... 100 
8.2.5 Figure S5 ....................................................................................................................... 100 
9. A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-
accuracy pre-transplant risk assessment of acute cellular rejection .................................................. 103 
9.1 Main text ........................................................................................................................... 104 
9.2 Supplementary materials .................................................................................................. 114 
9.2.1 Figure S1 ....................................................................................................................... 114 
9.2.2 Figure S2 ....................................................................................................................... 114 
9.2.3 Figure S3 ....................................................................................................................... 114 
9.2.4 Table S1 ......................................................................................................................... 115 
9.2.5 Table S2 ......................................................................................................................... 115 
9.2.6 Table S3 ......................................................................................................................... 116 
9.2.7 Table S4 ......................................................................................................................... 117 
9.2.8 Table S5 ......................................................................................................................... 119 
10. Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics 
modelling approach ............................................................................................................................ 121 
10.1 Main text ........................................................................................................................... 122 
10.2 Supplementary materials .................................................................................................. 142 
10.2.1 Figure S1 ................................................................................................................... 142 
10.2.2 Figure S2 ................................................................................................................... 142 
10.2.3 Figure S3 ................................................................................................................... 146 
10.2.4 Table S1 .................................................................................................................... 149 
10.2.5 Table S2 .................................................................................................................... 150 
10.2.6 Table S3 .................................................................................................................... 152 
10.2.7 Table S4 .................................................................................................................... 153 
11. Summary of the manuscripts in the context of personalized medicine ................................. 155 
11.1 Studying the prevalence, risk factors and consequences of combined viral reactivations: A 
thorough exploratory statistical analysis ........................................................................................ 155 
11.2 Improving prevention of cytomegalovirus complications: A hypothesis-based assessment of 
sex-treatment interactions on transplantation outcomes by means of multivariate statistics ..... 156 
11.3 Predicting acute cellular rejection employing pre-transplant antibody profiles: Identification 
of markers for risk assessment using a machine learning tool ....................................................... 157 
11.4 Inferring mechanisms of T cell response against BK virus: A mathematical model of viral 
dynamics ......................................................................................................................................... 158 
12. Outlook: Personalized medicine and big data ........................................................................ 161 
13. References .............................................................................................................................. 163 



















A Jeff, por más siglos de doctorado juntos /  





In this doctoral thesis, I present my work on personalized medicine for renal transplantation, 
with a focus on opportunistic viral infections. This work comprises insights on the 
demographic, clinical and therapeutic factors leading to a positive transplantation outcome, a 
risk assessment tool for cellular rejection, a common clinical complication, and a model of the 
antiviral immune response.  
In spite of the chirurgical and pharmacological developments in the last decades, long-term 
graft survival rates in kidney transplantation are still poor. Personalization of treatment is 
expected to lead to a drastic improvement in long-term outcomes. With this goal, a cohort of 
587 patients was characterized for a wide range of markers during the first post-
transplantation year to assess their long-term prognosis. Here, I describe along four 
manuscripts and two chapters the processes of management and analysis of the cohort data, 
and their use for hypothesis generation and hypothesis testing. 
In detail, we have studied the clinical evolution of patients after renal transplantation with 
emphasis on two most relevant complications: viral reactivations – particularly those of BK 
virus and cytomegalovirus – and acute rejection. We have analysed in depth these phenomena 
by (i) exhaustively analysing the associations between different viral reactivations and their 
influence on transplantation outcome, (ii) evaluating the effects of antiviral treatment 
strategies on viral reactivation and other transplantation outcomes with emphasis on sex-
associated differences, (iii) developing a tool for the pre-transplantation risk assessment of 
acute cellular rejection, and (iv) creating a mathematical model for the personalized 
characterization of the immune response against the BK virus under immunosuppression. 
Diverse analysis methods were applied to achieve these goals, both in exploratory and 
hypothesis-guided approaches, ranging from uni-, bi- and multivariate biostatistics to ordinary 
differential equation modelling and machine learning methods. Critical to the success of these 
analyses was a careful management of the large number of heterogeneous data collected in 
the study, especially in data cleaning, database integration, management of missing data and 
data pre-processing. 
Taken together, these four studies have the potential of improving patient care, optimizing 
monitoring of viral reactivations, stratifying antiviral prevention strategies, tailoring 
immunosuppression and monitoring to the individual risk of acute rejection, and contributing 
to personalization of immunotherapy. They demonstrate how the large volume of data 
obtained within a clinical study can be employed to further the development of personalized 
medicine, employing effective data management, analysis and interpretation strategies. We 
expect these results to eventually inform clinical practice, thereby improving long-term 





Die vorliegende Dissertation hat die Entwicklung personalisierter medizinischer Lösungen bei 
Nierentransplantationen, mit Schwerpunkt auf opportunistischen Virusinfektionen, zum 
Gegenstand. Sie umfasst (i) Einblicke in die demografischen, klinischen und therapeutischen 
Faktoren, die zu einem positiven Transplantationsergebnis führen, (ii) ein Tool zur 
Risikobewertung der zellulären Abstoßung, einer häufigen klinischen Komplikation, und (iii) 
ein Modell der antiviralen Immunantwort. 
Trotz der chirurgischen und pharmakologischen Fortschritte der letzten Dekaden ist das 
Langzeitüberleben von Nierentransplantaten noch unzureichend. Es wird erwartet, dass eine 
Personalisierung der Behandlung zu einer erheblichen Verbesserung der Langzeitergebnisse 
führt. Vor diesem Hintergrund wurde eine Kohorte von 587 Patienten im ersten Jahr nach der 
Transplantation untersucht um ein breites Spektrum von Markern für die langfristige 
Prognose etabliert.  In dieser Dissertation werden in vier Manuskripten und zwei Kapiteln die 
Prozesse des Managements und der Analyse der Daten der Kohorte, sowie deren Verwendung 
für die Formulierung und Überprüfung von Hypothesen beschrieben.  
Der klinische Verlauf von Patienten nach Nierentransplantation wurde untersucht. Zwei der 
wichtigsten Komplikationen standen hierbei im Vordergrund: Virusreaktivierungen – 
insbesondere der BK- und Cytomegalieviren – und akute Abstoßung. Diese Phänomene 
wurden unter Nutzung verschiedener Ansätze eingehend analysiert: (i) Systematische Analyse 
der Assoziationen zwischen verschiedenen Virusreaktivierungen und deren Einfluss auf das 
Transplantationsergebnis; (ii) Bewertung der Auswirkungen antiviraler Behandlungsstrategien 
auf die Reaktivierung von Viren und andere Transplantationsergebnisse; (iii) Entwicklung eines 
Tools zur Prätransplantation-Risikoeinschätzung der akuten zellulären Abstoßung und (iv) 
Erstellung eines mathematischen Modelles für die personalisierte Charakterisierung der 
Immunantwort gegen das BK-Virus unter Immunsuppression. In diesem Zusammenhang 
wurden verschiedene Analysemethoden angewendet, sowohl explorativ wie auch 
hypothesengeleitet, von uni-, bi- und multivariater Biostatistik bis hin zu gewöhnlichen 
Differentialgleichungsmodellen und Methoden des maschinellen Lernens. Kritisch für den 
Erfolg dieser Analysen war ein sorgfältiges Management der Vielzahl der in der Studie 
gesammelten heterogenen Daten, insbesondere bei der Datenbereinigung, 
Datenbankintegration, Verwaltung fehlender Daten und Datenvorverarbeitung. 
Zusammengenommen haben diese vier Studien das Potenzial, (i) die Patientenversorgung zu 
verbessern, (ii) die Überwachung von Virusreaktivierungen zu optimieren, 
(iii) Präventionsstrategien gegen virale Reaktivierungen zu stratifizieren, (iv) die 
Immunsuppression und das Monitoring der Patienten auf das individuelle Risiko akuter 
Abstoßung anzupassen, und (v) zur Personalisierung der Immuntherapie beizutragen. Die 
Studien zeigen, wie das große Datenvolumen einer klinischen Studie zur Weiterentwicklung 
der personalisierten Medizin unter Einsatz effektiver Strategien für Datenmanagement, 
Analyse und Interpretation genutzt werden kann. Es ist zu erwarten, dass diese Ergebnisse die 
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5.1 Personalized medicine: Promise and challenges 
The medicine of the future is envisaged as personalized, predictive, preventive and 
participatory.1–3 The development of techniques to tailor medical decisions based on 
individual patient needs is the main goal of research in personalized medicine.4–6  In this 
framework, also known as precision or P4 medicine, patients are stratified based on their 
disease subtype, genotype, treatment response, etc. so that medical decisions are based on 
individual patient characteristics rather than on general population characteristics.4–7  
Personalized approaches are thus expected to lead to better disease prevention and 
optimized treatment, thereby extending and improving the life of patients.1,5,8  
Tailoring medical decisions to the patient has been a goal of medicine ever since antiquity, 
and a certain degree of personalization based on single variables has long been standard, e.g. 
adjusting of dose for body mass or adjusting therapy according to clinical history.3,7 However, 
high-throughput omics have made it possible to obtain an unprecedented amount of complex 
and heterogeneous data on each individual patient, opening new possibilities for the 
development of personalized medicine.7,9,10 Systems medicine approaches aim to take 
advantage of these multi-dimensional data, integrating it with information from other sources 
e.g. clinical and lifestyle data, with the goal of better grasp the complexity of disease, as the 
result of multiple biological interactions.7,9,11 A systems understanding could therefore be 
especially adequate for the prevention, diagnosis and therapy design of complex illnesses – 
such as complications of renal transplantation.2,4,12,13   
However, major challenges in personalized systems medicine remain to be addressed.5,8,14,15 
While generation of quality data has become increasingly fast and cheap, current bottlenecks 
pertain mainly data management and analysis – including but not limited to data storage and 
management issues, concerns in analysis of heterogeneous data, interpretation of complex 
results and performance of prediction models.4,5,7 Consequently, more effective data 
management and analysis strategies are paramount. 
5.2 Personalized approaches to renal transplantation 
Transplantation is the best available treatment for kidney failure.16–18 In the last thirty years, 
the development of new immunosuppressive protocols has led to a clear improvement of 
short term patient and graft survival.19,20 However, this progress has not resulted in similar 
improvements in the long-term: median graft survival time still remains at around ten years.19–
21 Moreover, in spite of functioning grafts, complications associated with immunosuppression 
– e.g. viral reactivation, cardiovascular disease, cancer, diabetes, etc. – result often in a 
decrease of quality of life and premature death of the patient.13,19–24  Under-
immunosuppression, on the other hand, can lead to acute rejection, causing graft dysfunction 
and eventually graft loss.16,25–27 Therefore, in a context of increasing incidence of kidney failure 
and difficulties in decreasing the waiting time for an organ donation, personalized approaches 
to immunosuppressive treatments could improve transplantation outcomes.13,16,19,25,28–30  
Current approaches in personalized medicine for renal transplantation include, among others: 
(i) improvement of organ allocation, better defining HLA mismatches critical to the 
development of complications; (ii) describing the immunological characteristics leading to 
graft tolerance in absence of immunosuppression and improving techniques to induce this 
state; (iii) investigating the efficacy and safety of drug protocols in stratified cohorts; (iv) 
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developing non-invasive markers for the early detection of complications; and (v) developing 
tools to predict the risk of individual patients to suffer certain complications, especially acute 
rejection.16,31–35 In Table 1, a non-exhaustive selection of studies comprising these five 
directions is shown.* Interestingly, several study approaches are based on multi-omics or 
multicomponent data, i.e. medium to large volumes of heterogeneous data. These studies 
attempt to model transplant complications or outcomes based not on mono-factorial 
analyses, but by capturing systemic patterns and interactions. 












Matching† NCT03818698 Observational 
Assessment of 
association of HLA 
mismatching and 
rejection 
HLA typing 1000 Ongoing 
HLA-DQ‡ NCT03896919 Observational 
Assessment of 
association of HLA-
DQ  mismatching 
and rejection 
HLA-DQ typing 30 Ongoing 
ARTIST NCT01516177 Observational 
Assessment of 
frequency of known 
operational 
tolerance signatures 
B cell receptor 
sequence 
250 Completed 




 6 Ongoing 






 300 Completed 
nEverOld NCT01631058 Interventional 
Evaluation of 
immunosuppressive 
therapy for elderly 
population 
 90 Ongoing 
Harmony NCT00724022 Interventional 
Validation of 
immunosuppressive 
therapy for low risk 
constellation 
 600 Completed 
TAC3A5 NCT03020589 Interventional 
Validation of 
immunosuppressive 
regime based on 
genotype 
Genotype 260 Ongoing 




therapy for normal 
risk constellation 
 400 Ongoing 








* See Table S5 in 9.2.8 for an exhaustive selection and comparison of studies on the early prediction of acute 
rejection in kidney transplantation. 
† The official name of the study is “Study of Eplets Matching in Kidney Transplantation”; no official acronym was 
found. 




KTD-innov NCT03582436 Observational 
Development of 
non-invasive 
rejection markers  
Multi-omics 750 Ongoing 
ROCKET - Observational 
Early diagnosis and 
prediction  of 
complications 
Multi-omics >2000 Ongoing 
iBOX NCT03474003 Observational 
Risk assessment tool 
of long-term graft 
survival 
 8000 Ongoing 
TOGETHER NCT03873623 Observational 
Validated risk 





EU-TRAIN NCT03652402 Observational 
Risk assessment tool 







BIOMARGIN NCT02832661 Observational 
Validation of 
biomarkers for  graft 
lesions 
Multi-omics 500 Ongoing 
e:KID  Observational 
Risk assessment tool 





Table 1. A non-exhaustive selection of studies in kidney transplantation relevant for personalized 
medicine. Source of information is the registry ClinicalTrials.gov, except for the ROCKET and the e:KID studies; 
for the former the source is era-learn.eu, for the latter sys-med.de. The patient cohort of the e:KID study 
corresponds to that of the Harmony study. The category multi-component refers to studies incorporating data 
from heterogeneous sources (DNA, RNA, proteins, metabolites, etc.) but not necessarily multi-omics, as in Lee et 
al.36  
In this dissertation, the results of work performed as part of the e:KID study is presented.* The 
main goal of this study is to optimize the treatment of patients starting at the first weeks after 
transplantation. The e:KID approach regards the immune system as a whole, considering the 
interplay of its components at molecular, cellular and physiological levels. For this, a wide 
range of immune system and complication markers were measured in patients including e.g. 
cell type populations, gene expression and concentration of cytokines and metabolites. e:KID 
does not employ an unsupervised high throughput multi-omics approach with the goal of 
generating a large amount of data.11,12,37 Rather, unlike many systems medicine studies, the 
choice of markers was based on the expertise of the consortium partners. For example, the 
expression of tolerance associated genes were measured, as they might be markers for the 
effectivity of immunosuppression; metabolomics profiling of urine was performed based on 
previous knowledge of their diagnostic capacity for acute rejection.26,38,39 
Combining the measured markers with data on the clinical course of the patients, the e:KID 
approach is expected to achieve a deeper understanding of the processes leading to a good 
transplantation outcome, and how these outcomes could be improved. A wide range of 
analytic methods – encompassing biostatistics, machine learning and mathematical modelling 
– were envisaged. Therein, predictive models on the outcomes and main transplantation 
complications are to be developed; main interest areas comprise renal function, acute 
rejection and viral reactivations. Further, exploratory and hypothesis-guided studies were 
planned to assess the contribution of demographic factors, therapeutic strategy and 
complications on transplantation outcome. The results of the e:KID study as a whole are then 
to be integrated and validated in a upcoming second phase of the study. As a final result, an 
 
* For more detail on the study design, see section 6.1. 
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exhaustive systems medicine-based model is envisioned, with the goal of allowing clinicians 
to optimize the treatment based on individual criteria. 
5.3 Basic concepts of data management  
The final goal of data management is achieving high-quality data, and submitting them on time 
to those responsible for data analysis.40,41 According to the US Institute of Medicine, high 
quality data are those data “strong enough to support conclusions and interpretations 
equivalent to those derived from error-free data”.42 Data management can be defined as the 
development, execution and supervision of practices to control, protect, deliver and enhance 
the value of data.43 Data management is a multidisciplinary endeavour, with no “one-size-fits-
all” solutions, and requires the expertise of specialized data scientists.40,44,45 Data 
management strategies are critical for data analysis, and therefore reporting on the followed 
strategies is a recommended practice.46 
5.3.1 The stages of data management 
Data management is a complex procedure, including database design, data entry, data 
integration, data cleaning, management of missing data, database locking and data pre-
processing.40,41,47 
The design of the database has to meet the needs of the study, especially taking into account 
the process of data entry.40,48 A well-designed database is vital for the subsequent integration 
of the data from different, heterogeneous experiments.  Database design should not be 
performed blindly, but be the result of a requirement analysis, considering the nature of study 
and the key research questions to be answered, as well as the background of the researchers 
who are to make use of the database.48 Data entry within a clinical trial is usually performed 
employing an electronic case report form (eCRF). 40,49 Similar to the database, eCRFs are 
specially tailored for the needs of a specific study, containing questions on the results of each 
clinical examination, adverse events, medication change etc.40,49 A careful design of the eCRF 
can partially prevent the introduction of errors, e.g. allowing the selection of categorical 
variables to avoid typewriting mistakes and defining hard cut-offs for numeric values.49  
In a systems medicine study, the clinical data entered through the eCRF have to be integrated 
with further, experimental data of heterogeneous characteristics.4,7 The goal of data 
integration is to allow users to fetch data from the different sources, combining, manipulating 
and employing them for the analysis.50–52 But the integration of heterogeneous data from 
different sources is not a trivial task where data can be just blindly juxtaposed within a 
database; it depends on the biological and statistical problem at hand and the heterogeneity 
and origin of the data.50–52 Furthermore, for certain data types, e.g. genomic data, pre-
processing of the data is necessary for their integration due to their high degree of noise.52 
Therefore, data integration is a duty that requires input from both data scientists and the 
experimentalists responsible for the data, employing agreed standards.50–52 
The resulting integrated database of a clinical study is then in a semper reformanda state, i.e. 
it is in need of corrections within a continuous process of cleaning. Data cleaning should not 
be understood as a mere intermediate step before data integration into the database, but 
rather as an iterative process, in which the goal is to ideally achieve high quality data.40,41,47 
For more details on how high quality data are defined, and on the handling of errors, see 
section 5.3.2. However, to prevent that the data cleaning process eternizes and arbitrary 
changes are performed in the database, the database has to be closed for edition at some 
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point so that it cannot be altered in any way.40 This process is known as database locking; 
database locking is performed after the data integration and cleaning are considered to be 
complete and it is the end of data management activities.40 
5.3.2 Defining and achieving quality data 
There are several theoretical frameworks on data quality for clinical studies; a useful 
framework employed in this work regards quality as the sum of three dimensions: 
conformance, completeness and plausibility.53,54 Conformance of data is defined as its 
compliance with the pre-specified standards, which can be variable- or study-specific.53,54 Data 
completeness evaluates the presence or absence of data and whether these agree with the 
expectations in the study, independently of the value of these data.53,54  Lastly, plausibility 
describes whether the data values are believable, based on expert knowledge on the variable 
at hand and the techniques employed for its measurement.53,54 
Conformance encompasses three sub-categories: value conformance, relation conformance 
and computational conformance.53,54  Value conformance describes whether the value of a 
data point is in the allowable range and the right format, relational conformance describes 
whether data points agree with the information of other data points, while computational 
conformance corresponds to whether values where calculated correctly. For the detection of 
non-conformances in data, the implementation of hard cut-offs for the allowable range, as 
well as the merging of databases can be of use.46 
Missing data can be due  to several causes, including the patients skipping a study visit, loss of 
samples, errors in data entry, interruptions in data flow, as well as decisions taken by 
experimentalists.46 Missing data are classified in three categories:  
1. Missing completely at random: Data with no systematic differences between missing 
and observed values, e.g. missing measurement because of a technical problem.55–57 
2. Missing at random: Data with systematic differences between missing and observed 
values that can be explained with available data, e.g. an increased number of missing 
measurements among older patients of an age-dependent variable.55–57 
3. Missing not at random: Data with systematic differences between missing and 
observed values that can only be explained by the missing data themselves, e.g. an 
increased number of missing measurements in patients with a pathological value of 
the variable.55–57 
Missing data can have profound consequences on the data analysis: They reduce the statistical 
power of the study, thereby reducing the ability to detect differences between groups.55,57,58  
More importantly – in the case of missing data at random and missing data not at random – 
missing data introduce a bias into the results of data analysis.55,57,58 When missing data are 
unexpectedly encountered, the data flow has to be investigated, as in some cases measured 
data are lost due to breaks in data flow.46 In case the data were never measured, several pre-
processing methods can be employed to handle the missing data points (for more details, see 
sub-section 5.3.3).55,57,58 
Implausibility of data is also a multi-factorial phenomenon. It can be caused by e.g. errors in 
the experiment, data entry and data integration, leading to implausible values or implausible 
distributions of data.46,59  These can be detected using graphical exploration of their statistical 
distribution: Typing errors in the data collection can lead to extreme outliers; differing units 
in the data can be a cause of a multimodal distribution of a variable.46,47 Expert knowledge on 
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the data is necessary for investigation of implausibility, leading to the need of assistance in 
data cleaning.46 
5.3.3 Data pre-processing for data analysis 
Data in a cleaned and locked database might not necessarily be in the form needed for analysis 
– data pre-processing is necessary under several circumstances. This is particularly the case 
for datasets with missing data points. There is a number of pre-processing techniques that can 
be employed in this case, including the use of only complete cases (which can introduce a bias 
in the results), replacing missing values by the last measured value (for variables with small 
changes in time) as well as imputation methods.55,57,58 Imputation methods attempt to 
estimate the values of the missing data by using the available data, based on the assumption 
that they are missing at random: single imputation methods provide an estimated value for 
each missing value; multiple imputation generates several imputed data sets to take into 
account the uncertainty of imputation.55,57,58 
A further reason for data pre-processing can be the requirements of the analytical 
techniques.60–62 For example, parametric tests such as the t-test require a normal distribution 
of the variable at hand; logistic regression techniques requires a binary dependent 
variable.63,64 Moreover, while a certain data structure might not be a strong requirement, 
some analytical techniques lead to better results when employing certain normalization 
techniques e.g. in neural networks.60 There are several techniques that can be employed to 
transform the data into a certain structure, including log transformation, z-score 
normalization, rank transformation or binarization; detailed knowledge of the underlying 
assumptions of the employed analytical techniques as well as of the structure of the employed 
data is paramount.60,65,66     
Another factor that should be considered when pre-processing the variables in any multi-
centre study are centre effects.67 Centre effects are differences in the results of the study 
caused by differences between the participating centres.67 Possible causes include differences 
in the demographic composition of each centre sub-cohort, in the treatment of the patients 
and in the sample analysis.67 Only the third cause of centre effects can be avoided relatively 
easily by implementing a central measurement of all samples. A possible approach for the pre-
processing of variables with strong centre effects is the normalization of the data.65 In such 
approaches, the results obtained from each study centre are scaled and centred, so that e.g. 
the mean value and the standard deviation of the data is the same for all transplantation 
centres.65 However, such approaches assume that the mean value and standard deviation 
should be the same for all transplantation centres, i.e. there are no differences in demographic 
composition and outcomes. Therefore, such approaches cannot be applied without 
knowledge of the expected centre effects for the variable. 
5.4 Data analysis methods for systems medicine 
Data analysis has to take into account the intrinsic high degree of complexity of the data, 
which makes the unaided interpretation impossible.4,5 A large plethora of methods, including 
machine learning, ordinary differential equation mathematical modelling, biostatistics, 
network analysis and time series analysis, are currently employed in systems medicine 
studies.4,5,10,12,68  These methods can be applied for four different categories of analytics: 
(i) descriptive analysis, to describe the patient outcomes;  (ii) diagnostic analysis, to explain 
the patient outcomes; (iii) predictive analysis, to anticipate future patient outcomes; and (iv) 
prescriptive analysis, which attempts to change patient outcomes.69 However, the application 
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of these methods for data analysis is not trivial, and it is important that the data scientist 
understands the medical problem at hand, the method in-depth and the goal of the 
analysis.4,69 Different methods are adequate for the acquisition of different insights, e.g. 
machine learning techniques are excellent for the detection of complex predictive patterns, 
but can hardly provide a diagnostic understanding of the patterns –  a mathematical model 
might be thus more adequate for this problem.5,69,70 
In the next sections, basic concepts of the methods employed in this thesis are provided, with 
special emphasis on how they can be employed to achieve descriptive, diagnostic and 
predictive insights for personalized medicine. 
5.4.1 Statistical analysis of clinical studies 
5.4.1.1 Clinical statistics: Basic concepts and methods 
The classical approach for the analysis of a clinical study is based on the concept of end-
point.71,72 An end-point is a clinical variable that informs of the success of an intervention, e.g. 
the mortality rate or the rate of response to a therapy.71 Clinical studies usually have one 
primary end-point and may have one or more secondary end-points; the primary end-point is 
the most relevant for the research question, while secondary end-points can be used to better 
interpret the primary end-point.71 In interventional trials, the differences in the end-points are 
assessed for two or more groups receiving different treatments; in observational studies the 
influence of other variables such as demographic characteristics on the end-point is 
assessed.73,74 However, the wealth of data generated within a clinical study allows for far more 
than end-point assessment in pre-defined groups: Exploratory analyses can be undertaken to 
gain further understanding of the physiological and pathological processes taking place during 
the study.75 
Common methodologies employed for the statistical analysis of clinical studies include uni-, 
bi- and multivariate approaches.76,77 Univariate analysis provides a description of the data 
distribution, i.e. central tendency and dispersion; visualisation techniques to provide an 
intuitive understanding of the distribution are also recommendable.77,78 Bivariate analysis can 
be employed to compare end-points between patient groups in interventional and 
observational studies.72 The differences in a categorical end-point between two or more 
groups can be compared through the chi-square test (Fisher’s exact test for a small number of 
patients); for continuous end-points, the Mann-Whitney U test (t test if normally distributed) 
is employed for two groups, while for three or more groups ANOVA is recommended.77,78 
Pearson’s and Spearman correlation tests are useful to compare two continuous variables.78 
Multivariate techniques, ranging from regression to machine learning, can be employed to 
model more complex relationships between variables, e.g. determining the demographic 
characteristics predictive for a certain outcome.76,79 
5.4.1.2 The interpretation of multiple tests and non-randomized studies 
Importantly, the interpretation of the results of bio-statistical tests depends highly on the 
study design. A clear and detailed definition and pre-specification of the groups and end-
points, a small number of hypotheses and outcomes, as well as prior strong biological evidence 
are necessary to consider results as confirmatory, both for observational and interventional 
studies.75,80 On the other hand, a large number of groups, hypotheses and outcomes lead to 
the performance of multiple statistical tests.81 Multiple testing inflates the type I error (i.e. 
falsely detected associations) to unacceptable limits, with 99.4% probability of at least one 
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false positive test out of 100 and 23% for only five tests for the conventional alpha value of 
0.05.81,82 Several statistical methods can be employed to minimise the type I error for multiple 
independent tests, such as the Bonferroni adjustment; but these methods increase the risk of 
type II errors (non-detected associations).80–82 Because of this, multiple testing correction is 
essential for confirmatory analyses, even for a relatively low number of tests. But for 
exploratory analyses – since the goal is to generate hypotheses for further study – multiple 
testing correction might be even counterproductive.80–82 Non-adjusted results of multiple 
tests should therefore be clearly reported as exploratory.81,82 
Among interventional studies, randomised controlled trials are the gold standard design for 
assessing the effect of different treatments on the pre-defined end-points.83,84 The 
randomisation process, if properly implemented, makes the treatment group(s) and the 
control group comparable with respect to known and unknown factors affecting the 
outcome.73,83 Therefore, it can be assumed that any significant differences in outcome 
between the groups is caused by the different treatments.85–87 On the other hand, differences 
between groups in a non-randomized trial can be potentially caused by a confounder.74,83,88,89 
Confounders are factors associated with both the treatment groups and the end-points; they 
can mask the effect of a treatment or lead to spurious associations between treatment and 
end-point.88–91 Confounders might be demographic factors, e.g. age and sex, or be study-
specific, such as protocol differences between centres.83,90 Therefore, to avoid bias in the 
interpretation of data from non-randomized trials, it is essential to control for 
confounders.83,90,91 There are several techniques for controlling for confounders, including the 
comparison of baseline characteristics between groups, stratification or matching of patients 
for suspected confounders and multiple regression.83,91 
Multiple regression – linear regression for continuous and logistic regression for categorical 
end-points – is considered the most powerful tool for dealing with confounders.83,91 Then 
again, the choice of potential confounders to be included in a regression model is not trivial: 
While some authors highlight the importance of background knowledge to guide confounder 
selection, this is not possible in all cases, so that data-driven approaches are necessary.83,92,93 
A popular strategy selects the variables based on their bivariate association with end-point 
and/or treatment groups, but this excludes confounders that can only be detected in 
multivariate analysis, e.g. two variables negatively associated with each other  but with a 
positive effect on the end-point.83,92–94 On the other hand, controlling for all relevant variables 
in a full regression model can lead to overfitting and multicollinearity, especially for studies 
with a low number of patients and high number of variables.83,95,96 Variable selection methods 
can prevent the problems associated with full models without resorting to bivariate analysis 
and are thus the most adequate approach to control for confounders – backward elimination 
is a standard and recommended approach for that.93,96 Conventional backward elimination 
starts with a full model and removes variables sequentially based on the P value, until all 
variables have a P value below a set threshold.92 Nevertheless, this selection can be arbitrary 
and inflate the significance of the rest of the factors.93,96 The use of a selection criterion based 
on information theory, such as Akaike’s information criterion, has been suggested to 
overcome these problems.93,96 
However, in spite of the approaches for controlling for confounders, non-randomized 
interventional studies are considered to lead to exploratory results, rather than 
confirmatory.74,83,91  The reason for that, among others, is that no method can control for 
confounders that have not been measured.83,89,91 On the other hand, the results of such 
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studies can be very valuable, as they might suggest previously unknown relationships between 
the treatment and outcome, leading to a larger output and higher efficiency in the analyses of 
a large clinical trial.73,75,83 
5.4.2 Machine learning approaches for disease biomarker discovery 
5.4.2.1 Introduction to machine learning 
A complex phenomenon cannot be captured based solely on one significant difference in one 
end-point between two sub-groups.97,98 The confirmatory study approach, described above, 
disregards individual differences to achieve (sub-)population-wide insights – other analytical 
approaches are more appropriate to create personalized solutions.97,98 With the increase in 
high-throughput data and computation capacity, machine learning approaches have become 
nearly ubiquitous for the analysis of complex phenomena.5,99,100  
Machine learning algorithms basically teach computers how to learn from the data. In contrast 
to regression, they are not based on the application of a set of mathematical rules, but learn 
directly and automatically from the data, making no assumption on the relationship between 
input data (so called features in the machine learning jargon) and the clinical outcome of 
interest.100–102 Machine learning methods can be classified into two broad categories: 
unsupervised learning algorithms, which require only the input features and attempt to unveil 
structures within the data; and supervised learning algorithms, which employ labelled data 
and attempt to predict the value of the labels based on the features.100,102 For example, while 
an unsupervised approach can classify patients in n clusters based on their transcriptomic 
profile, supervised approaches can be used to predict their age based on the same data.100,102  
Machine learning models are built based on a training data set; for supervised learning it is 
possible to estimate the prediction performance in terms of specificity and sensitivity.100,102 
Yet, this measure might not be representative of the performance in the general population 
as the model might overfit the training set, i.e. the model fits the data in an arbitrary way only 
due to a high number of features.100,102 Therefore, it is recommendable to split the available 
data in three sets, where the first is employed for training, the second for model selection and 
the third for model performance assessment.100,102 For smaller data sets that cannot be split, 
alternative techniques can be employed to assess the performance.102,103 These include 
internal cross-validation and permutation tests or label shuffling.102,103 Furthermore, feature 
selection algorithms can be beneficial to increase the efficiency and accuracy of the learning 
process, reducing the complexity of the data and prioritising features potentially informative 
or important for prediction.104–106 
Support vector machines (SVM) are a popular supervised machine learning methodology in 
biological and clinical research.79,107–109 It is usually employed for binary classification, but 
there are SVM implementations for multiclass classification and regression problems.107,110,111 
SVM regard data as points in a high-dimensional space.107,112 For example, a data set consisting 
of the expression of three genes from forty patients, half of them with a positive disease 
progression, is regarded as forty labelled points in a three-dimensional feature space (see 
Figure 1). The algorithm attempts to determine the label disease progression for each patient 
based on their position in this three-dimensional space; this is performed dividing the space 
with a plane that splits the space in half and separates the patients based on their progression, 
so that the plane has the maximum possible distance to the points.112 In real implementations 
of SVM with a higher number of features, this three-dimensional plane becomes one or more 
hyperplanes.107,112 As a linear separation of the data still might not be feasible, a kernel 
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function can be applied to generate non-linear hyperplanes.107,112  There is a large diversity in 
the implementation of the core idea of SVM, ranging from the use of different kernel functions 
to alternative methods based on SVM.62,107,111–113 One of these alternative methods is the 
potential support vector machine (P-SVM).62 In contrast to classical SVM, P-SVM performs 
feature selection as well as the estimation of the prediction performance; furthermore it 
works satisfactorily for small patient cohorts and the experience has shown it to be especially 
appropriate for the search of biomarkers in certain contexts, such as antibody binding 
profiles.62 
A)      B)  
            
Figure 1. Two illustrative examples of classification employing SVM. (A) The algorithm separates two 
classes (represented as blue and red points) employing a linear three-dimensional plane. A 
combination of features 1 and 3 are employed for the classification. (B) The algorithm separates two 
classes employing a non-linear kernel, based on all three features. 
Other examples of machine learning methodologies include hierarchical, k-means and spectral 
clustering and sparse coding for unsupervised problems, and random forests and decision 
trees for supervised problems; artificial neural networks can be employed both for supervised 
and unsupervised problems.100,102,114 The latter are considered especially promising, as 
complex (multi-layer) neural networks are the basis of most deep learning methods.115–118 
Deep learning methods aim to extract abstract features from the raw input data, in a way 
roughly comparable to the way human brains process information, potentially improving the 
analysis of heterogeneous and complex data sets.115–118 
5.4.2.2 Machine learning in clinical research: Opportunities and challenges 
Machine learning methods are applied extensively in a wide range of biological and clinical 
studies, including the analysis of imaging technology output, processing of text annotations in 
literature, prediction of three-dimensional protein structure or the analysis of biological 
interactions in high-throughput experiments.118–120 Their capacity to detect patterns in large, 
heterogeneous datasets makes them essential for the development of personalized systems 
medicine, especially in the search for predictive disease biomarkers.5,68 In fact, machine 
learning is being employed in the search of biomarkers for virtually every complex clinical 
process, including cardiovascular disease, cancer, diabetes, Alzheimer, HIV, osteoporosis, 
Huntington’s disease, and even ageing.121–127 In kidney transplantation, the goals in biomarker 
discovery comprise the non-invasive, cost-effective monitoring of graft function, early 
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diagnosis of complications (especially rejection), evaluation of the effective 
immunosuppression and graft tolerance and prediction of long-term outcomes.12,13 While 
such a biomarker panel has not been clinically validated yet, there are several promising 
results.12 These include, but are not limited to: A non-invasive urinary marker for acute cellular 
rejection, several early risk assessment models for acute cellular rejection (see Table S5 in 
9.2.8 for an exhaustive comparison of predictors in the literature), a 595-gene expression 
signature of graft operational tolerance or validated genetic risk scores for the development 
of post-transplantation diabetes.12,35,128–131 
However, although machine learning approaches hold big promise for biomarker discovery, 
the prediction performance is often not sufficient to justify their validation and application in 
the clinic.5,99 Machine learning algorithms, as sophisticated as they might be, depend on the 
quality and quantity of the data and, importantly, on their adequacy for the research question 
– no algorithm can squeeze information out of data that hold no information.5,99,132 Moreover, 
the training of machine learning algorithms usually requires high quantities of data of a large 
number of patients, but many omics high-throughput data have high technical measurement 
errors.5,99 This is challenging, as there are no satisfactory methods to discriminate between 
signal and noise.5,99 Likewise, a careful choice of the training cohort is central to the 
performance of the algorithm in the general population, as machine learning procedures are 
highly sensitive to selection biases in the patient cohort.5,99,133 This has led in the past to racist 
and sexist algorithms, due to under- or over-representation of some ethnicities in the training 
set.5,134 
All the problems highlighted above will be improved with the development of cheaper, more 
precise high-throughput techniques, allowing the performance of measurements in large, 
representative patient cohorts. But there are deeper issues pertaining the core of machine 
learning that hinder their use in clinic: They can be very difficult to interpret.5,133,135 Machine 
learning methods do not detect causal relationships between biomarker and outcome, but 
capture a highly complex biomarker signal and employ it for an outcome prediction, i.e. they 
do not necessarily provide a mechanistic understanding of the problem at hand.101,135,136 
Because of this, machine learning approaches cannot replace classical hypothesis-based 
research yet, but rather complement and enrich it.5 Moreover, most algorithms are “black 
boxes”: They work, but we do not understand why or how, as the used patterns cannot be 
intuitively understood.5,135,137  The issue of interpretability will likely become more acute with 
the development of deep learning algorithms.5,115,135 This is highly problematic, as trust in the 
algorithm by clinicians and patients is essential for their application in real life medicine.5,133 
Therefore, there are now increasing efforts to develop software to better interpret the results 
of machine learning models.115,133,135,137–139  Understanding why the machine gives a diagnosis 
or predicts an outcome will thus be key to the application of these algorithms in day-to-day 
clinical practice, therefore improving patient care and quality of life. 
5.4.3 Mathematical modelling as a tool for mechanistic understanding 
5.4.3.1 Introduction to mathematical modelling in clinical research 
The classical research approach in biology – in contrast to the newer, data-driven machine 
learning approach – is based in the generation and verification of hypotheses.5,136,140,141 A 
hypothesis is a qualitative model of a biological mechanism (if A then B) with implications that 
can be tested through experimental procedures; the results of the experiment determine 
whether the model has to be modified.136 Mathematical modelling is an extension of the same 
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concept, as they are a quantitative, objective, abstract description of a set of hypotheses. 
136,142,143 In contrast to traditional hypotheses, mathematical models are “working” 
hypothesis, whose behaviour can be directly studied.142,143 As such, they can be employed for 
the testing of hypotheses, and have to be revised in light of experimental results.136,142–144 
Mathematical models compile the existing knowledge on a biological question in a rigorous 
way, highlighting gaps in knowledge.143,144 A validated model can be employed to simulate 
different conditions and perturbations, which would be very costly to perform in an 
experiment.143–146  
Mathematical modelling is an essential tool in many scientific areas – including physics, 
chemistry, meteorology, seismology – and are widely employed in engineering, where they 
have accelerated and improved development.142,146,147 Although mathematical models are not 
as widely used for clinical questions as for engineering problems – probably due to the 
inherent complexity of biological processes – there are considerable efforts in areas as diverse 
as cancer, degenerative disease, vaccines, immunology and pharmacokinetics.144,146–154  
The process of model development in biology is not trivial, as the same process can be 
described in more than one way, employing different mathematical formalisms.143,146,155 
Moreover, different approaches for studying the same problem may provide different 
insights.143,155  To decide the type of modelling approach, it is essential to clearly formulate 
the research question to be addressed.143,155 With a research question, the available 
experimental data and information from the literature including existing models can be 
employed to determine the general type of the model.143,155 There are several possibilities for 
model architectures, including Boolean networks (determinist models with binary variables), 
partial differential equation models (determinist models with continuous variables 
considering time and space differences) or stochastic models (models taking into account 
random effects).9,155 Among all modelling frameworks, ordinary differential equations (ODE) 
are the simplest modelling deterministic framework with quantitative variables.155,156 ODE 
models describe the variations of a set of variables over time, disregarding spatial differences 
for the variables.9,155  Because of this, ODE models are by far the most common framework 
for various kinds of biological problems, including modelling of metabolic pathways, ecological 
or immune dynamics.155–157  
Based on the structural decisions, a first version of the model can be built.143,155 This first 
version contains parameters that have an essential influence on the behaviour of the 
model.143 While some parameters might have been determined in previous studies, often 
many parameters are not generally determined, as they depend on e.g. experimental 
conditions, patients and even the time of the measurement – in fact, many biological 
parameters are not even determinable.147,155  The value of these parameters for the given 
research question has to be estimated by fitting the model to the experimental data.155 Fitting 
is performed by optimising the model so that the predicted results approximate as much as 
possible the experimental data.155,158 The deviation of the predicted data from the 
experimental data is quantified by the objective function.155 During fitting, the possible 
combinations of parameter values are scanned; the parameter set leading to the lowest value 
of the objective function is selected.155,158 Although several functions can be employed, the 
sum of squared residuals is a common objective function, which can be employed for model 
selection.155 
After the parameters have been tentatively fitted, the quality of the model – including both 
the structure and the values of the parameters – can be assessed based on its capacity to 
24
reproduce the training experimental data set, as well as other validation data sets.155 In 
practice, modelling often involves several cycles of model generation, fitting and testing.155 
5.4.3.2 Application of mathematical models for viral dynamics 
Modelling has a considerable history of applications in the area of viral infections and the 
immune response against them: After pioneer work on HIV, there are models describing (parts 
of) the dynamics of influenza virus, Hepatitis B and C, West Nile virus, Epstein-Barr virus, 
cytomegalovirus or BK virus, among others.70,154,166–171,156,159–165  These modelling efforts have 
greatly increased our knowledge of infection dynamics, with insights spanning from basic 
biology to clinical decisions.156,172  A paradigmatic case is HIV, which was thought to be a 
slowly-replicating virus (similarly to other lentiviruses): Two mathematical models suggested 
for the first time in 1995 that the virus was replicating and being cleared very fast, leading to 
an apparent steady state.156,173,174 These rapid dynamics have deep consequences in the 
treatment, as fast viral replication is associated with the apparition of drug resistances.156,173  
More recently, mathematical modelling of HIV has suggested the presence of latent infected 
cells that occasionally reactivate; modelling is also employed to interpret the viral kinetics 
during and after antiviral therapy and to predict the success (or failure) of different tentative 
therapies.175–177 In the case of influenza, mathematical modelling has been among others 
successfully used to predict the viral load kinetics of infection, the efficiency of antiviral 
immune responses, the efficacy of vaccines and mechanisms of co-infection with other 
pathogens. 178–182  The latter case is especially interesting, as it was a mathematical model that 
first suggested an effect of influenza in reducing Streptococcus pneumoniae clearance –this 
effect has been experimentally validated.172,178,183–186 In fact, the experimentally observed 
decrease in anti-streptococcus immune response corresponds with the estimated value of the 
parameter in the model.172,178,183,184,186 Importantly, the fact that there were various 
inaccuracies in the model did not hinder its capacity to make accurate predictions on the virus-
bacteria interactions.172,183,186  
For BK virus, although the number of existing models is reduced, mathematical modelling has 
been employed to demonstrate its fast replication and clearing dynamics and the cytopathic 
effects of the virus; likewise, the influence of immunosuppression on the BK virus proliferation 
and serum creatinine have been modelled.164,165,171 
Even though there are numerous mathematical approaches to model viral dynamics, the most 
commonly used model is the so-called basic or standard viral dynamics model (Figure 
2).70,172,187–189 The basic viral dynamics model is an ODE model based in the ecological 
predator-prey model.70,145,172 It consists of one compartment and three variables (target cells, 
infected cells and virus), where virus infect target cells leading to infected cells, which produce 
more virus; target cells replicate and die at a constant rate, while infected cells die at a higher 
rate and virus is likewise constantly cleared.70 Variations of the basic viral dynamics model 
have been used to model the infection of both acute and chronic infections, including HIV, 
influenza virus, hepatitis B, Dengue virus, yellow fever, cytomegalovirus and BK virus, among 
others.163,166,167,170,171,190,191   This is probably due to the fact that most viral infections have 
similar kinetics, with exponential increase in the beginning and a peak, after which a mono- 
bi- or tri-phasic decay leads to clearing or a steady state (depending on whether it is an acute 
or a chronic infection).178  
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Figure 2. The basic viral dynamics model. 
The basic model of viral dynamics, as described by Perelson et al. 2002, is depicted as (A) a system of 
differential equations and (B) a graphical representation.70 
5.4.3.3 Interpretation of modelling results: Parameter identifiability and model selection 
Parameter estimation attempts to approximate the real parameter set i.e. the parameters 
that determine the studied dynamics assuming that the model structure is an adequate 
approximation to the problem.155 However, different parameter sets may lead to the same 
final value of the objective function, meaning that there is no unique solution to the parameter 
estimation.155,192–194 This situation is defined as non-identifiability, which can be of structural 
or of practical nature.155,192–194 Structural non-identifiability is caused by the very definition of 
the model, so that no possible experimental data could lead to identifiable parameters; on the 
other hand, practical non-identifiability is caused when the quantity or quality of the data is 
not sufficient to approximate the value of all parameters.155,192–194 Structural identifiability is 
a necessary condition for practical identifiability.192,195  Practical non-identifiability is especially 
likely if the model has too many parameters for the measured data, potentially leading to an 
overfitted model.155,192,194 
There are several techniques that can be employed to detect non-identifiability and how 
experimental data should be to lead to identifiable parameters.192–194 They can be applied at 
the design stage, before model fitting to the experimental data is performed, and even before 
the experimental data are collected.192–194 Procedures for assessing structural identifiability 
include the direct test and differential algebraic methods; for the practical identifiability 
Monte Carlo approaches or sensitivity analysis can be employed.192,196,197  Moreover, due to 
measuring error, even if a model is identifiable, the parameters can only be estimated within 
a certain confidence interval.193 Confidence intervals can be calculated through bootstrapping 
and analytic techniques.193,198–200 A wide confidence interval denotes a variable whose value 
has not been determined precisely and might even be practically unidentifiable.193,195,201  
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However, non-identifiability of parameters does not necessarily mean that the model is not 
useful or appropriate for the research question.172,194,198  Relevant quantitative conclusions 
about the parameter values can be gained from over-parameterized models.147,172 Moreover, 
the estimation of parameters is often not the final goal of a mathematical model.194 The 
relevance of model identifiability depends thus on the objective of the modelling approach; it 
is central when the actual values of the parameters are part of the research question, or when 
the goal is to predict the dynamics of a variable (e.g. infected cells) that cannot be directly 
measured.194 If these conditions do not apply, models with non-identifiable parameters can 
provide qualitative and quantitative information, especially in rejecting certain hypotheses 
over others.147,172,194 
Modelling different biological hypotheses to test and compare them is a method of achieving 
new insights on the data.172 In this approach, several models representing different 
hypotheses are fitted to the data set, where the degree of agreement of the data can be 
employed to prefer or reject certain hypotheses.172 It has been employed to gain biological 
insights, for example on the immune response after influenza or yellow fever 
vaccination.172,190,202 While hypothesis testing can be performed examining the model 
behaviour and comparing it with qualitative data, fitting the model to quantitative data opens 
the possibility for formal model selection.155,172,203 
In model selection, a better fit of the data is not sufficient evidence by itself to prefer a model 
over others.155 This is because a model with a higher number of parameters might be able to 
overfit the data, leading to a lower value of the objective function.155 To account for this effect, 
selection criteria based on information theory are employed: The most widely-used are 
Akaike’s information criterion (AIC), the corrected Akaike’s information criterion (AICc) and 
the Bayesian information criterion (BIC) – the main difference between the criteria is how 
much they penalize the number of free parameters, where BIC and AICc are preferred for 
small sample sizes.155,204 These selection criteria are based in the maximum likelihood function 
of the model. 155,204 Assuming independent, normally distributed errors, the likelihood is 
considered to be equivalent to the sum of squared residuals.155,204 Selection criteria allow to 
rank models where those with a lower value have a higher degree of empirical support; while 
there is no notion of significance, a difference in the range [0,2] with the best performing 
model is considered to give the hypothesis substantial support.155,204 Other approaches for 
model selection include the likelihood ratio test for nested models, swarm optimization or the 
least squares approximation methods.155,157,205,206 
Importantly, employing several models to test hypotheses does not result in the confirmation 
of the best model according to a given criterion, i.e. it cannot confirm that the chosen model 
is the real one.147 Like in statistical hypothesis testing, the real question is not whether a model 
is confirmed, but whether it is rejected or not, where a rejection means that the given model 
is not a reasonable explanation for the experimental data.147 If there is no further information, 
the results of a non-rejected model – even the best performing model – are to be regarded as 
suggestions that have to be validated through model-driven experiments.147   
5.5 Scope and structure of this dissertation 
In the subsequent chapters, I present my work on personalized medicine for renal 
transplantation patients, performed within the systems medicine research alliance e:KID, in 
which I participated as a data scientist. This doctoral thesis describes the results achieved 
within the consortium, framed as a perspective on the very broad methodological possibilities 
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for data analysis and interpretation in systems personalized medicine. The next chapters are 
structured as follows: (i) a chapter describing the data management strategies applied within 
the e:KID study in detail, as these strategies were critical for the presented results and are 
therefore an integral part of my doctorate; (ii) four chapters containing the publications of this 
thesis and their respective supporting information; (iii) a chapter summarising the results of 
the publications in the context of personalized medicine and, finally, (iv) an outlook on future 
analytical approaches that are already possible with current data and personal reflections on 
the future possibilities of systems personalized medicine. 
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6. Data management in the e:KID study 
In this chapter, the data management strategies employed within the e:KID study are 
described in detail, as these strategies were critical for the presented results and are therefore 
an integral part of my doctorate. As explained in the introduction (section 5.3), effective data 
management strategies are essential for achieving high-quality data, adequate for data 
analysis and interpretation.40–42 Here, following the recommended best-practices on data 
management, I report on the processes of database design, data entry, database integration, 
data cleaning and data pre-processing in the e:KID study.46 Additionally, background 
information on the e:KID study and consortium is provided in section 6.1, as a detailed 
understanding of the study is essential for the management of its data.  
Even though my role in the e:KID consortium was primarily in data analysis and interpretation, 
because of these activities I worked intensively on the database. Therefore while I did not 
have the opportunity to participate at the design of the e:KID database, I have been able to 
participate in the processes of data cleaning and pre-processing. In this chapter, I report on 
the whole process of data management, highlighting my personal contribution.  
6.1 Background: e:KID, a systems medicine study for kidney transplantation 
6.1.1 Design of the e:KID study: Patient cohort and selected markers  
e:KID was designed as an experimental sub-study of the large multi-centre Harmony clinical 
trial (NCT00724022), profiting from the measurements and samples collected during the trial. 
Harmony is an open-label, randomised controlled study that examined the impact of 
immunosuppressive therapies in transplantation outcomes one year after renal 
transplantation.31 The standard practice for immunosuppressive therapy, the so-called 
quadruple therapy comprising basiliximab induction therapy, corticosteroids maintenance 
therapy, mycophenolate mofetil (MMF) and tacrolimus was compared with two alternative 
triple therapies: (i) basiliximab, MMF and tacrolimus and (ii) rabbit antithymocyte globulin, 
MMF and tacrolimus.31  
A total of 615 low immunological risk patients from 21 transplantation centres were recruited 
for the study; 587 patients underwent renal transplantation between 2008 and 2012.31 Blood 
and urine samples were collected in parallel from the participants of the study along eight 
visits during the first post-transplantation year.31 Over three thousand samples were analysed 
for clinical variables, including renal function, rejections, infections, diabetes markers and 
cardiovascular risk factors.31 The primary end-point was the incidence of acute transplant 
rejection; secondary end-points included patient and graft survival, graft function, viral 
reactivations and diabetes occurrence, among others.31  
While no advantage of the triple maintenance therapies was found for the primary end-point, 
the study demonstrated that these therapies are comparable in regard to safety with the 
standard quadruple therapy: For low immunological risk patients, (i) antithymocyte globulin 
and basiliximab induction therapies can be employed equivalently and (ii) corticosteroids 
maintenance is not necessary.31 In summary, the Harmony study was a major step towards 





Figure 3. The e:KID approach. Figure adapted from previous work by Nicole Wittenbrink. 
As explained in the Introduction, the main goal of e:KID is to optimize the treatment of 
patients, by creating a personalized profile that can be used to understand the key individual 
factors determining transplantation outcome. As a continuation of Harmony, e:KID employed 
its measurements and observations, as well as the large number of samples collected during 
the trial. In order to establish the personalized profile, these samples were further 
characterized for markers of the immune system and transplantation complications by the 
e:KID consortium (Figure 3); for the list of measured parameters see Table 2.  
Sample 
type 





T cells, CD4+ cells, CD8+ cells, T regulatory cells, follicular B helper T cells, 
natural killer cells, B cells and neutrophilic granulocytes 8 
Whole 
blood 
Gene expression of 
tolerance and 
rejection markers 
CD79B, CD200, CD247, CD274, CXCL10, FCRL1, FCRL2, FOXP3, HMMR, 
HS3ST1, LAG3, MAN1A1, MS4A1, NAV3, PNOC, SH2D1B, SLC8A1, TCL1A, 




IL17, TNFα, IL6, IL19, IL-22, SCF, sST2, BD2, angiogenin and endostatin 
11 Urine IP10 
Serum Antibody reactivity 
profile 
Anti-HLA-1 and anti-HLA-2 116 
Whole 
blood Viral load 
BK virus 
3 
Serum Cytomegalovirus and Epstein-Barr virus 
Urine Nuclear magnetic resonance metabolomics spectrum 377 
Table 2. Summary of the markers measured as part of the e:KID study. 
6.1.2 Organizational aspects of the consortium 
The e:KID approach would not be possible without the expertise of a multidisciplinary 
consortium. Therefore, an alliance of ten partners was created, encompassing hospitals, 
research centres and private companies (see Figure 4). The team was highly heterogeneous, 
and incorporated clinicians, data scientists and experimentalists specialized in the different 
markers measured within the study. Sample management, experimental data generation, 
database management, data cleaning, data analysis and data interpretation were undertaken 
as an iterative process, in which new markers are measured based on the obtained results. 
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This iterative character allows for an ever-improving quality of the analysis, taking advantage 
of the combined expertise of clinicians, experimentalists and data scientists. 
Data scientists worked mainly within three e:KID partners, all with roles in data management, 
analysis and interpretation. While there was some degree of specialization – e.g. a dedicated 
partner for management – a network-centric structure was decided to take advantage of the 
different areas of expertise of the data scientists.207 Therein, most decisions on data cleaning 
and data pre-processing were taken by the whole data scientist team, in communication with 
the rest of the consortium. Analysis was likewise performed by the data scientist team, based 
on the research questions and expertise of the rest of the partners; interpretation of the 
results was discussed with clinicians and experimentalists.  
 
Figure 4. Structure and approach of the e:KID consortium. Organizatory structure of the e:KID 
consortium, including the function of the different partners. Experimental partners are shown in the 
upper part of the figure; data science partners are shown in the lower part. 
6.2 Database design and integration for the e:KID study 
In this section, the processes of database design and integration in e:KID are reported, 
explaining the background and goals of the main structural decisions. Many of the structural 
decisions are motivated by the Harmony trial and structure of its database. Therefore, a short 
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overview on the Harmony database is provided first in sub-section 6.2.1, as it is necessary to 
understand the database design (6.2.2) and integration processes (6.2.3) in e:KID.  
6.2.1 Structure of the original Harmony database 
The Harmony database is composed by a total of 53 tables (see Table 3) in SAS format. It 
comprises e.g. data on the baseline characteristics of the patient cohort, their evolution and 
outcomes in the first year post-transplantation and the medication employed during the 
study. The large majority of the tables correspond to patient data; the rest contain metadata 
necessary for the understanding of the database.  
Table Name Visit Nº Entries Nº Variables Patient Data? 1P-1R? 
Chronic Kidney Disease  1 631 25 Yes Yes 
Demography 1 637 28 Yes Yes 
Osteodensitometry  2 592 31 Yes Yes 
Osteodensitometry  8 509 31 Yes Yes 
Exclusion  1 633 34 Yes Yes 
Inclusion  1 635 22 Yes Yes 
Laboratory Analysis 1 630 127 Yes Yes 
Laboratory Analysis 2 594 106 Yes Yes 
Laboratory Analysis 3 567 118 Yes Yes 
Laboratory Analysis 4 547 121 Yes Yes 
Laboratory Analysis 5 529 134 Yes Yes 
Laboratory Analysis 6 503 121 Yes Yes 
Laboratory Analysis 7 477 125 Yes Yes 
Laboratory Analysis 8 513 143 Yes Yes 
Medical History I  1 632 41 Yes Yes 
Medical History II  1 631 34 Yes Yes 
Physical Examination  1 631 61 Yes Yes 
Reminder  2 590 24 Yes Yes 
Reminder  3 565 24 Yes Yes 
Reminder  4 545 24 Yes Yes 
Reminder  5 528 24 Yes Yes 
Reminder  6 497 24 Yes Yes 
Reminder  7 471 24 Yes Yes 
Reminder  8 506 24 Yes Yes 
Transplantation  1 632 62 Yes Yes 
Virology  1 630 25 Yes Yes 
Vital Signs  2 604 25 Yes Yes 
Vital Signs  3 583 25 Yes Yes 
Vital Signs  4 555 25 Yes Yes 
Vital Signs  5 537 25 Yes Yes 
Vital Signs  6 514 25 Yes Yes 
Vital Signs  7 487 25 Yes Yes 
Vital Signs  8 524 25 Yes Yes 
Study Completion / Withdrawal   636 59 Yes Yes 
Study Population Definition  637 4 Yes Yes 
Study Medication   16424 22 Yes No 
Trough Levels   19473 18 Yes No 
Adverse Event   6619 31 Yes No 
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Opportunistic Infections   412 29 Yes No 
Non Opportunistic Infections   511 28 Yes No 
Concomitant Medication   29142 28 Yes No 
Biopsy / Rejection   867 36 Yes No 
Days of Hospitalization   1887 19 Yes No 
Unplanned Laboratory Analysis   252 143 Yes No 
Unplanned Virology   418 25 Yes No 
Unplanned Osteodensitometry   6 31 Yes No 
Comments  966 16 Yes No 
Laboratory Definition   27 14 No  
Normal Range   1525 22 No  
Centres  31 13 No  
Visits Coding  23 9 No  
Option Sets Coding  140 6 No  
Option Sets Definition  670 7 No  
Table 3. Tables of the Harmony database. 1P-1R denotes those tables with only one row per patient. 
Such data structures, with a high number of tables with thousands of elements each, are 
common in large clinical studies. The structure is determined by the method employed for the 
data collection, the electronic case report form (eCRF).40,49 At each visit of the Harmony study, 
the physician/study nurse had to fill a set number of eCRFs, including a reminder form 
interrogating on events between the visits and prompting the filling of other forms based on 
the responses. The data introduced in the eCRF (as well as the metadata of the responses) 
were cleaned by the Harmony consortium, becoming the Harmony database, which can be 
interpreted with help of a separate report detailing the contents of the eCRF. This database 
collects the whole bulk of information generated within the study – largely exceeding the goals 
of the clinical trial – making it an invaluable source of information for further studies on the 
cohort.  
The data is organized according to the unique patient identifier (PID). It is an unambiguous 
identifier for each patient, used throughout the Harmony database. The PID also contains the 
reference of the transplantation centre, allowing for an easy classification of the patients.  
The tables containing patient data are heterogeneous in their structure, as in some cases each 
patient is described in only one row (1P-1R), while other tables may contain more than one 
row per patient (1P-MR). The majority of the 1P-1R tables correspond to observations 
performed within the eight pre-programmed visits of the clinical study. The rest of the tables 
containing patient data correspond either to unplanned observations or to observations that 
can be potentially performed at any point in the study. The large majority of these are 1P-MR, 
with each row corresponding to a measurement performed at a different time point. Thus, to 
identify a row of a 1P-MR table unambiguously, one date variable is necessary, together with 
the PID identifier. Likewise, at least one date variable is included for most 1P-1R tables. As the 
date variables are defined independently for each table, differences between them are 
possible e.g. the Vital Sign and Laboratory Analysis tables may contain a different date for visit 
3 of patient 4900101. This is necessary for the correct annotation of observations performed 
at different dates but corresponding to the same visit and was central in the considerations 
for data management and cleaning of the e:KID study. 
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6.2.2 Design of the e:KID database 
For the database of the e:KID study, a radically different design was chosen, in order to 
accommodate the new data as well as the needs of the project. As explained in section 6.1, 
for the e:KID study a new longitudinal data set was generated using the samples collected 
during the eight visits of the Harmony study. These new data should be integrated with all the 
information from the Harmony database deemed relevant for achieving the goals of the e:KID 
study. The new data set had a substantially lower degree of complexity – it was largely 
quantitative and no variables were measured outside the pre-defined visits. These data were 
generated in an experimental setting, in contrast to the clinical setting of the Harmony 
database.  
The iterative workflow of e:KID, as well as the high number of data scientists who would 
employ the data set for the analyses required an easy-to-handle database. It was therefore 
decided that the database was to take the form of a single file in a standard format in order 
to make the data transmission within the consortium easier. This implies a series of design 
decisions that fundamentally affect the work with data. 
The first structural decision concerned the inclusion of study metadata, which explain the 
meaning of all measured variables. In this case, there were two main alternatives, either to 
create a detailed description in the form of a report, or to summarize the information as a 
secondary table in the main database file. The main advantage of the first option was the 
facilitation of the transmission of knowledge on the database, making it easier for an 
uninvolved data scientist to eventually analyse the results in the future, as was the case in the 
Harmony study and its eCRF report.  However, the second option was preferred, as it fitted 
better the goals of our project: Achieving a flexible, simple transmission of the data in a 
context in which several versions of the database are to be created.  
Figure 5. Two possible structures for the e:KID database. (A) The long table structure incorporates 
more than one row per PID and a visit variable. (B) The wide table structure incorporates one row per 
PID and several columns per measured variable, accounting for the different visits. 
A key question was the structure of the main database. Longitudinal data can be represented 
as a long table and a wide table (Figure 5).208 A long table contains each measured variable as 
one column, so that longitudinal measurements of the variable are shown as different rows; 
the wide table format represents each patient as one row, so that longitudinal measurements 
of each variable are shown as different columns of the table.208 Each structure has advantages 
and disadvantages. The long structure is much simpler to handle: It is easy to select the values 
of a variable for a concrete visit or the time course for one patient. On the other hand, non-
longitudinal data, such as the demographic information of the Harmony database, would have 
to be included as a second additional table or, alternatively as an additional visit of the main 
table, greatly complicating the data structure. Moreover, not all Harmony study variables 
A) 
PID Visit Variable 1 Variable 2 
4900101 1   
4900101 2   
4900101 3   
4900102 1   
 
B) 






4900101    
4900102    




were measured at the eight visits – for some variables (e.g. drug trough levels) there are even 
more available measurements. Lastly, the wide structure makes the iterative incorporation of 
new measurements in the database substantially easier, as the new measurements can just 
be added as additional columns at the end of the table. Because of all the referred reasons, a 
wide table format was elected as the basis for the e:KID database. 
The third structural issue that had to be addressed for the creation of the e:KID table was the 
handling of multiple date values referring to distinct collected samples and clinical 
observations, but pertaining to the same visit and patient. As explained above, the date of the 
clinical observations and sample collection in the Harmony database is defined separately for 
each table (in some tables there is even more than one date variable), so that there can 
potentially be different measurement dates for the same visit and patient. This feature of the 
Harmony database was elected to allow for more flexibility and precision in the recording of 
sampling times and clinical observations, as it is potentially possible that two medical 
examinations pertaining the same visit were performed on different days. In the e:KID 
database it would have been possible to collapse these dates into only one consensus date, 
allocating a single date to each visit. This would make analyses simpler due to the lower 
number of variables but would also imply a loss of information. Therefore, it was decided to 
keep the different dates in the database. 
Based among others on the outlined structural decisions, the database e:KID-DB-Basic was 
designed with the goal of optimizing data management. Simultaneously, scripts were 
developed for the adaptation of the e:KID-DB-Basic for use within the consortium. These 
scripts transform the large, difficult to handle wide table with multiple date variables into 
several smaller tables (e:KID-DB-Active). This working structure comprises one long table for 
each e:KID marker type (viral load, cytokine concentration, etc.) together with several long 
tables for events that are not associated with a visit (e.g. acute rejection events) and an 
additional table for the demographic characteristics of the cohort. The tables on the e:KID 
data were structured based on the visit number together with PID as the unique identifiers of 
each row; date variables were collapsed for the sake of simplicity as the median of all available 
dates of each visit. The scripts were designed in parallel to e:KID-DB-Basic using the data 
management and analysis software R, so that for every new version of e:KID-DB-Basic, a new 
version of e:KID-DB-Active would be generated. 
6.2.3 Data integration in the e:KID study 
In the e:KID consortium, data are integrated into the main database as an iterative process, 
so that analyses could be begun before all expected data have been measured and submitted. 
For the inclusion of new data, the experimentalists create a table in Excel or CSV format, 
ordering the data according to a sample number, PID, date of the measurement and visit. Data 
standards, such as the employed pre-processing methods and detection limits, are defined by 
the experimentalists according to their expertise and informing the data scientists. For 
example, in the case of the nuclear magnetic resonance spectra data, it was decided to include 
them after transformation through binning, in order to reduce the dimensionality of data; 
gene expression data were likewise normalized for three house-keeping genes.209,210 
Experimentalists also provide the data needed for the interpretation of the variables, which 
are then included in the metadata secondary table. Afterwards, the data scientists clean the 
data (for more details see section 6.3), consulting with the experimentalists in case of 
discrepancies, and adding the new data as additional columns to the existing database. 
Likewise, the selection of Harmony data to include in the e:KID database is operated as an 
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iterative process, so that different variables were included or excluded based on the changing 
demands of the partners.  
However, data integration is not seen as a task finished with the incorporation of newly 
generated data into the e:KID-DB-Basic; further data integration decisions can be taken based 
on the results of data analysis. Consequently, the same experimental data were in some cases 
incorporated in several different forms into e:KID-DB-Basic. For instance, viral load data were 
first included only as the raw measurements for each sample. But, as a result of the performed 
analyses on viral reactivations (see chapter 7), raw viral load data were transformed into 
categorical data classifying patients according to their peak viral load.211 These categorical 
data were incorporated as well to the database, as they are essential for the reproduction of 
the obtained results.211 Similarly, for antibody reactivity profiles, in the first versions of the 
database only mixed antigen bead results were included for the sake of simplicity. But as it 
became clear that raw single antigen bead reactivities can be employed for prediction of acute 
rejection (see chapter 9), it was decided to incorporate these data into e:KID-DB-Basic as 
well.130 
As a result of the above described database design and integration decisions, e:KID-DB-Basic 
was created as an R-Data object containing two tables: a main table containing 4651 variables 
in its current version and a description table with the description of these variables. There is 
as of July 2019 no final, locked version of the database; 16 versions of e:KID-DB-Basic have 
been generated and distributed to the e:KID consortium between November 2015 and March 
2019. In parallel, scripts for the conversion of the data into the working e:KID-DB-Active were 
generated. These databases and the scripts are the basis for the work of the consortium, 
including this dissertation. 
6.3 Data cleaning in the e:KID study 
The data cleaning process of e:KID-DB-Basic is especially interesting from a theoretical point 
of view, as it combines data from the cleaned and locked Harmony database, which – as all 
large databases – still contains errors and discrepancies, and newly generated data. Therefore, 
all cleaning approaches should encompass an examination and correction of both new and 
old data. In this section, I describe the data cleaning process of e:KID-DB-Basic based on the 
criteria of conformance, completeness and plausibility and my contribution to this process, 
employing paradigmatic examples and highlighting the importance of these corrections in the 
analyses performed as part of the manuscripts of this thesis.  
6.3.1 Improving conformance of the database 
Errors in the database can be detected and corrected based on the criterion of conformance 
(see sub-section 5.3.2). Following this criterion, a transplantation date in the year 3012, a 
second study visit 378 days after transplantation or a value of cytomegalovirus viral load of 
2.231234 copies·mL-1 can be replaced by year 2012, 13 days after transplantation and a viral 
load below detection limit, respectively. On the other hand, there are cases in which it is not 
possible to make an educated guess on the real value e.g. a negative concentration, leaving as 
the only option the deletion of the data point.  
In the case of e:KID-DB-Basic, the criterion of relational conformance was especially useful for 
data cleaning, due to its structural characteristics: As explained in sub-section 6.2.1, the data 
collected within Harmony at each one of the eight visits were recorded at several tables, each 
one containing at least one date variable. Therefore, for the same visit and patient, all date 
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variables should be the same or have a difference of a few days. Moreover, information on 
the date was also coded through the visit number as it implies a temporal frame (visit 1 is pre-
transplantation, visit 2 two weeks afterwards, etc.). This abundance of time-related 
information shall be referred here as quasi-redundancies: In e:KID-DB-Basic, these quasi-
redundancies were kept and further date variables were recorded for each newly measured 
marker. 
These quasi-redundancies in the database can be employed for the cleaning of e:KID-DB-Basic, 
as they provide multiple observations of the real data. However, data cleaning based on the 
relational conformance of the data cannot be based solely on the criterion of majority, as an 
error in one annotation at one Harmony table can be propagated if this variable is used as a 
reference in e:KID markers, becoming the most common in e:KID-DB-Basic. Therefore, data 
flows between variables have to be considered, prioritising independent and older 
observations over newer or dependent observations, i.e. date variables directly imported 
from the Harmony tables will be more accurate observations of the correct date compared to 
those in e:KID-DB-Basic.46,212 
Based on the principle of conformance, I performed a manual cleaning of all the data 
concerning viral loads in e:KID-DB-Basic. In total, I cleaned the data for 3330 samples and 3 
different variables, finding and resolving 360 inconsistencies regarding date and/or visit 
number of the measurement and detecting and removing 60 duplicated data entries from the 
database. These changes were incorporated into the 1.2. version of e:KID-DB-Basic, and were 
essential for the analyses of viral reactivations performed in two of the here presented 
manuscripts (chapters 7 and 8).211,213 
6.3.2 Management of missing data 
There was no single patient in the e:KID study with available measurements for all markers 
and visits (Figure 6). This is not surprising, and a large part of the missing values can be easily 
explained and do not introduce a bias into the data: Some marker types (e.g. cytokines and 
tolerance gene expression) were only routinely measured at visits one, two and five for a sub-
cohort (ACRS) of the study, in order to reduce the costs of the study. The ACRS sub-cohort was 
chosen to study the causes of acute cellular rejection and was composed by the patients who 
suffered rejection and a control group who had no serious adverse events. Therefore, the 
limitations were part of the study design and samples were measured using a uniform 
criterion, to ensure a high degree of completeness within the sub-cohort: These missing values 
do not imply a reduction of the statistical power for the sub-cohort, but rather a limitation in 




Figure 6. Representation of the data completeness in the e:KID study. Each row represents one 
patient of the study, ordered by PID, and each column a variable at a certain study visit. Missing values 
are represented as empty (white) cells; each measured marker type corresponds to a colour. The 
letters on the left side denote the (pseudonymized) study centres. Vertical grey lines delimit the 
marker types, while the black horizontal lines delimit the study centres. It should be noted that a 
coloured cell denotes only that at least one marker of the corresponding type was measured; for some 
marker types (e.g. cytokines or gene expression), not all markers were measured for all samples. Figure 
generated with Rodrigo Blázquez Navarro. 
For some centres, such as G and L, a reduced number of markers were measured if at all, due 
to low sample availability. Such cases of missing values do not necessarily suppose a bias in 
the results, they are missing (completely) at random (see sub-section 5.3.2) – it is unlikely that 
there is a relationship between outcome and centre and even in this case, the variation could 
be explained with observed variables. However, there is a large number of missing values that 
– if not carefully considered – may introduce a bias into data analyses: Variables measured in 
urine (IP10 and metabolomics spectrum) could only rarely be measured at the first visit for 
medical reasons; many data are missing at the later visits even for the most frequently 
measured markers, which is likely a consequence of these patients being lost to follow-up. 
As explained in the introduction (sub-section 5.3.2), when missing data are encountered that 
cannot be explained, the data flow has to be investigated, as in some cases the data have been 
in fact measured but have been lost during data collection or management and can be 
recovered.46 An example of break in data flow is the pre-transplantation blood pressure values 
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of the patients, which were missing in e:KID-DB-Basic. After detecting that these data were 
systematically missing for visit 1, I revised the Harmony database, finding that these data were 
part of the Harmony table “Physical Examination”, while the corresponding measurements for 
the rest of the study visits were in the tables “Vital Signs”. This difference in naming led most 
likely to the break in data flow, which was corrected in e:KID-DB-Basic version 1.15.  
Alternatively, in the cases a variable was never measured in a sample, the consortium was 
responsible for deciding whether these should be performed. For the cases in which they 
cannot or should not be measured, there are data pre-processing tools which can help 
increase the statistical power and reduce the bias of the analysis (see sub-section 5.3.3); the 
managing of missing data in the four manuscripts of this dissertation is described in sub-
section 6.4.4.  
6.3.3 Evaluating the plausibility of data with biostatistical methods 
As explained in the introduction (sub-section 5.3.2), the plausibility of data points can be 
assessed employing a large array of methods, including frequency and distribution 
analysis.46,47   
An illustrative example of the use of frequency analysis within the e:KID study is the cleaning 
of the Epstein-Barr viral (EBV) load data. These EBV load data were included for the first time 
in the version 1.8. of e:KID-DB-Basic. But I observed that these data were not plausible: While 
for the other viruses over three thousand samples were measured, in the case of EBV there 
were values only for 309 samples. Moreover, there was a surprisingly high prevalence of viral 
load over the detection limit (250 copies·mL-1) in the samples (63%), compared to BK virus 
(14%) and cytomegalovirus (5%), which are known to be similarly prevalent as EBV in the 
human population.214–216 I found the reason of these irregularities in conversation with the 
experimentalist who had generated the data: The coding employed for the calculation of the 
viral load generated an error message for loads below the detection limit, as it attempted to 
perform a division by zero; a value of zero was used to denote missing samples. This 
convention was not immediately evident: The error messages had been interpreted by the 
database manager as missing values and zero values as loads below detection limit. The data 
were therefore corrected in a new version of e:KID-DB-Basic. The new data on EBV showed 
that 3163 samples had been measured and a prevalence of viral load over detection limit of 
5% had been found – very similarly to cytomegalovirus. These corrected data were employed 
in our analyses of EBV viral reactivations performed in two of the here presented manuscripts 




Figure 7. Histogram of the distribution of five clinical variables at visit 8 from the e:KID-DB-Basic 
before cleaning. These variables were collected in the Harmony database and imported into the 
version 1.2. of e:KID-DB-Basic and correspond to the final study visit, one year after transplantation. 
Shaded is the interval corresponding to extreme outliers, defined by Tukey’s fences with k=3. Note 
that the y-axis is truncated at frequency 50 to make the outliers more easily identifiable. 
Statistical distribution analysis variables was also employed for the identification of 
implausible values. In Figure 7, the distribution of some clinical variables one year after 
transplantation is shown, as recorded in e:KID-DB-Basic 1.2. These clinical variables were 
originally measured within the Harmony study, cleaned and recorded in the table “Laboratory 
Analysis (Visit 8)”.  
As it can be observed in the figure, there were extreme outliers for white, red blood cells and 
C reactive protein; these could potentially be caused by typing errors or different units. An 
examination of centre effects revealed that the patients with extreme outliers were not 
grouped into one centre, thereby discarding a systematic difference in the units employed. 
While such high white blood cell counts and C reactive protein concentrations can be found in 
the literature, my discussions with the clinical laboratory revealed that the outliers in red 
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blood cell count are not biologically possible and were most probably due to an experimental 
error.217–219 Therefore, I proposed the removal from the database of the outliers in the red 
blood cell count, while the outliers of white blood cells and C reactive protein were kept in the 
database. 
The case of creatinine – a marker of kidney function – is especially interesting. There was a 
very large number of outliers and a bimodal distribution: The large majority of the patients 
(N=387, 87.4%) had a blood concentration below 10 mg·dL-1, while for the rest of the patients 
(N=56, 12.6%), concentration was over 30 mg·dL-1. Such a large difference strongly suggested 
that the data were in different units; the fact that 96.4% of the patients with creatinine over 
30 were transplanted in one centre (centre B) further supports this suspicion. Moreover, 
creatinine levels of 30 mg·dL-1 are not possible, as already a serum creatinine ≥4 mg·dL-1 
indicates the need of dialysis.220 My analyses showed that assuming these outlier 
concentrations were actually measured in μmol·L-1 (a widely used standard for creatinine 
levels) led to a normalization of the distribution (see Figure 8). The resulting distribution 
therefore supports the suspicion on the different units. These corrected creatinine data were 
essential for the analyses of renal function performed in two of the here presented 
manuscripts (chapters 7 and 8).211,213 
In the case of haemoglobin, a solution was not as evident, as in spite of the bimodality of the 
distribution, all individual values can be considered possible.221,222 However, there were strong 
centre effects, again for centre B: In this centre 100% (N=55) of the patients had haemoglobin 
levels ≤12 g·dL-1 (considered diagnostic for anaemia)221, while for the other centres the 
prevalence was of 37.2%. Therefore, I concluded that haemoglobin levels in centre B were 
measured in mmol·L-1, another standard unit. The results of the conversion can be observed 
in Figure 5; as it can be seen, the patients from centre B now distribute similarly to the rest of 
the population. The newly calculated data for haemoglobin concentration were therefore 
incorporated into e:KID-DB-Basic.  
 
Figure 8. Histogram of the distribution of creatinine and haemoglobin concentrations at visit 8 after 
cleaning. In green is depicted the distributions in patients from centre B, in blue the distribution for 
the rest of the cohort.  Shaded is the interval corresponding to extreme outliers, defined by Tukey’s 
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fences with k=3. As it can be observed, the patients from centre B are now distributed similarly to the 
rest of the cohort. 
These examples show the opportunities and limitations of the methods based on examination 
of statistical distributions. While they can be performed very fast and without special clinical 
knowledge, decisions cannot be taken solely based on the statistical distribution: The same 
phenomenon, i.e. extreme outliers, has a different interpretation for red blood cell counts as 
for C reactive protein or creatinine concentration. They also highlight how many mistakes in 
clinical databases are not typographic, but rather the result of employing different 
conventions (units, coding, etc.). In this case, for multi-centric studies it is useful to explore 
systematic centre-associated differences, even if all values are in the range of possible, as in 
the case of haemoglobin. In summary, these examples demonstrate that a basic 
understanding of the clinical values, their expected distribution, the different employed 
standards and their information flow is paramount to any data cleaning based on the 
examination of statistical distributions. 
6.4 Data pre-processing in the e:KID study  
Often data cannot be employed in the state in which they are contained in the e:KID-DB-Basic: 
Some raw variables are of difficult use and require pre-processing. This pre-processing is 
different from data cleaning, as it is context-dependent: It does not suppose the correction of 
errors, as the values are (supposedly) correct per se, but rather the adaption of the values for 
a concrete data analysis procedure. Therefore, the results from data pre-processing do not 
necessarily lead to the generation of a new version of e:KID-DB-Basic but result in changes in 
the database e:KID-DB-Active for data analysis. In this section, I will address some examples 
pre-processing of the e:KID data necessary employed in data analysis, including management 
of missing data. 
6.4.1 Generation of new variables for data analysis 
The requirement of pre-processing variables for their ulterior use in analysis can be due to 
different causes.  One common case is that of variables not explicitly collected because they 
can be easily calculated using other data. This is the case for e.g. body mass index and EBV 
mismatch (a function of donor and recipient serostatus). These newly calculated variables 
should not be included in the main database e:KID-DB-Basic, as they would constitute a 
redundancy, unnecessarily increasing the size of the database and the probability of 
introducing new errors. Nevertheless, since they were needed for data analysis, they are 
automatically calculated in the scripts generating e:KID-DB-Active. 
Often more than one measurement of the same variable for the same patient and time point 
can be found in the database. These are replicates, which can be used to monitor the precision 
of an experiment.223 In the e:KID-DB-Basic 1.7., for example, two replicates (measured at two 
different time points) for cytomegalovirus (CMV) viral load were included. A total of 728 
measurements (23.4%) were replicated, for which the majority (96.7%) showed a small 
difference in the results of the replicates (<500 copies·mL-1). As the precision of these 
measurements is comparable, the average was used for data analysis and was included as a 
new variable in e:KID-DB-Active. However, this did not seem an adequate solution for the few 
cases with very large differences (e.g. sample 805 had 19114 copies·mL-1 in the first replicate 
and no detectable viral load in the second). Therefore, in conversation with the 
experimentalist responsible for the measurements, it was decided to measure these 
discrepant values a third time: 32 samples – including both discrepant and non-discrepant 
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viral loads – were re-measured. The average of all three replicates is inappropriate for the 
analysis of discrepant data, as it takes into account values that differ extremely from the other 
two: Therefore, from that point on, the median was employed as the reference variable for 
data analysis of CMV reactivations (chapters 7 and  8).211,213 
6.4.2 Statistical transformation and normalization of variables 
In the e:KID study, a mixed approach was taken for the statistical transformation of variables: 
Part of the data had to be transformed before their integration in e:KID-DB-Basic, e.g. 
metabolomics and gene expression data (see sub-section 6.2.3). However, most data are 
included in the raw state, leaving the possibility open for different transformations that are 
adequate for the use in the analysis approaches.  
An example of the importance of variable transformation can be found in our manuscript on 
predictive antibody profiles for acute cellular rejection, which is part of this doctoral thesis 
(chapter 9).130 Binding interactions of serum antibodies with HLA antigens were measured as 
a list of quantitative variables, which denote the intensity of binding for each antigen.130 But 
conventional methods employed to predict acute rejection require a binary value (presence-
absence of binding) of the binding interactions.224–230 However, it is controversial how the 
binarization of the data should be calculated – some authors favour a fixed threshold, while 
others prefer an individual threshold for each patient.130,231 Moreover, a binarization of the 
data necessarily leads to a loss of information on the strength of the interactions. Therefore, 
in this manuscript we investigated the influence of the data transformation method on the 
quality of prediction of acute rejection, comparing the performance of raw data, normalized 
quantitative data and binarized data.130 Our results showed that quantitative, normalized data 
had the best performance employing the P-SVM machine learning algorithm.62,130 This 
demonstrates the central importance of data transformation for the obtaining of satisfactory 
results. 
6.4.3 Dealing with strong centre effects: The case of GFR 
A particularly relevant case of variable with a strong centre effect was the glomerular filtration 
rate (GFR). GFR is an estimation of renal function and is widely employed both in the clinic and 
in research.232 It is calculated using the serum creatinine concentration and the demographic 
characteristics of the patient, employing different formulae.233–235 After examining the data 
distribution of GFR, I observed very strong differences between centres, with centre O having 
significantly higher GFR values. A large part of the variation stemmed from the fact that two 
different formulae were employed in Harmony: MDRD-IV and Cockcroft-Gault.234,235 The 
reason for this is that GFR is an important decision tool in the clinic – it is recommendable for 
a good patient outcome that physicians work with the standard they have experience on. To 
avoid confusions, the formula employed for each calculation was recorded in the Harmony 
database. However, the results of MDRD-IV and Cockcroft-Gault are not comparable: They 
employ different units and have a slightly different biological meaning (Cockcroft-Gault is 
considered rather an estimation of creatinine clearance).234–236 Furthermore, there were 
additional differences in the way in which each centre calculates the GFR, as some centres cap 
all values below or above a certain threshold, based on their clinical experience.  
Because of all this, we decided to avoid centre effects in the GFR calculation by recalculating 
it centrally for all samples, based on the available data collected in the Harmony study. 
Additionally to MDRD-IV and Cockcroft-Gault, the newer CKD-EPI formula for the calculation 
was employed (see Figure 9) for a comparison of the results with the centre GFR values). 
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232,234,235 The GFR calculated through all three formulae was incorporated into e:KID-DB-Basic 
1.14; we employed the CKD-EPI formula as the reference for data analysis in two of the 
manuscripts presented in this doctoral thesis (chapters 7 and 8), as it has been shown to be 
the most accurate formula.232,236 
 
Figure 9. Comparison of the newly calculated GFR values with the values in the clinical for all 
samples. The colour and point type denote the (pseudonymized) centre where the sample was 
collected. No units are given for the original GFR, as it is a mixture of values calculated in mL·min-
1·1.73m-2 (MDRD-IV) and mL·min-1 (Cockcroft-Gault). As it can be observed, most values correlate 
linearly with the newly calculated GFR; the clearest exception was centre O, which was the only one 
employing exclusively Cockcroft-Gault. Note the capping of the GFR values in centres F (≥60), H (≤20) 
and J (GFR≥80). 
However, it should not be assumed that the newly calculated GFR is free from centre effects: 
The variable still relies on the serum creatinine concentrations measured at each 
transplantation centre, so that protocol differences between centres may introduce a bias. 
Moreover, the variable can be influenced by differences in patient demographics and 
management between the centres. Because of this – especially for studies seeking to identify 
a causal relationship between a factor and GFR – the variation introduced by centre effects is 
to be taken into account into the study. This was the case in our manuscript on the differences 
in outcome between two different therapeutic strategies (see chapter 8).213 
6.4.4 Working with variables with missing values 
While in other analyses performed within the e:KID study imputation was essential for the 
analyses, it was not needed in any of the four manuscripts of this doctoral thesis; missing 
values were handled depending on the data analysis methods, as well as on the study 
design.130,211,213,237 The reason for that was based on methodological considerations, as well 
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as on data completeness. Here, I will shortly describe how missing values were taken into 
account into the design of our work. 
In our two manuscripts employing biostatistical methods (chapters 7 and 8), the effects of 
missing data had to be considered in the analysis.211,213 In these manuscripts, the glomerular 
filtration rate (GFR) was the main outcome variable, and its distribution for patients with 
different viral reactivation history or different therapeutic strategies was compared.211,213 As 
the loss of patients to follow-up increases the number of missing GFR values in the later visits 
of the study, the statistical power of the GFR comparison one year after transplantation was 
reduced.211,213 However, the statistical effect was high enough to observe significant effects 
for conditions associated with a 20% reduction of median GFR.211,213 Moreover, the risk of bias 
in the analyses introduced by missing values was reduced, as all analyses were run taking into 
account the entire GFR time course, from the second visit (in which missing values are very 
reduced).211,213  
While imputation of missing values is often performed in machine learning methods, it was 
not necessary in the case of our manuscript (chapter 9): Only half of the patients of the sub-
cohort had available measurements, but these measurements had no missing values.130 Lastly, 
missing values were not considered in our manuscript on mathematical modelling of the 
immune system (chapter 10) due to the analysis method.237 Each patient time course was 
modelled individually at different time points, therefore the modelling approach explicitly 
estimates all values between the available measurements.237 For this estimation it is 
indifferent whether there is an available measurement x days after transplantation for all 
patients, the critical factor is rather the frequency of the available measurements.  
These examples from our work demonstrate that there is no “one-size-fits-all” strategy for the 
handling of missing data.55,57,58 We employed only available data for the analysis, and while 
imputation strategies were considered, they were not deemed adequate due to their intrinsic 
uncertainty.  However, for further, future works (such as the search of predictive markers for 
viral reactivation) employing a large number of markers and patients, imputation might prove 
to be an adequate and useful strategy for the handling of missing values. In summary, the 
strategies have to take into account the goals and methods of the analysis, as well as the 
number of available measurements, the evidence of possible bias due to missing data not at 
random and the practical possibility of data imputation.  
6.5 Lessons learned from data management at the e:KID study  
Data management in the e:KID study has been and is a complex endeavour: Two different data 
sets are integrated into the study, including an older, cleaned and locked clinical database and 
newly generated, heterogeneous study data. These data are measured, integrated, cleaned 
and analysed in an iterative process; to this day, new data are still being generated, including 
the acquisition of long-term follow-up data of the patients. Likewise, the structure of the data 
science team, working at different partners but centrally organized, requires a high degree of 
communication and coordination that is not easily attainable. The size of the consortium, with 
ten different partners from the clinic, academia and industry, adds up to the complexity of the 
study, as these partners have patently different preferences and expertise: All these research 
focuses have to be harmonized and taken into account into the data management process. 
While there are formal education programmes on data science and data management in 
particular, these programmes cannot cover the increasing demand for data scientists.44,238 
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Because of this, many data scientists have no formal training and learning is based on the 
experience of peers and the personal, practical experience. This was also my case. 
Here I present a summary of my personal experience working at e:KID in form of some 
practical advice on data management:  
1. Design your data management for the study you wish. While generic solutions seem 
like an easy way out for database design, integration and cleaning, they can make the 
process more error-prone. A deep understanding of the study goals and the expected 
data is necessary to guide data management in a successful way.     
2. A standard is useless if you are the only one who knows it. Data integration cannot be 
performed without standards that have been previously agreed with the 
experimentalists, in order to avoid confusions in how the results should be 
interpreted. Ideally, these standards should be established before experiments are 
performed. 
3. When in doubt, go to the original source. All former versions of the data are to be 
kept, especially as submitted by the experimentalists. Tracking the data flow is 
essential for correcting mistakes occurring during data management. 
4. Possible does not mean plausible. The definition of thresholds does not suffice for the 
detection of anomalous data, as errors can also manifest as inliers. The distribution of 
the data as a whole has to be considered: An analysis of the differences between 
centres can be of use. 
5. An image is worth a thousand tests. Data visualization is essential for achieving a deep 
understanding of the data and to notice patterns that would stay unrecognized 
otherwise; it can help to detect implausible data distributions and outliers better than 
any statistical test. 
6. Understand the experiments as if you had done them yourself. Data integration and 
cleaning cannot be performed without knowledge of the experimental procedures 
and the underlying physiology. It is not enough that the experimental and clinical 
partners have this knowledge: The data managers need broad, interdisciplinary 
knowledge to work on the data. 
7. Always talk to the people. Even if the data managers have a broad knowledge of the 
physiological processes and the experiments, the clinicians and experimentalists know 
better and can help them make informed decisions on the data. 
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7. BKV, CMV, and EBV interactions and their effect on graft function 
one year post-renal transplantation: Results from a large multi-
centre study 
This chapter refers to the manuscript published as: 
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, Westhoff TH, 
Sawitzki B, Reinke P, Thomusch O, Hugo C, Or-Guil M and Babel N (2018). BKV, CMV, and EBV 
Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results 
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Background: BK virus (BKV), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations are common
after kidney transplantation and associated with increased morbidity and mortality. Although CMV might be a
risk factor for BKV and EBV, the effects of combined reactivations remain unknown. The purpose of this study
is to ascertain the interaction and effects on graft function of these reactivations.
Methods: 3715 serum samples from 540 kidney transplant recipients were analysed for viral load by qPCR. Mea-
surements were performed throughout eight visits during the first post-transplantation year. Clinical character-
istics, including graft function (GFR), were collected in parallel.
Findings: BKV had the highest prevalence and viral loads. BKV or CMV viral loads over 10,000 copies·mL−1 led to
significant GFR impairment. 57 patients had BKV-CMV combined reactivation, both reactivations were signifi-
cantly associated (p= 0.005). Combined reactivation was associated with a significant GFR reduction one year
post-transplantation of 11.7 mL·min−1·1.73 m−2 (p = 0.02) at relatively low thresholds (BKV > 1000 and
CMV> 4000 copies·mL−1). For EBV, a significant association was found with CMV reactivation (p= 0.02), but
no GFR reduction was found. Long cold ischaemia times were a further risk factor for high CMV load.
Interpretation: BKV-CMV combined reactivation has a deep impact on renal function one year post-
transplantation and therefore most likely on long-term allograft function, even at low viral loads. Frequent
viral monitoring and subsequent interventions for low BKV and/or CMV viraemia levels and/or long cold ischae-
mia time are recommended.
Fund: Investigator Initiated Trial; financial support by German Federal Ministry of Education and Research
(BMBF).









EBioMedicine 34 (2018) 113–121
⁎ Correspondence to:Michal Or-Guil, Systems Immunology Lab, Department of Biology,
Humboldt-Universität zu Berlin, Philippstr. 13, 10115 Berlin, Germany
⁎⁎ Correpondence to: Nina Babel,Medical Department 1, Universitätsklinikumder Ruhr-
Universität Bochum, Ruhr-Universität Bochum, Hölkeskampring 40, 44625 Herne,
Germany
E-mail addresses: m.orguil@biologie.hu-berlin.de (M. Or-Guil), nina.babel@charite.de
(N. Babel).
1 Corresponding authors contributed equally to this work.
https://doi.org/10.1016/j.ebiom.2018.07.017
2352-3964/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.com
48
1. Introduction
Viral reactivations are a major cause of morbidity and mortality for
recipients of solid organ transplantation [1]. In kidney transplantation,
BK virus (BKV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV)
are major pathogens. These viruses are very common in healthy
population, with an approximate prevalence of 80%, 60%, and 90%, re-
spectively [2–4]. Primary infection usually occurs during childhood,
but the virus stays latent and asymptomatic under normal conditions
[5,6]. Individuals with compromised immune systems, i.e. after a solid
organ transplantation, are prone to both primary infection and
reactivations with clinically relevant symptoms [7,8].
BKV is an emerging pathogen and the cause of BKV-associated ne-
phropathy (BKVAN), a major complication in renal transplantation [6].
It is linked to kidney malfunction and rejection, leading to graft loss in
up to 60% of affected patients [6,8,9]. The incidence of BKVAN is 1–10%
in renal transplantation [10]. BKVAN is usually encountered in a context
of over-immunosuppression, even though it is not associated with a
specific immunosuppressive drug [9,11,12]. Early diagnosis is vital for
a successful treatment, but BKVAN progression occurs without clinical
signs except for increasing serumcreatinine concentrations and diagno-
sis relies on renal biopsy [9,11]. However, BKV serum load over 10,000
copies·mL−1 is a generally accepted surrogate marker defining
“presumptive BKVAN” [11].
CMV is a major viral pathogen after kidney transplantation, linked
among others to retinitis, pneumonitis, colitis, encephalitis and impor-
tantly, allograft damage, allograft loss and death [5,8,13,14]. CMV prolif-
eration may occur through reactivation of a latent infection, a new
donor-transmitted infection or acquired from the general population
due to the immunosuppression [13]. However, the highest risk is
encountered by CMV seronegative patients receiving a transplant from
a seropositive donor (D+R−) [13]. EBV in kidney transplantation is
mainly associated with post-transplant lymphoproliferative disorders
(PTLD) [5,7]. PTLD is a severe complication in solid organ transplanta-
tion, occurring in around 1% of patientsmostly after the first post-trans-
plant year [7,15,16]. It comprises a very broad spectrum of disorders,
from spontaneously regressing to lethal B cell proliferations [4,7].
In this work, we assess the impact and relevance of BKV, CMV, and
EBV reactivations in a large, prospective multi-centre study, analysing
renal transplant in clinical follow-up during the first year after trans-
plantation. Our work focuses on potential interactions between viruses
and their combined impact on graft function, as well as the risk factors
associated with each virus, including the role of immunosuppressive
therapy.
2. Patients and Methods
2.1. Patient Population
We conducted a sub-study within the randomized, multi-centre, in-
vestigator-initiated Harmony trial (NCT 00724022) [17] to prospective-
ly monitor viral load of BKV, CMV, and EBV at predetermined eight
study visits and correlate it with clinical outcomeparameters. Following
the KDIGO clinical guideline, BKV viral load monitoring was performed
in serum rather than urine, as the former has a higher BKVANdiagnostic
value [18,19]. Viral monitoring was non-interventional and centrally
performed. The study was carried out in compliance with the Declara-
tion of Helsinki and Good Clinical Practice. A total of 540 patients under-
going kidney transplantation between 08/2008 and 11/2012 were
analysed (Fig. 1).
2.2. Patient Medication
Patients were randomized to one of three therapeutic groups, as
described before [17]. The immunosuppressive therapy included induc-
tion with either monoclonal IL-2R antibody basiliximab (arms A and B)
Research in context
Evidence Before this Study
Viral reactivations of BK virus (BKV), cytomegalovirus (CMV), and
Epstein-Barr virus (EBV) are common complications in recipients of
renal transplantation. Combined reactivations of these viruses have
been observed repeatedly in the past and interplay between BKV
andCMVhasbeenshown in vitro.Different interactionmechanisms
have been proposed. However, it is currently unclear whether there
are associations in viral reactivations in vivo.Moreover, it is not clear
so farwhat is thecauseof suchcombined reactivationsandwhether
combined reactivations have more serious impact on graft function
than the corresponding mono-reactivations. To obtain information
on the state-of-art, we searched MEDLINE, PubMed, and Google
Scholar for papers published after January 2003, using the terms
“renal transplantation BKV”, “renal transplantation CMV”, “renal
transplantation EBV”, “coinfection BKV CMV”, “coinfection BKV
EBV”, “coinfection CMV EBV”. No language restrictions were
employed. The quality of evidence was assessed prioritizing epide-
miological studies over case reports and in vitro studies.
Added Value of this Study
This is the first large, prospectivemulti-centre study to systematical-
ly analyse the clinical course of BKV,CMV, andEBV reactivations at
eight pre-defined time points during the first post-transplantation
year. Almost ten thousand viral load measurements were per-
formed. It is the first study to provide clinical evidence of the rele-
vance of BKV-CMV combined reactivations, showing, already at
moderateviral loads (BKV>1000andCMV>4000copies·mL−1),
an impact on renal functiononeyear post-transplantationwith ame-
dian drop in renal function of 11.7 mL·min−1·1.73 m−2. This obser-
vation is reinforced by the fact that a significant association was
found between BKV and CMV during the first post-transplantation
year. Moreover, it is the first large study to find an association be-
tween cold ischaemia time and high level CMV viral load: High-
level CMV (>10,000copies·mL−1)was associatedwith significant-
ly longer cold ischaemia time for cadaveric graft (median difference:
284 min), compared to patients without CMV or CMV below the
threshold. Furthermore, this study shows BKV as themost relevant
viral adverse event in kidney transplantation, as it had the highest
prevalence, the highest viral loads and lowest clearing rate. Our re-
sults have revealed a prevalence of presumptive BKV nephropathy
of 10.9% (over the 1–10% prevalence in the literature), in spite of
the patients belonging to an immunological low-risk cohort. In con-
clusion, it is a confirmation that BKV is an emergent pathogen that
must be tackled in order to improve the efficacyof current transplan-
tation protocols.
Implications of All the Available Evidence
Wehaveprovided themost systematic analysis so far ofBKV,CMV,
and EBV virus reactivations in renal transplantation, as part of a
large, prospective multi-centre study. Their viral loads were
analysed at eight time points during the first transplantation year.
With our results, we showed a clinical impact of BKV-CMV
combined reactivation, even at low viral load levels. In addition,
weperformed in-depthanalysesof the impactofdifferentmodifiable
and non-modifiable risk factors on virus reactivation. Therefore, we
consider our work as crucial for the management of viral
reactivations after kidney transplantation, leading to a better moni-
toring and treatment for kidney transplantation patients with BKV
and/orCMVlowviral loads, aswell aspatientswith longcold ischae-
mia times and additional CMV risk factors.
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(Simulect®, Novartis) or rabbit ATG (arm C) (Thymoglobulin®, Sanofi).
Maintenance immunosuppression consisted of tacrolimus (Advagraf®,
Astellas) and mycophenolate mofetil (MMF) with (arm A) or without
steroids (arms B and C). Patients with mismatch-based risk (seronega-
tive recipient and seropositive donor) for CMVor EBV aswell as patients
fromarmC received at least a 3 months prophylaxiswith valganciclovir.
2.3. Patient Monitoring
Patients were monitored for creatinine along eight visits, scheduled
at day 0 (pre-transplantation), 2nd week, 1st month, 2nd month, 3rd
month, 6th month, 9th month, and 12th month. Glomerular filtration
rate was calculated using the CKD-EPI formula; values are given in
mL·min−1·1.73 m−2 [20]. Tacrolimus blood trough levels were
measured independently of the eight visits described above, according
to the internal study centre standards. Suspected episodes of acute
rejection had to be confirmed through biopsy; histologic characteristics
were described according to the Banff criteria of 2005 [21]. Routine
surveillance biopsieswere allowed but notmandatory. Borderline rejec-
tions were disregarded in the analysis.
2.4. Screening of BKV, CMV, and EBV Viraemia
Peripheral blood samples from the eight visits were centrally moni-
tored for BKV, CMV, and EBV by TaqMan quantitative polymerase chain
reaction (qPCR), as described previously [19]. Briefly, DNA was isolated
Fig. 1. Trial profile.
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from serum (BKV) or whole blood (CMV and EBV) using a QIAampDNA
Mini Kit (Qiagen Corp, Hilden, Germany) according to the
manufacturer's instructions. PCR was based on the TaqMan platform
and used the Prism 7700 Sequence Detector (ABI). In the case of BKV,
PCR amplificationswere set up in a reaction volumeof 25 μL using prim-
er and probe at final concentrations of 900 nM and 5 μM [19]. Primers
and probe were designed to amplify the VP1 gene [19]. CMV and EBV
were amplified using the same protocol; primers and probe sequences,
as well as reagent concentrations are shown in Table 1. The detection
level was the lowest viral load measured within the range of linearity.
2.5. Clinical Management of BKV, CMV, and EBV
BKV, CMV, and EBV reactivations and disease were monitored ac-
cording to intern centre standards. qPCR (and/or pp65 CMV
antigenemia tests) and symptom monitoring were performed. Viral
loads over 10,000 copies·mL−1 for BKV and over 1000 copies·mL−1
for CMV and EBV were considered clinically relevant. Reactivations
were treated based on centre internal standards. According to the
study protocol, suggested treatment included a reduction of the total
immunosuppression e.g. reduction of tacrolimus and MMF dose. For
CMV, patients would receive additionally a (val)ganciclovir treatment
for three weeks according to local standards, followed by
(val)ganciclovir prophylaxis for, at least, four weeks. After reactivation,
patients were regularly monitored for viral load, first weekly, than
monthly and then three-monthly until the end of the study.
2.6. Viraemia-Based Patient Classification
Patientswere classified based on their peak viral load values for BKV,
CMV, and EBV during follow-up (Table 2). Patients with viral loads over
detection level were classified as BKV+, CMV+, or EBV+. Patients of the
former group with, at least, one measurement over 2000 copies·mL−1
were classified as elevated viraemia (eBKV, eCMV, and eEBV); patients
with viral load over 10,000 copies·mL−1 were classified as high-level
viraemia (hBKV, hCMV, and hEBV). Altogether, patients were classified
into up to nine overlapping groups.
2.7. Statistical Analysis
Qualitative variables were described using counts and frequencies
and compared using Pearson's chi-square test with continuity correc-
tion (unless otherwise stated), odds ratio (OR) and 95% confidence in-
tervals (95%CI) are provided. Quantitative variables are described as
median and interquartile range (IQR). The differences between contin-
uous variables are analysed using the Mann-Whitney test. Three-di-
mensional contingency tables are reduced to two dimensions
(flattened) for chi-square test analysis, iteratively controlling for each
one of the three variables; average of the three obtained p values is
given. A cut-off of 0.05 for the p value was used on all tests to discard
or confirm significant associations. Analyses were performed with R
(Version 3.1.1).
2.8. Statistical Analysis of Immunosuppressant Usage
The relation between immunosuppressant usage (MMF daily dose
and tacrolimus trough levels) and viral reactivations was analysed by
comparing the usage between patients with reactivation (sample) and
patients with no viral reactivation (control).
In detail, the analysis was performed as follows: The sample group
was defined as the patients with viral load for the virus v over a thresh-
old th at any visit, while the control group were all patients with no re-
activation for virus v. Monitoring of drug usage was performed for the
sample group at the first visit with reactivation over th, and for the con-
trol group for randomly selected visits so that the analysed visits have
the same frequencies as in the sample group and that each patient is
taken into account only once. For MMF daily drug dose, the dose at
viral load monitoring was compared, for tacrolimus trough levels the
last measurement before monitoring visit was considered. Only viral
reactivations occurring after transplantation were considered.
Mann-Whitney test with 100 replicates was employed for the com-
parison, with the null hypothesis that drug usage in the sample group
was not higher than in the control group. A difference was considered
significant if the null hypothesis was rejected (p < 0.05) for at least
80% of the replicates. Statistics of drug usage are given as the median
over all replicates of the median and IQR of the sample and control
groups, as well as median p value.
2.9. Role of the Funding Source
The trial was designed and run by NB, who received financial sup-
port from the German Federal Ministry of Education and Research
(BMBF). The funders had no role in data collection, data analysis, data
interpretation, or writing of the manuscript. ABN, CH, MO, and NB had
full access to all study data and had final responsibility for the decision
to submit for publication.
3. Results
3.1. BKV Is the most Relevant Viral Reactivation in Renal Transplantation
Recipients
A total of 3715 blood samples from 540 patients (18 centres) were
analysed for BKV, CMV, and EBV. Detection limit (DL) was 250
copies·mL−1. Demographic and clinical characteristics of the patients
are shown in Table 3. Prevalence, viral load, temporal sequence and
Table 1




5′-CTG CGT GAT ATG AAC GTG AAG G-3′ 300 nM
CMV Reverse
primer
5′-GCT GTT GGC GAA ATT AAA GAT GA-3′ 900 nM
CMV Probe 5′-CGC CAG GAC GCT GCT ACT CAC GA-3′ 5 μM
EBV Forward
primer
5′-TCC CGG GTA CAA GTC CCG-3′ 900 nM
EBV Reverse
primer
5′-TGA CCG AAG ACG GCA GAA AG-3′ 900 nM




Summary of viraemia-based patient classification sub-groups.
Abbreviation Definition Threshold












eBKV Elevated BKV viral load for at least one visit >2000 copies·mL−1
eCMV Elevated CMV viral load for at least one
visit
>2000 copies·mL−1
eEBV Elevated EBV viral load for at least one visit >2000 copies·mL−1
hBKV High-level BKV viral load for at least one
visit
>10,000 copies·mL−1
hCMV High-level CMV viral load for at least one
visit
>10,000 copies·mL−1
hEBV High-level EBV viral load for at least one
visit
>10,000 copies·mL−1
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recurrence are presented in Table 4 and Fig. 2. Overall, BKV was the
most relevant reactivation,with the highest prevalence, viral loads, inci-
dence of prolonged reactivations and the lowest rate of clearing: 260 of
the patients (48.1%) were BKV+ (see Viraemia-based patient classifica-
tion section), 121 (22.4%) were eBKV and 59 (10.9%) were hBKV; 109
(20.2%) patients had prolonged viraemia; median viral load peak
valuewas1505 [779–8452] copies·mL−1 and rate of clearingwas 80.5%.
3.2. Elevated CMV Is Significantly Associated with Higher Cold Ischaemia
Time
Demographic and clinical characteristics were analysed univariately
for associationwith each one of the nine viraemia groups (Table 5). Fol-
lowing characteristics were analysed: sex, age, body mass index, donor
type, number of previous transplants, EBV and CMVdonor and recipient
serostatus andmismatch-associated risk, and cold ischaemia time. CMV
donor seropositivity was significantly associated with CMV reactivation
for all three thresholds, as was CMVmismatch-associated risk. Interest-
ingly, CMV mismatch-associated risk was similarly associated with
eEBV. eEBV was also associated with CMV recipient seronegativity,
CMV mismatch-associated risk and EBV mismatch-associated risk. Fi-
nally, we found a relation between CMV and cold ischaemia time for pa-
tients with cadaveric transplants: this difference was observed for both
eCMV and hCMV, with increasing difference for higher viral loads. For
BKV, no significant differences were found for any of the three
thresholds.
3.3. CMV Reactivation Is Significantly Associated with BKV and EBV
We examined the association between the reactivations, including
pair-wise analyses (Fig. 3). 13 patients (2.41%) had viraemia over DL
for all three viruses. The association was significant (average p =
0.0021); the number of triple-infected patients was 45% higher than ex-
pected for no association.
Therewas a highly significant association between BKV and CMV for
all three thresholds: BKV+-CMV+(p = 0.0052; OR = 1.97, 95%CI =
1.24–3.11), eBKV and eCMV (p = 0.0216; OR = 2.33, 95%CI = 1.18–
4.60) and hBKV and hCMV (Fisher's exact test: p = 0.0016; OR =
5.75, 95%CI = 1.80–17.0). There was a significantly higher number of
sera positive for both virus (p = 0.0145; OR = 1.72, 95%CI = 1.13–
2.62). There was no clear temporal pattern: 45.6% had detectable BKV
before CMV, and 33.3% had CMV before BKV.
CMV and EBV were also significantly associated for CMV+-EBV+ (p
= 0.0237; OR= 1.85, 95%CI = 1.11–3.08) and for eCMV-eEBV (Fisher's
exact test: p = 0.0416; OR= 2.76, 95%CI = 1.05–7.08) – there were no
hCMV-hEBV patients. There was a significantly higher number of sera
simultaneously positive for both virus (p = 0.0193; OR = 2.07, 9%CI
= 1.17–3.69). EBV preceded CMV in 51.9% of cases and was observed
after CMV in 29.6%.
There was no significant association between BKV and EBV.
3.4. CMV Serostatus Is the Only Demographic Characteristic Associatedwith
Combined Reactivations
Weanalysed thedifferences of demographic and clinical characteris-
tics for combined reactivations with respect to the rest of patient popu-
lation. BKV+-CMV+ was associated with CMV seropositivity of donor
(p < 0.00001; OR = 5.34, 95%CI = 2.37–12.0) and CMV mismatch-
based risk (p = 0.0001; OR = 3.02, 95%CI = 1.72–5.30); eBKV-eCMV
was associated with CMV mismatch-based risk (p = 0.0278; OR =
3.64, 95%CI = 1.24–10.7). CMV+-EBV+ was likewise associated with
CMV seropositivity of donor (p = 0.0127; OR = 3.97, 95%CI = 1.35–
11.6).
3.5. Therapy Arm Was Not Associated with Elevated or High-Level Viral
Loads
EBV+ was significantly associated with immunosuppressive regi-
men (p = 0.0303): Arm C (ATG and rapid steroid withdrawal) had a
higher EBV+ prevalence (p= 0.0225; OR= 1.69, 95%CI = 1.10–2.60).
Interestingly, the lowest EBV+ prevalence was found in arm B
(basiliximab and rapid steroid withdrawal) (p = 0.0432; OR = 0.59,
95%CI = 0.37–0.96). This effect was not found for higher viral load
thresholds. There were no significant differences between therapeutic
arms for BKV or CMV or their combinations.
Table 3
Patient demographic and clinical characteristics, treatment details and transplantation
outcomes. Data are given in number (percentage) or median (interquartile range) and
range.
Variable Measurement Total (N =
540)
Male sex 346 (64.1%)
Age (years) Median (IQR) 56 (45–64)
Range [19, 75]
BMI (kg m−2) Median (IQR) 25.8
(23.2–29.0)
Range [16.2, 49.1]
Living donor 66 (12.2%)
Second transplantation 22 (4.1%)
Cold ischaemia time: only cadaveric donors
(min)
Median (IQR) 660 (488–880)
Range [35, 1712]
Average MMF daily dose (mg·day-1) Median (IQR) 1505
(1058–1990)
Range [0–3994]
Average tacrolimus trough level (ng·mL-1) Median (IQR) 9.5 (8.5–10.5)
Range [5.5, 27.0]
Graft loss one year post-transplantation 22 (4.1%)
Death one year post-transplantation 16 (3.0%)
Graft survival one year post-transplantation 504 (93.3%)






Viral reactivation statistics. Data are given in number (percentage) or median (interquartile range) and range. The percentages of the first four categories refer to the total number of pa-
tients (N= 540). For the clearing statistics, the percentage corresponds to the ratio of: number of patientswith detectable viraemia (at least once between visits 1 and 7) andwith no viral
load in the eighth visit (clearedpatients), and the total number of patientswith detectable viraemia; patientswhodid not have viral loadmeasurements at the last time point (visit 8)were
excluded from the analysis.
BKV CMV EBV
Patients with detectable viraemia (>DL) 260 (48.1%) 92 (17.0%) 109 (20.2%)
Patients with elevated viraemia (>2000 copies·mL−1) 121 (22.4%) 39 (7.22%) 37 (6.85%)
Patients with high-level viraemia (>10,000 copies·mL−1) 59 (10.9%) 18 (3.33%) 11 (2.04%)
Patients with prolonged viraemia (more than one positive measurement) 109 (20.2%) 35 (6.48%) 36 (6.67%)
Viraemia patients with no detectable viraemia one year post-transplantation (clearing) 128 (80.5%) 61 (95.3%) 48 (85.7%)
Time until first detectable viraemia (days) Median (IQR) 61 (23–178) 66 (54–185) 27 (7–80)
Range [0, 380] [0, 370] [0, 386]
Peak viraemia per patient (copies·mL−1) Median (IQR) 1505 (779–8452) 1491 (710–5850) 926 (550–3075)
Range [DL, 3849694] [DL, 136722] [DL, 1369425]
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3.6. High Tacrolimus Trough Levels Were Associated with Detectable CMV
Reactivation
High tacrolimus trough levels were significantly associated with
CMV+: With 100 replicates, we obtained a significant p value for 96%
of replicates (median p= 0.0142).While themedian of the last tacroli-
mus trough level measured before CMV reactivation was 9.1 [7.1–11.1]
ng·mL−1, the trough levels for the control group of patients without
CMV reactivation were 8.2 [6.4–10.2] ng·mL−1. On the other hand, we
did not find any effect of MMF daily dose on viral reactivation, as
there were no significant replicates for any combination of threshold
and virus.
To discard the possibility that the lack of detection of an associ-
ation of MMF daily doses with reactivation is caused by a poor
choice of thresholds, the analysis was repeated for both drugs and
all thresholds between DL and 20,000 copies·mL−1, with steps of
1000 copies·mL−1. However, the results demonstrated no effect
of MMF daily dose levels on viral reactivation, as well as no effect
of tacrolimus trough levels on BKV or EBV, with 0% of significant
replicates.
3.7. High-Level CMV Viraemia Was Positively Associated with Acute
Rejection
hCMV was significantly associated with acute rejection (Fisher's
exact test: p = 0.0393; OR= 3.27, 95%CI = 1.08–9.41). Three patients
(60.0%) had viral load over DL before acute rejection; only one of the pa-
tients had a CMV load>10,000 copies·mL−1 before rejection. No signif-
icant association was found between acute rejection and BKV or EBV.
Patients who received an anti-rejection therapy did not have a sig-
nificantly higher incidence of viral reactivation for any of the pre-de-
fined thresholds. Furthermore, there was no significant association
between the use of steroid or ATG anti-rejection therapies and viral
reactivation.
3.8. Severe PTLD Was a Rare Event in Conjunction with High EBV Load
There were two cases of PTLD (0.37%) in the cohort, of which one
was severe. Even though both PTLD cases affected patients in arm C,
there was no significant association between therapy arm and PTLD
Fig. 2.Viral dynamics of BKV, CMV, and EBV during the first post-transplantation year. Prevalence and viral load levels for BKV (blue), CMV (red), and EBV (green) are plotted for the eight
visits of the study. The size of the points is a function of the prevalence of positivemeasurements (viral load over detection level). The height of the points represents themedian viral load
(copies·mL−1) of positive measurements; the bars indicate the interquartile range. Asterisks indicate a significant difference calculated with the Mann-Whitney test (* p < 0·05; ** p <
0·01; *** p < 0·001) in viral load (only samples with detectable viral load) for each virus.
Table 5
Results of univariate analysis. Demographic and clinical characteristicswere analysed for associationwith each one of the nine pre-defined viraemia sub-groups (Table 2), compared to the
rest of population. The effect size is shown according to the employed test: OR (95%CI) for Chi-squared and Fisher's exact test andmedian of sub-group (IQR) vs. median of rest of cohort
(IQR) for Mann-Whitney test. Only significant (P < 0·05) differences are shown.
Variable Viraemia Group P Value Test Effect size
CMV donor seropositivity CMV+ <0.00001 Chi-squared 3.75 (2.12–6.64)
eCMV 0.0024 Chi-squared 3.89 (1.60–9.45)
hCMV 0.0237 Chi-squared 5.45 (1.24–23.9)
CMV recipient seropositivity eEBV 0.0154 Chi-squared 0.39 (0.19–0.81)
CMV mismatch-based risk (D+R−) CMV+ 0.0002 Chi-squared 2.46 (1.54–3.93)
eCMV 0.0025 Chi-squared 2.87 (1.47–5.60)
hCMV 0.0254 Fisher's exact 3.09 (1.17–8.16)
eEBV 0.0053 Chi-squared 2.70 (1.37–5.31)
EBV mismatch-based risk (D+R−) eEBV 0.0236 Chi-squared 3.77 (1.31–10.9)
Cold ischaemia time (min) (only cadaveric donors) eCMV 0.0199 Mann-Whitney 819 (539–1078) vs. 660 (484–855)
hCMV 0.0140 Mann-Whitney 944 (702–1058) vs. 660 (484–859)
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incidence (Fisher's exact test: p = 0.21). The patient with severe PTLD
had EBV viral load over DL for visits 4 and 5, with a peak viral load of
12,271 copies·mL−1; the patient with mild PTLD showed no EBV viral
load. None of the patients showed viral load over DL for CMV or BKV.
3.9. High-Level BKV and CMV Were Associated with Lower Graft Function
One Year Post-Transplantation
Patients with hBKV had a significantly lower GFR (42.3 [31.9–50.6]
mL·min−1·1.73 m−2 –p= 0.0096) one year after transplantation com-
pared to patients with no viraemia (BKV, CMV, and EBV below DL; 51.2
[35.4–63.6] mL·min−1·1.73 m−2) (Fig. 4). Median reduction was 8.9
mL·min−1·1.73 m−2. Patients with hCMV had a significant GFR loss
from the 6th month onwards, with a median difference of 13.9
mL·min−1·1.73 m−2 one year after transplantation (p = 0.0021–37.3
[29.1–45.4] vs. 51.2 [35.4–63.6]mL·min−1·1.73 m−2) (Fig. 4). The rela-
tionship of BKV and CMVwith GFR losswas robust for a verywide range
of thresholds (Figs. S1 and S2). No significant relationshipwas observed
between EBV and GFR.
3.10. A Combination of BKV and CMV Viraemia Leads to Lower Graft Func-
tion Already at Moderate Viral Loads
To better capture the possible effect of combined viral reactivations
on graft function, as well as the effect of the viral load threshold used
to classify the patients into viraemia groups, a systematic exploration
of viral load thresholdswasperformed (Fig. S3). Patientswith combined
BKV and CMV viraemia had lower GFR already for low viral load levels.
For example, patients with BKV > 1000 copies·mL−1 and CMV > 4000
copies·mL−1 (N= 16) demonstrated a significant impairment of GFR
from the ninth month onwards and a median loss of 11.7
mL·min−1·1.73 m−2 compared to non-reactivating patients at the
first post-transplantation year (p = 0.0172; 39.5 [30.7–46.6] vs. 51.2
[35.4–63.6] mL·min−1·1.73 m−2) (Fig. 4). Moreover, these patients
had (non-significant) lower GFR than patients with mono-reactivation
(N= 166; BKV > 1000 or CMV > 4000 copies·mL−1) from the second
week of the study onwards, with a median difference one year post-
transplantation of 3.33mL·min−1·1.73m−2.
There was no bias in the use of antiviral treatment for combined
reactivations (Fisher's exact test: p = 0.70): 68.8% of the patients with
BKV > 1000 and CMV > 4000 copies·mL−1 were treated with
(val)ganciclovir, while for patients with BKV < 1000 and CMV > 4000
copies·mL−1 the prevalence of treatment was 58.3%.
4. Discussion
In this work, the prevalence of BKV, CMV, and EBV and their impact
on patients undergoing kidney transplantation have been analysed for
the first time in a large multi-centre study. With the increasing efficacy
of immunosuppressive therapies and the subsequent decrease of acute
rejection, reactivations are expected to gain clinical importance in
renal transplantation. The main findings of our study include:
- Superiority of BKV over CMV and EBV from the epidemiological
point of view with the highest incidence and viral load;
- Significant association between CMV with BKV or EBV, but not be-
tween EBV and BKV;
- Combined BKV and CMV reactivation significantly associated with
lower graft function one year post-transplantation, even at low
viral load levels.
Our results show that BKV, with the highest incidence rate and me-
dian peak viral load and the lowest clearing rate, is the most relevant
viral reactivation of the three from the epidemiological point of view
for kidney recipients. Prevalence of presumptive BKV nephropathy
(BKV > 10,000 copies·mL−1) [11] was on the higher end of the com-
mon estimations for BKV nephropathy (1–10%) [11,22], although the
patient cohort consisted of immunological low-risk patients. In contrast
to BKV, CMV, and EBV were observed with a lower but still substantial
prevalence in around one fifth of the patients. In both cases, viraemia
had most frequently an episodic character, with viraemia clearance
rates over 85%.
A key finding of our study is the impact of BKV-CMV combined re-
activation on GFR one year post-transplantation – an important predic-
tor of transplant survival [23]– even at relatively low viral load levels.
Patients with no viral reactivation experimented an increase in theme-
dian GFR between the third and the twelfth post-transplantation
month. Such positive GFR slopes in patients without transplant compli-
cations have been observed before in the literature, e.g. Guba et al. [24].
However, in patients with BKV or CMV viral load over 10,000
copies·mL−1, no such increase was observed, leading to a significantly
lower GFR. Remarkably, patients with moderate BKV-CMV combined
reactivation (BKV > 1000 copies·mL−1 and CMV > 4000 copies·mL−1)
also had a significantly lower GFR (median difference: 11·7
mL·min−1·1.73 m−2). This finding is especially interesting since cur-
rently only much higher BKV levels are generally considered of clinical
relevance so far [25]. Thus, our data provide evidence regarding BKV-
CMV combined reactivation as a relevant complication of the post-
transplantation period.
The impact of BKV-CMV combined reactivation on GFR is especially
relevant due to the reciprocal effects between the viruses. BKV-CMV
combined reactivations have been observed repeatedly in the past and
interactions between both are plausible [9,14,26–29]. However, the ex-
istence of an epidemiological association is controversial: A previous
large retrospective study from our group identified a significant associ-
ation between CMV and BKV viraemia [9], but a large prospective study
by Elfadawy et al. showed a negative association between antecedent
CMV and BKV incidence [14]. Moreover, Elfadawy et al. did not find
any effect of BKV, CMV or their combination on GFR and only symptom-
atic CMVwas linked with graft survival. A reason for the first difference
Fig. 3. Frequency of triple, combined andmono-reactivations of BKV, CMV, and EBVduring
the first post-transplantation year. Number of patients with reactivations and all their
possible combinations are plotted as a Venn diagram. Fig. 3a depicts the combinations of
BKV+, CMV+, and EBV+, i.e. viral load over detection level. Fig. 3b depicts the
combinations of elevated viral load sub-groups (eBKV, eCMV, and eEBV, > 2000
copies·mL−1). Fig. 3c depicts the combinations of high-level viral load sub-groups
(hBKV, hCMV, and hEBV, > 10,000 copies·mL−1).
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lies probably on the fact that Elfadawy et al. was an interventional study
[14]. As the authors suggest, interventions following CMV diagnosis are
a plausible cause for the seemingly protective effect of CMV against BKV
[14]. For the contradiction on GFR effects, the most likely cause is the
different stratification strategies of viral reactivations: while in our
study systematic viral load cut-offs were employed, Elfadawy et al.
employed a symptom-based approach for CMV and no stratification
strategy for BKV [14]. However, as shown in our results (e.g. Fig. S1–
S3), the choice of viral load threshold is important for the identification
of virus-associated renal function impairments. Our results show that
stratification of reactivations according to viral load is key to identifying
which patients might develop a lower GFR as a consequence of appar-
ently asymptomatic reactivations.
Our study also showed a significant association between CMV and
EBV. This in agreement with a previous study showing an association
of these viruses [30]. However, no clinical relevance of this association
was found, possibly due to the low number of affected patients. Litera-
ture offers likewise an unclear picture on the clinical relevance of this
combined reactivation: Even though a previous study showed a link be-
tween CMV-EBV combined reactivation and PTLD in liver transplanta-
tion recipients [31], we found no case of PTLD in patients with CMV-
EBV combined infection. The only case of severe PTLD in the cohort suf-
fered from high-level (>10,000 copies·mL−1) EBV mono-reactivation.
Nevertheless, our results cannot exclude a relationship between CMV-
EBV combined reactivation and PTLD, as the majority of PTLD cases in
adult renal transplantation occur after the first post-transplantation
year [7,15,16]. There are to our knowledge no recent studies showing
a clinical relevance for CMV-EBV combined reactivation in kidney
recipients.
Acute rejection was significantly associated with high-level CMV
viral loads (>10,000 copies/mL). A mutual relation of these two phe-
nomena,where CMVboosts rejection and rejection boosts reactivations,
seems likely. However, the number of cases was too low to offer an un-
ambiguous cause-effect relation. No relationship with acute rejection
was found for BKV or EBV. This is remarkable for BKV, as it is known
from the literature to be associatedwith rejection [9]; the absence of as-
sociation could be linked to the remarkably low rejection rate found in
the patient cohort [17].
Regarding risk factors, therapy arm did not have any significant ef-
fect on BKV or CMV incidence. This highlights the safety of both rabbit
ATG and steroid withdrawal therapies in renal transplantation with re-
spect to BKV and CMV [17]. On the other hand, EBV reactivations were
significantly associatedwith arm C (ATG and rapid steroidwithdrawal).
This finding is consistent with a previous study [32]. Likewise, the only
two cases of PTLD in the cohort were encountered in arm C, but the as-
sociation was not statistically significant. Interestingly, arm B
(basiliximab and rapid steroid withdrawal) had a significantly lower
EBV prevalence than the rest. However, it should be emphasized that
there was no association between arm and elevated (>2000
copies·mL−1), high-level EBV (>10,000 copies·mL−1), or PTLD. Finally,
no significant relationship was found between MMF daily dose and
viraemia. In agreementwith Elfadawy et al., we found that higher tacro-
limus trough levels were however a risk factor for detectable CMV reac-
tivation [14]. On the other hand, there was no evidence for an effect of
tacrolimus on BKV or EBV reactivation. Other clinical risk factors
showedno associationwith BKV. This highlights the current uncertainty
on its risk factors, with the literature yielding inconsistent results [9,33–
36]. CMV and EBV were, as expected, significantly associated with pa-
tient-donor serologicalmismatch. Interestingly,we have observed a sig-
nificant association between high-level CMV viraemia (>10,000
copies·mL−1) and longer cold ischaemia time for cadaveric organs, an
association first observed in a very recent studywith only eight patients
[37]. Since such viral loads are associated with lower GFR, our data sug-
gest reinforcing CMV-surveillance after transplantations with a long
cold ischaemia time, especially for cases of high CMVmismatch-associ-
ated risk.
Our study has some limitations. First, the follow-up period – one
year – is too short to observe long-term effects. Our analyses were ex-
plorative and are not corrected for multiple testing to maximize the ob-
tained information, on the basis of the precautionary principle.
Secondly, other factors affecting renal function (e.g. bacterial infections,
use of nephrotoxic drugs)were not analysed.Moreover, transplantation
outcomes were assessed on the basis of estimated GFR and not on a his-
tological basis. Nevertheless, the fact that GFR is a recognised predictor
for long-term transplantation outcomes supports the relevance of our
conclusions [23]. However, these limitations are outweighed by the
Fig. 4.Graft function dynamics of patients with BKV and CMVmono-reactivations and combined reactivations, in comparison to non-reactivating patients. Median GFR (mL·min−1·1·73
m−2) for patients with BKV-CMV combined reactivation (red; N= 16), hBKV (blue; N= 59), hCMV (green; N= 18) and non-reactivating (black; N= 208) for the last seven visits is
plotted. Coloured groups are not mutually exclusive – a patient might belong to more than one sub-group. The bars indicate the interquartile range. Coloured asterisks indicate a
significant difference calculated with the Mann-Whitney test (* p < 0·05; ** p < 0·01) in GFR of the corresponding group with respect to the non-reactivating group. Day 0 is not
shown, as it is pre-transplantation.
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fact that it is the first large multi-centre study that has examined BKV,
CMV, and EBV in kidney transplantation in a systematic and parallel
way, as well as the first to offer a detailed analysis of viral associations
and their impact on transplantation outcomes. Almost ten thousand
viral load measurements were performed along the eight pre-pro-
grammed visits – all measurements were performed in the same centre
and following the same, standardised protocol, thereby ensuring the
comparability of results.
In conclusion, our work offers an extensive outlook on the impact
and relevance of BKV, CMV, and EBV and their interactions after kidney
transplantation. In our study, BKV emerges as the most relevant viral
complication from the epidemiological point of view, with the highest
prevalence, highest viral load, and the lowest clearing rates. Long cold
ischaemia time is confirmed to be significantly associated with elevated
CMV viraemia. An association between CMV and EBV is shown, albeit
without any evidence of enhancement of their clinical effects. Finally,
we further demonstrate a highly significant association between BKV
and CMV reactivations, shown for the first time to be of clinical interest,
with an increase of damaging effects by both viruses already at moder-
ate viral loads. The results of our study have the potential to change the
BKV and CMV management, appealing for a stricter monitoring and in-
tervention in kidney transplantation patientswith BKVor CMV lowviral
loads as well as long cold ischaemia times.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.07.017.
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7.2 Supplementary materials 
7.2.1 Figure S1 
Influence of BKV threshold on median GFR loss one year post-transplantation 
 
A systematic exploration of the influence of BKV viral load threshold choice on GFR one year post-
transplantation was performed. Patients with BKV peak viral load over the threshold were compared 
with the patients with no viral reactivation (BKV, CMV and EBV below DL, N = 208). All thresholds 
between 0 and 20,000 copies·mL−1, with steps of 500 copies·mL−1, were evaluated. Significance was 
evaluated through the Mann-Whitney test. The height of the points indicates the median difference 
in GFR one year post-transplantation between the BKV sub-group and the non-reactivating sub-
group. Non-significant differences were plotted as red crosses, significant differences (p < 0.05) as 
black points whose size indicate the p value. As it can be observed, for all thresholds there was a 
negative effect of BKV on GFR one year post-transplantation, which was significant for all thresholds 
between 4000 and 20,000 copies·mL−1. 
7.2.2 Figure S2 
Influence of CMV threshold on median GFR loss one year post-transplantation 
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A systematic exploration of the influence of CMV viral load threshold choice on GFR one year post-
transplantation was performed. Patients with CMV peak viral load over the threshold were compared 
with the patients with no viral reactivation (BKV, CMV and EBV below DL, N = 208). All thresholds 
between 0 and 20,000 copies·mL−1, with steps of 500 copies·mL−1, were evaluated. Significance was 
evaluated through the Mann-Whitney test. The height of the points indicates the median difference 
in GFR one year post-transplantation between the CMV sub-group and the non-reactivating sub-
group. Non-significant differences were plotted as red crosses, significant differences (p < 0.05) as 
black points whose size indicate the p value. As it can be observed, for all thresholds there was a 
negative effect of CMV on GFR one year post-transplantation, with increasing GFR loss for higher 
thresholds. GFR loss was significant for all thresholds between 6000 and 20,000 copies·mL−1. 
7.2.3 Figure S3 
Exploration of viral load thresholds for BKV and CMV and their influence on GFR one year 
post-transplantation. 
 
A systematic exploration was performed on the influence of viral load threshold choice on 
GFR one year post-transplantation for patients with BKV-CMV combined reactivation. For 
this, two sub-groups are generated for the comparison of their GFR at the end of the study: 
one (combined reactivation) with the patients that had BKV and CMV viral loads over certain 
thresholds; the second group (non-reactivating) with the patients that did not show any 
detectable viral load (BKV, CMV and EBV below DL, N = 208). For the BKV and CMV 
thresholds, all combinations between 0 and 20,000 copies·mL−1, with steps of 100 
copies·mL−1, were evaluated. Significance was evaluated through the Mann-Whitney test, 
the colour shows the P value for each combination. Shown is the space BKV ≤ 5000 
copies·mL−1, where all significant differences were found. In all cases, the combined 
reactivation group had a lower median GFR than the non-reactivating group.  
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8. Sex-associated differences in cytomegalovirus prevention: 
Prophylactic strategy is associated with a strong kidney function 
impairment in female renal transplant patients 
This chapter* refers to the manuscript published as: 
Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, Witzke O, 
Westhoff TH, Sawitzki B, Reinke P, Thomusch O, Hugo C, Babel N and Or-Guil M (2019). Sex-
associated differences in cytomegalovirus prevention: Prophylactic strategy is associated with 




* The chapter corresponds to the version of the manuscript available at submission of this dissertation 
(version 2). At the time point of the defense, an updated version of the manuscript was available. In 
this version, an improved method for the variable selection in multivariable regression was employed 
with the goal of increasing the specificity of the analysis; the results and discussion were modified 
accordingly. The updated version (version 3) is available at bioRxiv. 
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Abstract 
Cytomegalovirus (CMV) syndrome or disease, a serious health hazard after renal 
transplantation, can be prevented using the antiviral drug (val)ganciclovir. (Val)ganciclovir is 
typically administered following a prophylactic or a pre-emptive strategy. The prophylactic 
strategy entails early universal administration, the pre-emptive strategy early treatment in 
case of infection. However, it is not clear which strategy is superior with respect to 
transplantation outcome and viral clearance. We have retrospectively analysed 540 patients 
from the multicentre Harmony study: 308 were treated according to a prophylactic, 232 
according to a pre-emptive strategy. As expected, we observed an association of 
prophylactic strategy with lower incidence of CMV syndrome, delayed onset and lower viral 
loads compared to the pre-emptive strategy. However, the prophylactic strategy was 
associated with higher incidence of acute rejection (P=0.002) and – for female patients – a 
strong impairment of glomerular filtration rate (eGFR) one year post-transplant (P<0.001, 
median difference: 18.5 mL·min-1·1.73m-2). Additionally, the prophylactic strategy was 
associated with increased incidence of severe BK virus reactivation. Our results suggest for 
the first time that the prophylactic strategy might lead to inferior transplantation outcomes, 
providing evidence for a strong association with sex. 
ClinicalTrials.gov number: NCT00724022
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1. Introduction 
Cytomegalovirus (CMV) is a herpes virus often reported as the most important viral pathogen 
after kidney transplantation.1–3 It is a major cause of morbidity and mortality, being 
associated with retinitis, pneumonitis, colitis, encephalitis, allograft damage and allograft 
loss, among others.1–4 CMV syndrome or disease may occur as a consequence of 
reactivation of latent infections or through primary infection, acquired from the donor or from 
the environment.2 The major risk factor for CMV syndrome or disease is the pre-
transplantation serostatus: CMV seronegative transplant recipients with a seropositive donor 
(D+R-) have the highest risk, while seropositive recipients (R+) have an intermediate risk and 
seronegative recipients with seronegative donors (D-R-) have the lowest risk.2 Moreover, the 
use of immunosuppressive drugs like rabbit antithymocyte globulin (ATG) can additionally 
increase the incidence of CMV (re)activations.5  
The standards in prevention and treatment of CMV (re)activation are based on ganciclovir or 
its oral prodrug valganciclovir.6,7 Two prevention strategies are routinely employed in the 
clinic: prophylactic and pre-emptive.2,6,7 The prophylactic strategy is based on the universal 
administration of (val)ganciclovir in case of  patients with a CMV risk constellation, usually 
during 3-6 months after transplantation.6,7 In the pre-emptive strategy, patients are regularly 
monitored for CMV through quantitative polymerase chain reaction or pp65 antigenemia test; 
(val)ganciclovir is only administered after a positive test, ideally before any symptoms of 
CMV syndrome or disease manifest.6,7 The pre-emptive strategy thus leads to a reduction of 
unnecessary treatments, which is advantageous with respect to the appearance of side 
effects and resistances against antiviral drugs.6,7 
While the KDIGO guideline of 2009 preferred prophylaxis as the standard of prevention, the 
more recent reference CMV management guideline recommends both strategies for the 
prevention of CMV disease in patients with both high or intermediate CMV mismatch-based 
risk constellation.6,7 However, the differences in outcome with regard to other criteria, 
including renal function and other viral (re)activationsis largely unclear. In addition to antiviral 
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therapy, CMV-specific T cell immunity has been shown to control CMV viral reactivations, 
determining the outcome of disease.8–10 Interestingly, there is evidence of sex differences in 
both ganciclovir pharmacokinetics and the anti-CMV immune response.11–14 Thus, female 
patients have been shown to have a faster ganciclovir clearance, and distinct anti-CMV 
immunological profiles e.g. higher number of secreting anti-CMV T cells.11–15 In spite of this, 
there are to our knowledge still no studies on the influence of sex on the clinical outcomes of 
CMV prevention strategies. In this work, we provide evidence that prophylaxis might be 
associated with inferior transplantation outcomes – including a strong reduction of renal 
function in female patients – at the end of the first year post-transplant. 
2. Materials and Methods 
2.1. Patient population 
As part of the systems medicine project e:KID, we conducted a sub-study within the 
randomized, multi-centre, investigator-initiated Harmony trial (NCT 00724022)16,17 to 
determine the impact of CMV prevention strategy on transplant outcome. For this, CMV, 
Epstein-Barr virus (EBV) and BK virus (BKV) viral loads, white blood cell count and 
creatinine were measured at predetermined eight study visits.17  This viral monitoring was 
non-interventional and centrally performed and was independent from the internal, 
interventional viral monitoring (see section 2.3). The study was carried out in compliance with 
the Declaration of Helsinki and Good Clinical Practice. 
2.2. Patient medication 
According to study design, patients were treated with a quadruple (arm A) or triple (arms B 
and C) immunosuppressive therapy.16 Patients in arm A received an induction therapy with 
basiliximab and maintenance therapy consisting of tacrolimus (Advagraf®, Astellas), 
mycophenolate mofetil (MMF) and corticosteroids. Patients in arm B received the same 
treatment as in arm A, but corticosteroids were withdrawn at day 8. Patients in arm C 
received the same treatment as in arm B, except induction was achieved with ATG, instead 
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of basiliximab. 
2.3. Patient monitoring 
Patients were monitored for graft function along eight visits, scheduled at day 0 (pre-
transplantation), 2nd week, 1st month, 2nd month, 3rd month, 6th month, 9th month, and 12th 
month. To assess graft function, glomerular filtration rate was calculated using the CKD-EPI 
formula, measured in mL·min-1·1.73 m-2.18 Serious adverse events were defined following the 
Good Clinical Practice guidelines. Suspected episodes of acute rejection had to be confirmed 
through biopsy; histologic characteristics were described according to the Banff criteria of 
2005.19 Regarding the outcome assessment, acute rejection was analysed including and 
excluding borderline rejections. Routine surveillance biopsies were allowed but not 
mandatory.  
2.4. Clinical monitoring and management of clinical complications 
Viral (re)activations were monitored and managed at local centres as described previously.17 
CMV in particular was monitored for all patients, independently of the prevention strategy. 
Monitoring was performed independently from the above described CMV viral load 
measurements and was based on three different methods: serum PCR viral load 
measurements; test for pp65 antigenemia and symptom monitoring according to the internal 
centre standards. Diagnosis of CMV syndrome was likewise based on the methods, where a 
qPCR over 1000 copies·mL-1 was defined as positive. Patients with CMV syndrome were 
treated based on internal centre standards. Suggested treatment was (val)ganciclovir 
treatment according to local standards with/or without reduction of tacrolimus and MMF dose. 
No data on the time point of CMV syndrome diagnostic were available for this study; no data 
on CMV disease were available. 
2.5. Screening of CMV, EBV and BKV viraemia 
In parallel to the clinical monitoring performed at each centre, peripheral blood samples from 
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the eight visits were centrally monitored for CMV, EBV and BKV by TaqMan qPCR, as 
described previously.17 The centralized viral load assessment was non-interventional.  
2.6. Definition of CMV prevention strategy groups and characterization of antiviral treatments 
Patients were stratified into two prevention strategy groups based on the (val)ganciclovir 
treatments during the first 14 days.  All patients that started a (val)ganciclovir treatment 
during the first 14 days were assigned into the prophylactic strategy group; the rest of the 
sub-cohort was classified in the pre-emptive strategy group. The 14 day threshold was 
chosen to allow comparability with our previous prospective study on the topic (VIPP), in 
which recruiting took place during the first two post-transplant weeks.20,21 CMV syndrome 
was treated equally for both strategy groups, as explained above. Antiviral treatments with no 
data on the end time point were disregarded for the calculation of the treatment duration but 
considered for the calculation of median dose. Accordingly, reported MMF dose and 
tacrolimus trough correspond to the 14 day threshold. 
2.7. Viraemia-based patient classification 
To assess the efficacy of prevention strategies regarding viral (re)activations, patients were 
classified based on their peak viral load values for CMV, EBV and BKV, as previously 
published.17 Briefly, the classifications are defined as follows: “detectable viral load” 
corresponds to patients with at least one viral load measurement over detection limit (250 
copies·mL-1)17, “elevated viral load” to patients with at least one viral load measurement over 
2000 copies·mL-1, “high viral load” to patients with at least one viral load measurement over 
10000 copies·mL-1. These groups can overlap with each other. 
2.8. Analytical approach 
The association between transplantation outcomes and prevention strategy was analyzed 
using the following approach: First, crude single-parameter associations between prevention 
strategy and the outcome were assessed; whenever possible, the associations were also 
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calculated stratified for the risk constellations of the outcome at hand. Second, to assess 
independence from confounders of potential associations, multi-parameter backwards 
elimination regression analysis was performed. Third, the difference of single-parameter 
strategy-outcome associations between sexes were assessed. Lastly, if there was a 
significant difference between the sexes and a significant association with the outcome was 
observed for only one sex, the association was tested in that sub-group employing multi-
parameter backwards elimination regression analysis.  
2.9. Statistical analysis 
For descripticve statistics, categorical variables are summarised as numbers and 
frequencies; quantitative variables are reported as median and interquartile range (IQR). 
Differences between the groups were calculated using Pearson’s chi-square test with 
continuity correction (or two-tailed Fisher’s exact test, when stated); odds ratios (OR) and 
95% confidence intervals (95% CI) are provided. In all cases, odds ratio over 1 denote a 
higher prevalence of the adverse event in the pre-emptive strategy group. Differences in 
quantitative variables between groups are analysed using the two-tailed Mann-Whitney test. 
Kaplan-Meier curves for time to occurrence of the first CMV (re)activation were calculated 
using the R survival package (version 2.43-3); strategy groups were compared using the log-
rank test. Correlations are reported employing Spearman’s rho and P value). 
To control for the influence of confounders in the analysis of prevention strategies, multi-
parameter regression was employed.  Regression models incorporated as independent 
variables the prevention strategies and all potential confounding factors, and as dependent 
variable the outcome variable of interest. For categorical binary outcomes, logistic regression 
was employed, for continuous outcomes linear regression was used. For the peak viral load 
outcomes, the decimal logarithm was used. After logarithmisation, viral loads below detection 
level were set to zero. We considered as potential confounders all measured demographic 
factors (see Table 1 and Table S1) and centre effects. For the analysis of the eGFR one year 
after transplantation (eGFR-1y), CMV, BKV and EBV peak viral loads and acute rejection 
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were additionally included as potential confounders, as these events precede or are 
simultaneous to eGFR-1y and might hence have an influence on it. To exclude unimportant 
factors, backward elimination was performed, employing Akaike’s information criterion. 
Factors in the final regression model were therefore considered to be independently 
associated with the dependent variable, regardless of the corresponding P value. Resulting 
linear regression models were tested for homoscedasticity of their residuals employing the 
studentized Breusch-Pagan test; multicollinearity was assessed for all models calculating the 
generalized variance-inflation factors. If homoscedasticity cannot be assumed (P<0.050), 
robust standard errors are reported. For multicollinearity, a threshold of 5 for the generalized 
variance-inflation factors was employed to exclude a factor. 
The analysis of the interactions of sex effects with the effect of strategy group on outcomes 
was assessed with a single-parameter ANOVA type 3 for continuous variables and a single-
parameter analysis of deviance type 3 of a logistic model for categorical variables. In all 
cases, a P value below 0.050 was considered significant. P values were not corrected for 
multiple testing, as this study was of exploratory nature and we prioritized the minimization of 
type II errors.22–24 Analyses were performed using R (Version 3.3.2). 
3. Results 
3.1. Definition of study sub-cohorts 
To assess the effects of CMV prevention strategy on transplantation outcome, we 
retrospectively analysed the cohort of an existent study (N=540 patients) with a female ratio 
of 35.9% (N=194).16,17 Patients were grouped into two sub-cohorts, based on whether they 
started an antiviral therapy during the first two post-transplant weeks (prophylactic strategy 
group, N=308) or not (pre-emptive strategy group, N=232) (see 2.6). As described 
previously, viral load (CMV, EBV and BKV), graft function and other clinical markers were 
collected along eight visits during the first post-transplant year; a total of 3715 blood samples 
were analysed.17  
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In this work, we have evaluated the effects of prevention strategy on eGFR, incidence of 
acute rejection, incidence of CMV complications, and incidence of BKV and EBV 
(re)activations following the analytical approach detailed in section 2.8. After an assessment 
of the baseline characteristics of the sub-cohorts, we describe in detail the most important 
findings in the next sections.  
3.2. Study sub-cohorts characteristics  
To assess differences between the two prevention strategy sub-cohorts regarding 
demographics or treatment procedures, we performed comparative statistics (see Table 1, 
for cause of end-stage kidney disease see Table S1). As shown in Table 1, significant 
(P<0.050) differences were found for MMF daily dose, CMV mismatch-based risk and 







Female sex 104 (33.8%) 90 (38.8%) 0.265 
Caucasian race 304 (98.7%) 231 (99.6%) 0.397a 
Recipient age (years) 55 [46-64] 57 [44-64] 0.988 





High (D+R-) 119 (39.1%) 27 (12.1%) 
<0.001 Medium (R+) 137 (45.1%) 129 (57.8%) 





High (D+R-) 13 (5.1%) 11 (6.2%) 
0.583a 
 
Medium (R+) 239 (93.4%) 161 (91.0%) 
Low (D-R-) 4 (1.6%) 5 (2.8%) 
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Donor age (years) 55 [48-65] 55 [46-65] 0.931 
No previous transplantations 298 (96.8%) 216 (94.7%) 0.346 
Living donor 31 (10.1%) 35 (15.4%) 0.088 
Donors with expanded criteria 136 (44.2%) 99 (42.7%) 0.798 
Cold ischaemia time (min) 626 [427-844] 600 [414-840] 0.505 
Number of HLA A, B and DR mismatches 3 [2-4] 3 [1-4] 0.457 
No panel-reactive antibodies before transplantation 23 (7.6%) 17 (7.7%) 1.000 
White blood cell count (cells·L-1) 7.2 [5.7-8.9] 7.1 [6.0-8.5] 0.676 
Therapy 
arm 
A (basiliximab+steroids) 93 (30.2%) 96 (41.4%) 
<0.001 B (basiliximab) 92 (29.9%) 83 (35.8%) 
C (ATG) 123 (39.9%) 53 (22.8%) 
Low MMF daily dose (< 2000 mg·day-1) 37 (12%) 45 (19.4%) 0.025 
Tacrolimus trough level (ng·mL-1) 9.9 [7.4-12.5] 9.2 [7-12] 0.145 
Table 1 – Differences in patient baseline characteristics between strategy groups. Data are given as 
number (percentage) or median [interquartile range]. Donors with expanded criteria are defined as follows: age 
over 60 years or age over 50 years and at least two of the following factors: cerebrovascular accident as the 
cause of death, hypertension or a serum creatinine level over 1.5 mg·dL-1. P value is calculated based on 
Pearson’s chi-square test or Fisher’s exact test for binary variables (marked with a) and based on Mann-Whitney 
test for continuous variables. Data on the cause of end-stage kidney disease are summarized in Table S1. 
59 patients (25.4%) of the pre-emptive strategy group were treated with (val)ganciclovir after 
the second post-transplantation week. In total, 367 patients (68.0%) received (val)ganciclovir 
during the first post-transplant year, independently of their prevention strategy group; use of 





group treated with 
(val)ganciclovir  
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(N=59) 
Median time under 
(val)ganciclovir (days) 118 [87-182] 92 [46-155] 
Valganciclovir 
average daily dose 
(mg·day-1) 277 [165-450] 450 [205-454] 
Ganciclovir usage 34 (11.0%) 8 (13.6%) 
Intravenous 
ganciclovir usage 31 (10.1%) 7 (11.9%) 
Table 2 – Antiviral treatment details for the two strategy groups. Data are given as number (percentage) or 
median [interquartile range]. 
3.3. Prophylactic strategy group was associated with a serious impairment of graft function in 
female patients 
Patients in the prophylactic strategy group had, in general, a poorer transplantation course 
than those in the pre-emptive strategy group, as confirmed by their significantly higher 
incidence of total serious adverse events (64.6% vs. 54.3%, P=0.020, OR: 0.65 [0.45-0.94]). 
For the main outcome, renal function, single-parameter analysis likewise revealed a 
significant difference between the prevention groups. Thus, eGFR-1y was lower in the 
prophylactic strategy group compared to the pre-emptive group (45.6 [33.5-58.3] vs. 50.3 
[38.1-64.5] mL·min-1·1.73m-2, P=0.011). Of note, a significant difference in eGFR was 
detected for all visits from the third post-transplant month on (Figure S4).  
Multi-parameter analysis could not confirm an independent association of prophylactic 
strategy with decreased eGFR-1y (Table S2 A). However, we observed that this association 
is subject to a strong interaction with sex (P=0.003, see Table 3): The significant impairment 
of eGFR-1y in the prophylactic group was only observed for female patients, with a 
difference of 18.5 mL·min-1·1.73m-2 (38.4 [28.8-53.6] vs. 56.8 [41.3-67.9] mL·min-1·1.73m-2, 
P<0.001).  Among male patients, the prophylactic strategy group had a slightly higher median 
eGFR-1y (48.5 [36.3-61.5] vs. 47.2 [37.2-59.6] mL·min-1·1.73m-2, P=1.000). This significant 
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difference in eGFR for females can be observed already one month after transplantation 
(Figure 1). Importantly, the multi-parameter analysis confirmed that prevention strategy was 
independently associated with eGFR-1y in female patients (Table S2 B). 
Outcomes Effect size of prevention 
strategies in male patients 
(N=346) 
Effect size of prevention 
strategies in female 
patients (N=194) 
P value  
Serious adverse event 0.76 [0.48-1.19] 0.49 [0.26-0.91] 0.237 
eGFR-1y -1.3 [-4.8-4.7] 18.5 [8.2-20.7] 0.003 
Acute rejection 0.35 [0.13-0.81] 0.39 [0.12-1.12] 0.847 






















Syndrome 0.57 [0.31-0.99] 0.47 [0.19-1.07] 0.683 
















High viral load 0.49 [0.21-1.05] 0.71 [0.22-2.13] 0.545 










4.27 [0.79-43.19] 0.154 
 
High viral load 1.15 [0.22-5.46] 1.16 [0.01-91.65] 0.998 
 
Table 3 – Differences in effect size of prevention strategy between sexes with respect to outcomes. The P value refers to 
the P value of the interaction term, as assessed by a single-parameter ANOVA type 3 for continuous variables or a single-
parameter analysis of deviance type 3 of a logistic model for categorical variables. The effect sizes are given with 95% 
confidence intervals as OR (categorical variables) or as difference of medians (continuous variables). An OR over 1 indicates a 
higher incidence of the outcome in the prophylactic strategy group, compared to the pre-emptive; a positive difference of 
medians indicates a lower value of the median outcome in the prophylactic strategy group compared to the pre-emptive. For the 
definition of (re)activation severity degrees see Methods (2.7). 
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Figure 1. Graft function dynamics of the prevention strategy groups stratified for sex. To exclude the role of donor type in 
eGFR dynamics, only patients with a deceased donor are shown (for the eGFR dynamics of patients with living donors, see 
Figure S5). Median eGFR (mL·min-1·1.73 m-2) of the prevention strategy groups is plotted for each protocol visit. The bars 
indicate the interquartile range. The numbers indicate the p value of the difference in eGFR between the prevention strategy 
groups, as calculated using the Mann-Whitney test. Day 0 is not shown, as it is pre-transplantation. 
We further investigated the nature of the difference in eGFR between prevention strategies in 
female patients, examining the associations of dose and beginning of therapy with eGFR-1y. 
We did not observe any negative effect of high doses: We compared the female patients in 
the pre-emptive strategy group that received a valganciclovir treatment, with those in the 
prophylactic strategy group, as the first group had a significantly higher daily dose than the 
second (P=0.041). Thus, we observed that these patients had a significantly higher eGFR-1y 
than those in the prophylactic group (38.4 [28.8-53.6] vs. 57.7 [40.1-66.6] mL·min-1·1.73m-2, 
P=0.005), in spite of the higher valganciclovir dose. On the other hand, we observed a 
significant effect of therapy timing in eGFR-1y, with a positive correlation between day of 
treatment beginning and eGFR-1y (ρ=0.27, P=0.015) among female patients who received 
(val)ganciclovir. 
Based on the encountered strong interaction of sex and prevention strategy for renal 
function, we decided to evaluate systematically the sex effects for all transplantation 
outcomes.  While no differences between sexes with respect to transplantation outcomes 
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were observed (Table 4), further interactions of sex with prevention strategy were observed 
with respect to (Table 3), as described in detail below. 





Serious adverse event 204 (59.0%) 121 (62.4%) 0.493 
eGFR-1y 48.2 [36-5-61.4] 46.8 [33.3-58.8] 0.341 
Acute rejection 38 (11.0%) 22 (11.3%) 1.000 
CMV Detectable viral load 57 (16.5%) 35 (18.0%) 0.730 
Elevated viral load 24 (6.9%) 15 (7.7%) 0.866 
High viral load 13 (3.8%) 5 (2.6%) 0.629 
Syndrome 78 (22.5%) 35 (18.0%) 0.261 
BKV Detectable viral load 173 (50.0%) 87 (44.8%) 0.289 
Elevated viral load 76 (22.0%) 45 (23.2%) 0.825 
High viral load 41 (11.8%) 18 (9.3%) 0.438 
EBV Detectable viral load 74 (21.4%) 35 (18.0%) 0.414 
Elevated viral load 28 (8.1%) 9 (4.6%) 0.178 
High viral load 9 (2.6%) 2 (1.0%) 0.343a 
 
Table 4 – Differences in outcomes between sexes. Data are given as number (percentage) or median [interquartile range]. P 
value is calculated based on Pearson’s chi-square test or Fisher’s exact test for binary variables (marked with a) and on Mann-
Whitney test for continuous variables. For the definition of (re)activation severity degrees see Methods (2.7). As it can be 
observed, there were no significant differences between sexes with respect to the measured outcomes. 
3.4.  Prophylactic strategy was associated with higher incidence of acute rejection 
independently of sex 
Regarding the important complication acute rejection, a significantly higher incidence was 
found in the prophylactic strategy group (14.9% vs. 6.0%, P=0.002, OR: 0.37 [0.18-0.70]). 
The observed association between prevention strategy and incidence of acute rejection was 
confirmed to be independent from potential confounders by multi-parameter analysis (Table 
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S2 C).  As shown in Table 3, there were no significant differences between sexes for this 
association. 
3.5. The prophylactic strategy was associated with lower incidence of CMV (re)activation and 
syndrome than the pre-emptive strategy  
We further tested the effectivity of the strategies in the prevention of CMV complications. The 
single-parameter analysis showed a higher incidence of CMV viral load in the pre-emptive 
strategy group (19.8% vs. 14.9%, P=0.167); for CMV syndrome a significantly higher 
incidence was found in the prophylactic strategy group (see Table S3 A). The latter was not 
unexpected, as most patients with high CMV risk were in the prophylactic strategy group. 
Stratifying for CMV risk, a clear trend for lower incidence of CMV (re)activation was observed 
in the prophylactic strategy group; but not for CMV syndrome (Table S3 B). However, the 
results of the multi-parameter regression show that prophylactic strategy was independently 
associated with both lower peak CMV viral load and CMV syndrome incidence (Table S2 D-
E). No significant sex association were observed for these outcomes (Table 3 and Table S3 
D-E). 
Interestingly, CMV incidence showed significantly different temporal patterns in the two 
strategy groups (Figure 2): While in the pre-emptive strategy group 86.7% of all CMV load 
events occurred in the first 100 days post-transplant, in the prophylactic strategy group it was 
only 56.1% (Figure 2A). Moreover, a higher prevalence of detectable CMV viral load was 
observed in the prophylactic strategy group for all study visits after the third month (Figure 
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Figure 2. Incidence of CMV (re)activation in the prevention strategy groups during the first post-transplant 
year. (A) Kaplan-Meier curves for absence of CMV (re)activation during the first post-transplant year. CMV 
(re)activation was defined as viral load over detection limit. Prevention strategy groups were compared using the 
log-rank test. (B) Prevalence of CMV viral load over detection limit for each of the eight protocol visits. 
3.6. The prophylactic strategy was associated with lower incidence of EBV (re)activation 
among women and higher incidence of BKV (re)activation 
Regarding the effects of prevention strategy for other viruses, no effect of prevention strategy 
was found for EBV when considering both sexes, neither through (stratified) single-
parameter analysis (Table S3 A and S3 C), nor through multi-parameter analysis (Table 
S2F). However, there was a significant interaction of sex and prevention strategy for EBV 
(re)activation (P=0.009, Table 3). Thus, there was an association of prophylactic strategy 
with reduced incidence of EBV (re)activation only for female patients (P=0.049, OR: 2.26 
[1.00-5.25], see Table S3 D). An analysis stratified for viral risk constellations (Table S3 F) 
showed an even stronger association for female patients treated with ATG (P=0.005, OR: 
5.65 [1.56-22.86]). Similarly, the multi-parameter analysis showed that prophylactic strategy 
was independently associated with decreased peak EBV load in female patients (Table S2 
G).  
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On the other hand, we found a higher incidence of severe BKV (re)activation in patients of 
the prophylactic strategy group (P=0.056, OR: 0.55 [0.29-1.01]), see Table S3 A. The multi-
parameter analysis confirmed that prophylactic strategy was independently associated with 
increased peak BKV load (Table S2 H). No significant sex-associated effect was observed 
for BKV (re)activation (Table 3 and Table S3 D-E), even though male sex was independently 
associated with increased peak BKV load in the multi-parameter analysis (Table S2 H). 
4. Discussion 
The goal of our study was to evaluate the clinical efficacy and sex-associated differences of 
two common CMV prevention strategies in a large cohort of kidney transplant patients from 
the multi-centre Harmony study.  
The main finding of the study is the first evidence of superiority of the pre-emptive strategy 
with respect to acute rejection incidence and – for female patients – graft function.20,21,25–31 
While we have already reported a negative effect of prophylaxis on rejection within the VIPP 
study – albeit only for the D-R+ subgroup – this study is the first to report a significant 
association in the entire cohort.20,21 The observed association of prevention strategy with 
eGFR in female patients is especially relevant, as eGFR-1y is an accepted marker for long 
term transplantation outcomes.32  
Our results highlight the importance of sex-associated effects in transplantation. In recent 
years, sex differences have emerged as an essential factor in clinical studies.33 In 
transplantation, several complications are associated with sex, including acute rejection, graft 
loss and viral (re)activations.11,13,34,35 However, the underlying reasons for these sex 
differences are not well understood; possible causes include the hormonal regulation of the 
immune system, the effects of pregnancy, and differences in the metabolism of drugs 
routinely employed in transplantation.11 For example, there is tentative evidence of sex-
related differences in the pharmacokinetics of (val)ganciclovir.11,12 Thus, ganciclovir 
clearance has been observed to be 24% faster in female transplantation patients, suggesting 
higher activity of the organic anion transporter 1.11,12 Furthermore, it has been shown 
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repeatedly that women and men have different anti-CMV immunological profiles, with an 
impact in the graft function and even the phenotype of the immune system as a whole.13–15 
Notably, in a recent publication, Lindemann et al. have observed an association of high 
number of IL-21 secreting anti-CMV T cells with female sex and lower eGFR in a clinical 
transplantation context.13 
Our analyses may provide some evidence on the nature of the observed association of 
eGFR-1y with prevention strategies in female patients. Although the impaired graft function in 
the female prophylactic strategy group can be partly explained through the higher incidence 
of BKV severe (re)activation and rejection, the results of the multi-parameter analysis 
showed an independent association of prevention strategy with graft function, regardless 
these adverse events.17,36,37 Therefore, our results do not support the hypothesis that these 
adverse events are the main cause for the difference in eGFR-1y between sub-cohorts. 
Regarding possible nephrotoxic effects of the antiviral drug, we did not find any association 
of higher valganciclovir doses with lower eGFR – rather, the opposite association was 
observed – in contrast to Heldenbrand et al.38 The absence of a negative dose-dependent 
effect suggests that the observed difference was not a consequence of nephrotoxicity of 
valganciclovir. On the other hand, the time of beginning with the (val)ganciclovir therapy was 
determinant for the eGFR-1y: the later patients began the therapy, the higher the renal 
function. 
Albeit being highly speculative, we hypothesize that the observed results may be (at least in 
part) caused by an immunological mechanism. As we previously demonstrated, an increased 
number of CMV-specific T-cells upon CMV (re)activation is associated with reduced 
alloreactivity and improved graft function in renal transplantation patients.39 Similarly, in liver 
transplantation, primary CMV infection has been found to be associated with donor-specific 
CD8+ T-cell hyporesponsiveness and increased V 1/V 2  T-cell ratio – a surrogate 
marker for operational tolerance.40 Accordingly, the higher rate of asymptomatic CMV 
(re)activation found in the pre-emptive strategy group could potentially lead to regulatory 
 T-cell-based graft protection and explain the better graft function and lower incidence of 
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acute rejection; an early administration of (val)ganciclovir would therefore hinder the 
development of this protective immune response. Our hypothesis is compatible with the 
observed differences between male and female recipients, as sex-associated differences in 
the anti-CMV immunity have been shown by Lindemann et al. to correlate with graft 
function.13  Even though this effect cannot explain our observations, it demonstrates how sex 
and anti-CMV immunity can potentially interact and affect eGFR.13  Therefore, further 
research, including systems medicine approaches, is needed to better understand the effects 
of CMV prevention strategies from an immune, virological and pharmacokinetic point of view 
– with emphasis on sex-associated differences – and their effects on transplantation 
outcome.41,42 
Of interest, the prophylactic strategy group showed a higher incidence of late-onset CMV 
(from month six on); such increases of viral (re)activation incidence after the end of 
prophylaxis have been observed before.27,28 Regarding BKV, the observed association  of 
prophylaxis with increased incidence of severe (re)activation is in line with two recent 
studies.43,44 On the other hand, an association of EBV with prevention strategy was observed 
only for female patients.45 This is relevant, as there is currently no consensus in the literature 
on this topic. While a number of publications have observed an effect against EBV or post-
transplant lymphoproliferative disease (the main EBV-associated complication), a meta-study 
with 2366 participants saw no effect of prophylaxis for this disease.46–50  
This study is based on the prospective Harmony study, a trial designed with the goal of 
identifying which immunosuppressive drug combination is superior with respect to acute 
rejections and secondary to a number of other outcome variables, including graft function 
and viral (re)activations.16 A potential shortcoming of the present study consists therefore in 
the fact that prevention strategy groups were not randomized, and no power calculation was 
performed with respect to this question. Therefore, even though we have controlled for all 
measured demographic factors in the analyses, we cannot completely exclude bias in 
unmeasured factors as the cause of the observed differences. A further limitation is related to 
the criteria employed for choosing prevention strategy for each patient: As the decision to 
All rights reserved. No reuse allowed without permission. 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/726968doi: bioRxiv preprint first posted online Aug. 6, 2019; 
79
adopt a prophylactic or a pre-emptive strategy was taken by each individual physician or 
centre, it is difficult to ascertain the causes for the individual decisions, potentially introducing 
bias in the use of prevention strategies. On the other hand, our study does have some 
advantages: We have analysed a larger (N=540) and more heterogeneous cohort (patients 
with all CMV mismatch-based risk constellations) than most studies on the matter, thereby 
achieving higher statistical power.20,21,25–29 Moreover, our study design is closer to clinical 
reality, with similar valganciclovir doses and prophylaxis duration to those routinely employed 
in the clinic.51 Based on the limitations and advantages of the study, we deem our results as 
evidence that further research is needed to determine the effects of prevention strategies on 
transplantation outcome, especially the hypothetical interactions with sex. 
In summary, our study provides the first evidence in the literature suggesting that the pre-
emptive approach might be associated with improved graft function – especially in female 
patients. Even though the prophylactic strategy was associated with reduced prevalence of 
CMV (re)activation and syndrome, it was associated with higher incidence of acute rejection 
and, for female patients, with a strong impairment of the renal function. The effects of 
prevention strategy on graft function and acute rejection were shown in the multi-parameter 
analysis as independent from potential bias in the cohort. Further randomized controlled 
studies are needed to confirm these observations. 
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Description of Supporting Information 
 
Table S1. Differences in cause of end-stage kidney disease between strategy groups. 
Table S2. Detailed results of the multi-parameter analyses. 
Table S3. Results of the single-parameter analyses for virus-related complications. The 
detailed results of single-parameter associations of prevention strategy, including stratified 
analysis for risk constellation and sex, are reported. Following complications were analysed: 
CMV (re)activation and syndrome, EBV (re)activation and BKV (re)activation 
Figure S4. Graft function dynamics of the prevention strategy groups. Median eGFR (mL·min-
1·1.73 m-2) of the prevention strategy groups is plotted for each protocol visit. The bars 
indicate the interquartile range. The numbers indicate the P value of the difference in eGFR 
between the prevention strategy groups, as calculated using the Mann-Whitney test. Day 0 is 
not shown, as it is pre-transplantation. 
Figure S5. Graft function dynamics of the prevention strategy groups stratified according to 
sex, for patients with living donor. Median eGFR (mL·min-1·1.73 m-2) of the prevention 
strategy groups is plotted for each protocol visit. The bars indicate the interquartile range. 
The numbers indicate the p value of the difference in eGFR between the prevention strategy 
groups, as calculated using the Mann-Whitney test. Day 0 is not shown, as it is pre-
transplantation. For the eGFR dynamics of patients with deceased donors, see Figure 1. 
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8.2 Supplementary materials 
8.2.1 Table S1 
Differences in cause of end-stage kidney disease between strategy groups.  
Cause of end-stage kidney disease Prophylactic strategy group (N=308) 
Pre-emptive strategy group 
(N=232) 
P Value 
Hypertension or large vessel disease 111 (36.0%) 87 (37.8%) 0.738 
Glomerulonephritis 79 (25.6%) 69 (30.0%) 0.308 
Polycystic kidney disease (adult type, dominant) 64 (20.8%) 38 (16.5%) 0.256 
Diabetes 32 (10.4%) 23 (10.0%) 0.997 
Interstitial nephritis or pyelonephritis 20 (6.5%) 19 (8.3%) 0.539 
Secondary glomerulonephritis or vasculitis 7 (2.3%) 4 (1.7%) 0.765a 
Other hereditary or congenital diseases 11 (3.6%) 8 (3.5%) 1.000 
Neoplasms or tumours 4 (1.3%) 0 (0.0%) 0.139a 
Other 109 (35.4%) 72 (31.3%) 0.368 
Undefined cause 27 (9.3%) 24 (11.0%) 0.621 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Causes of end-stage kidney disease are not mutually exclusive. 
8.2.2 Table S2 
Detailed results of the multi-parameter analyses 
8.2.2.1 Table S2A 
Results of the multivariate analysis for eGFR-1 
Explanatory variables Estimate Standard error P value 
(Intercept) 110.2396 7.6568 <0.001 
Recipient age (years) -0.2233 0.0964 0.021 
Donor age (years) -0.4487 0.0718 <0.001 
Body mass index (kg·m-2) -0.9153 0.2174 <0.001 
Cause of end-stage renal disease: Diabetes 6.8268 3.8602 0.078 
White blood cell count (cells·L-1) -0.0062 0.0023 0.007 
Tacrolimus trough level (ng·mL-1) 0.5159 0.2412 0.033 
Acute rejection -6.9392 3.3713 0.041 
Peak BKV viral load -0.8511 0.5140 0.099 
Centre effects - - 0.003 
eGFR-1y was estimated by backwards elimination linear regression, employing all demographic factors 
(Table 1 and Table S1), CMV, BKV and EBV peak viral loads, acute rejection, and centre effects as 
independent variables. As it can be observed, prevention strategy was not an explanatory variable for 
eGFR-1y. Peak viral loads are employed in logarithmic scale (with a value of 0 for viral load below 
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detection limit). The multivariate analysis employs Akaike’s selection criterion for feature selection, so 
that some explanatory variables can have p values over 0.050. The P value for centre effects refers to 
the minimum P value of any transplantation centre.  
Antithymocyte globulin (ATG), BK virus (BKV), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
Estimated glomerular filtration rate one year after transplantation (eGFR-1y) 
8.2.2.2 Table S2B 
Results of the multivariate analysis for eGFR-1y in female patients. 
Explanatory variables Estimate Standard error P value 
(Intercept) 79.9233 13.3498 <0.001 
Prophylactic strategy -13.1533 3.1425 <0.001 
Number of HLA A, B and DR mismatches 
-3.6832 1.0715 0.001 
Donor age (years) -0.4428 0.1057 <0.001 
Body mass index (kg·m-2) -0.4533 0.2391 0.063 
Cause of end-stage renal disease: Glomerulonephritis 12.1778 3.7273 0.002 
Cause of end-stage renal disease: Polycystic kidney disease (adult type, dominant) 6.1548 3.6943 0.101 
Cause of end-stage renal disease: Other hereditary or congenital diseases 11.1914 6.1685 0.075 
Cause of end-stage renal disease: Other 15.6094 3.2340 <0.001 
Cause of end-stage renal disease: Undefined cause -10.1062 5.7397 0.084 
No previous transplantations 15.9178 8.6471 0.071 
Living donor 12.1540 4.1758 0.005 
Donors with expanded criteria 13.0148 4.2287 0.003 
No panel-reactive antibodies before transplantation 
-11.6819 3.8825 0.004 
Low MMF daily dose (< 2000 mg·day-1) -0.0060 0.0036 0.107 
Centre effects - - 0.034 
eGFR-1y was estimated by backwards elimination linear regression, employing all demographic factors 
(Table 1 and Table S1), CMV, BKV and EBV peak viral loads, acute rejection, and centre effects as 
independent variables. As it can be observed, prevention strategy was an explanatory variable for 
eGFR-1y in female patients. Peak viral loads are employed in logarithmic scale (with a value of 0 for 
viral load below detection limit). The multivariate analysis employs Akaike’s selection criterion for 
feature selection, so that some explanatory variables can have p values over 0.050. The P value for 
centre effects refers to the minimum P value of any transplantation centre. 
BK virus (BKV), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Estimated glomerular filtration rate 
one year after transplantation (eGFR-1y) 
8.2.2.3 Table S2C 
Results of the multivariate analysis for acute rejection 
Explanatory variables Estimate Standard error P value 
(Intercept) -4.4311 0.6013 <0.001 
Prophylactic strategy 0.6058 0.3746 0.106 
Number of HLA A, B and DR mismatches 0.4217 0.1126 <0.001 
Cause of end-stage renal disease: Polycystic kidney disease (adult type, dominant) 1.1537 0.4486 0.010 
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Cause of end-stage renal disease: Interstitial nephritis or pyelonephritis 1.1407 0.5709 0.046 
Cause of end-stage renal disease: Other 1.0108 0.4028 0.012 
Acute rejection was estimated by backwards elimination logistic regression, employing all 
demographic factors (Table 1 and Table S1) and centre effects as independent variables. As it can be 
observed, prevention strategy was an explanatory variable for acute rejection. The multivariate 
analysis employs Akaike’s selection criterion for feature selection, so that some explanatory variables 
can have p values over 0.050. Centre effects were not an explanatory variable. 
8.2.2.4 Table S2D 
Results of the multivariate analysis for CMV peak viral load 
Explanatory variables Estimate Standard error P value 
(Intercept) 1.3397 0.2663 <0.001 
Prophylactic strategy -0.7617 0.1866 <0.001 
Cause of end-stage renal disease: Other hereditary or congenital diseases 1.3151 0.6411 0.041 
CMV mismatch-based risk: Medium (R+) -0.3411 0.2170 0.117 
CMV mismatch-based risk: Low (D-R-) -1.2122 0.2216 <0.001 
White blood cell count at transplantation (cells/L) 0.0003 0.0104 0.973 
Therapy arm: arm B (basiliximab) 0.1139 0.1867 0.542 
Therapy arm: arm C (ATG) 0.4730 0.2002 0.019 
Peak viral load in logarithmic scale (with a value of 0 for viral load below detection limit) was estimated 
by backwards elimination linear regression, employing all demographic factors (Table 1 and Table S1) 
and centre effects as independent variables. As it can be observed, prevention strategy was an 
explanatory variable for CMV peak viral load. The multivariate analysis employs Akaike’s selection 
criterion for feature selection, so that some explanatory variables can have p values over 0.050. Centre 
effects were not an explanatory variable. 
Cytomegalovirus (CMV), Seronegative donor and seronegative recipient (D-R-), Seropositive donor and 
seronegative recipient (D+R-), Mycophenolate mofetil (MMF), Seropositive Recipient (R+) 
8.2.2.5 Table S2E 
Results of the multivariate analysis for CMV syndrome 
Explanatory variables Estimate Standard error P value 
(Intercept) 0.2976 0.8122 0.714 
Prophylactic strategy -0.8545 0.4769 0.073 
Donor age (years) 
0.0322 0.0130 0.013 
Cause of end-stage renal disease: Polycystic kidney disease (adult type, dominant) -0.7911 0.4894 0.106 
Cause of end-stage renal disease: Diabetes 1.4590 0.6467 0.024 
Cause of end-stage renal disease: Undefined cause -1.6710 0.7451 0.025 
CMV mismatch-based risk: Medium (R+) -0.9432 0.4523 0.037 
CMV mismatch-based risk: Low (D-R-) -4.9270 1.2280 <0.001 
Living donor -2.7670 0.8390 0.001 
White blood cell count at transplantation (cells/L) 0.0024 0.0100 0.810 
Centre effects - - <0.001 
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CMV syndrome was estimated by backwards elimination logistic regression, employing all 
demographic factors (Table 1 and Table S1) and centre effects as independent variables. As it can be 
observed, prevention strategy was an explanatory variable for CMV syndrome. The multivariate 
analysis employs Akaike’s selection criterion for feature selection, so that some explanatory variables 
can have p values over 0.050. The P value for centre effects refers to the minimum P value of any 
transplantation centre. 
Cytomegalovirus (CMV), Seronegative donor and seronegative recipient (D-R-), Seropositive donor and 
seronegative recipient (D+R-), Epstein-Barr virus (EBV), Seropositive Recipient (R+) 
8.2.2.6 Table S2F 
Results of the multivariate analysis for EBV peak viral load 
Explanatory variables Estimate Standard error P value 
(Intercept) 1.1734 0.3800 0.002 
Number of HLA A, B and DR mismatches 0.0956 0.0504 0.059 
Cause of end-stage renal disease: Hypertension 0.3177 0.1741 0.069 
Cause of end-stage renal disease: Polycystic kidney disease (adult type, dominant) -0.5856 0.2140 0.007 
Cause of end-stage renal disease: Diabetes -0.5938 0.2920 0.043 
Cause of end-stage renal disease: Neoplasms or tumours 2.6790 0.9231 0.004 
Cause of end-stage renal disease: Other -0.2552 0.1758 0.148 
Cause of end-stage renal disease: Undefined cause -0.4536 0.2667 0.090 
Donors with expanded criteria 0.3159 0.1722 0.068 
No panel-reactive antibodies before transplantation -0.6180 0.2861 0.032 
Low MMF daily dose (< 2000 mg·day-1) -0.0003 0.0002 0.077 
Peak viral load in logarithmic scale (with a value of 0 for viral load below detection limit) was estimated 
by backwards elimination linear regression, employing all demographic factors (Table 1 and Table S1) 
and centre effects as independent variables. As it can be observed, prevention strategy was not an 
explanatory variable for EBV peak viral load. The multivariate analysis employs Akaike’s selection 
criterion for feature selection, so that some explanatory variables can have p values over 0.050. The P 
value for centre effects refers to the minimum P value of any transplantation centre. 
Epstein-Barr virus (EBV), Seronegative donor and seronegative recipient (D-R-), Seropositive donor and 
seronegative recipient (D+R-), Mycophenolate mofetil (MMF), Seropositive Recipient (R+) 
8.2.2.7 Table S2G 
Results of the multivariate analysis for EBV peak viral load in female patients 
Explanatory variables Estimate Standard error P value 
(Intercept) 3.9382 1.5158 0.012 
Prophylactic strategy -0.4585 0.3007 0.132 
Body mass index (kg·m-2) 
-0.0365 0.0236 0.128 
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Cause of end-stage renal disease: Hypertension 0.6433 0.3184 0.048 
Cause of end-stage renal disease: Polycystic kidney disease (adult type, dominant) -0.8790 0.2901 0.004 
Cause of end-stage renal disease: Undefined cause -0.8497 0.5349 0.117 
EBV mismatch-based risk: Medium (R+) 0.6816 0.9875 0.493 
EBV mismatch-based risk: Low (D-R-) -1.5917 1.5922 0.321 
No previous transplantations -1.4546 0.8374 0.087 
No panel-reactive antibodies before transplantation 
-0.7155 0.3862 0.069 
Low MMF daily dose (< 2000 mg·day-1) -0.0006 0.0003 0.077 
Centre effects - - <0.001 
Peak viral load in logarithmic scale (with a value of 0 for viral load below detection limit) was estimated 
by backwards elimination linear regression, employing all demographic factors (Table 1 and Table S1) 
and centre effects as independent variables. As it can be observed, prevention strategy was an 
explanatory variable for EBV peak viral load in female patients. The multivariate analysis employs 
Akaike’s selection criterion for feature selection, so that some explanatory variables can have p values 
over 0.050. The P value for centre effects refers to the minimum P value of any transplantation centre. 
Epstein-Barr virus (EBV), Seronegative donor and seronegative recipient (D-R-), Seropositive donor and 
seronegative recipient (D+R-), Mycophenolate mofetil (MMF), Seropositive Recipient (R+) 
8.2.2.8 Table S2H 
Results of the multivariate analysis for BKV peak viral load 
Explanatory variables Estimate Standard error P value 
(Intercept) 1.3949 0.2858 <0.001 
Prophylactic strategy 0.4350 0.2351 0.065 
Number of HLA A, B and 
DR mismatches -0.1121 0.0702 0.112 
Male sex 0.3888 0.2434 0.111 
Cause of end-stage renal 
disease: 
Glomerulonephritis 
0.8651 0.4604 0.061 
Cause of end-stage renal 
disease: Other 0.5334 0.2538 0.037 
Peak viral load in logarithmic scale (with a value of 0 for viral load below detection limit) was estimated 
by backwards elimination linear regression, employing all demographic factors (Table 1 and Table S1) 
and centre effects as independent variables. As it can be observed, prevention strategy was an 
explanatory variable for BKV peak viral load. The multivariate analysis employs Akaike’s selection 
criterion for feature selection, so that some explanatory variables can have p values over 0.050. Centre 
effects were not an explanatory variable. 
BK virus (BKV) 
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8.2.3 Table S3 
Results of the single-parameter analyses for virus-related complications 
8.2.3.1 Table S3A 
Differences in viral events between strategy groups 







P value OR [95% CI] 
CMV 
(re)activation 
Detectable viral load 46 (14.9%) 46 (19.8%) 0.167 1.41 [0.87-2.27] 
Elevated viral load 19 (6.2%) 20 (8.6%) 0.357 1.43 [0.71-2.92] 
High viral load 10 (3.2%) 8 (3.4%) 1.000 1.06 [0.36-3.05] 
CMV 
syndrome 
All 78 (25.3%) 35 (15.1%) 0.005 0.52 [0.33-0.83] 
Mild 39 (50.0%) 24 (68.6%) 
0.204 - Moderate 31 (39.7%) 9 (25.7%) 
Severe 8 (10.3%) 2 (5.7%) 
EBV 
(re)activation 
Detectable viral load 62 (20.1%) 47 (20.3%) 1.000 1.01 [0.64-1.57] 
Elevated viral load 17 (5.5%) 20 (8.6%) 0.215 1.61 [0.78-3.37] 
High viral load 6 (1.9%) 5 (2.2%) 1.000a 1.11 [0.26-4.42] 
BKV 
(re)activation 
Detectable viral load 157 (51.0%) 103 (44.4%) 0.153 0.77 [0.54-1.10] 
Elevated viral load 78 (25.3%) 43 (18.5%) 0.077 0.67 [0.43-1.04] 
High viral load 41 (13.3%) 18 (7.8%) 0.056 0.55 [0.29-1.01] 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees see Methods (2.7). With respect to severity of CMV syndrome, the percentage refers to the 
total number of CMV syndromes. 
BK virus (BKV), Cytomegalovirus (CMV),  95% Confidence interval (95% CI), Epstein-Barr virus (EBV), 
Odds ratio (OR). 
8.2.3.2 Table S3B 
Differences in cytomegalovirus complications between strategy groups stratified for CMV risk 
constellation 
CMV risk 











Detectable  31 (26.1%) 9 (33.3%) 0.598 1.42 [0.51-3.75] 
Elevated  13 (10.9%) 6 (22.2%) 0.123a 2.31 [0.65-7.48] 
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High  6 (5.0%) 3 (11.1%) 0.368a 2.34 [0.35-11.9] 
Syndrome 
 All 43 (36.1%) 8 (29.6%) 0.677 0.75 [0.26-1.97] 
 Mild 14 (32.6%) 6 (75.0%) 
0.062a -  Moderate 22 (51.2%) 1 (12.5%) 




Detectable  12 (8.8%) 35 (27.1%) <0.001 3.86 [1.84-8.63] 
Elevated  5 (3.6%) 13 (10.1%) 0.066 2.95 [0.95-10.88] 
High  3 (2.2%) 5 (3.9%) 0.490a 1.8 [0.34-11.81] 
Syndrome 
 All 30 (21.9%) 27 (20.9%) 0.966 0.94 [0.5-1.77] 
 Mild 23 (76.7%) 18 (66.7%) 
0.460a -  Moderate 7 (23.3%) 8 (29.6%) 




Detectable  2 (4.2%) 1 (1.5%) 0.570a 0.35 [0.01-6.94] 
Elevated  0 (0.0%) 1 (1.5%) 1.000a - 
High  0 (0.0%) 0 (0.0%) - - 
Syndrome 
 All 3 (6.2%) 0 (0.0%) 0.070 0 [0-1.7] 
 Mild 2 (66.7%) 0 (0.0%) 
1.000a -  Moderate 0 (0.0%) 0 (0.0%) 




Detectable  21 (17.1%) 9 (17%) 1.000 0.99 [0.37-2.49] 
Elevated  10 (8.1%) 5 (9.4%) 0.774a 1.18 [0.3-4.02] 
High  5 (4.1%) 2 (3.8%) 1.000a 0.93 [0.09-5.88] 
Syndrome 
 All 29 (23.6%) 8 (15.1%) 0.287 0.58 [0.21-1.43] 
 Mild 14 (48.3%) 4 (50.0%) 
0.878a -  Moderate 10 (34.5%) 2 (25.0%) 
 Severe 5 (17.2%) 2 (25.0%) 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees see Methods (2.7). With respect to severity of CMV syndrome, the percentage refers to the 
total number of CMV syndromes. 
95% Confidence interval (95% CI), Cytomegalovirus (CMV), Seronegative donor and seronegative 
recipient (D-R-), Seropositive donor and seronegative recipient (D+R-), Odds ratio (OR), Seropositive 
Recipient (R+). 
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8.2.3.3 Table S3C 











P value OR [95% CI] 
D+R- 
(N=24) 
Detectable  3 (23.1%) 3 (27.3%) 1.000a 1.24 [0.13-12] 
Elevated  2 (15.4%) 3 (27.3%) 0.630a 2.00 [0.18-29.33] 
High  1 (7.7%) 1 (9.1%) 1.000a 1.19 [0.01-101.86] 
R+ 
(N=400) 
Detectable  49 (20.5%) 32 (19.9%) 0.979 0.96 [0.56-1.63] 
Elevated  12 (5.0%) 14 (8.7%) 0.209 1.80 [0.75-4.39] 
High  5 (2.1%) 3 (1.9%) 1.000a 0.89 [0.14-4.64] 
D-R- 
(N=9) 
Detectable  1 (25.0%) 1 (20.0%) 1.000a 0.77 [0.01-78.24] 
Elevated  0 (0.0%) 0 (0.0%) - - 
High  0 (0.0%) 0 (0.0%) - - 
Arm C 
(N=176) 
Detectable  28 (22.8%) 18 (34%) 0.173 1.74 [0.80-3.73] 
Elevated  8 (6.5%) 6 (11.3%) 0.362a 1.83 [0.49-6.39] 
High  2 (1.6%) 3 (5.7%) 0.162a 3.60 [0.40-44.31] 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees, see Methods (2.7).  
95% Confidence interval (95% CI), Seronegative donor and seronegative recipient (D-R-), Seropositive 
donor and seronegative recipient (D+R-), Epstein-Barr virus (EBV), Odds ratio (OR), Seropositive 
Recipient (R+).  
8.2.3.4 Table S3D 
Differences in viral events between strategy groups stratified by sex 
Sex Viral Event Severity Prophylactic strategy group 
Pre-emptive 





Detectable viral load 29 (14.2%) 28 (19.7%) 0.226 1.48 [0.80-2.73] 
Elevated viral load 11 (5.4%) 13 (9.2%) 0.254 1.77 [0.71-4.50] 
High viral load 7 (3.4%) 6 (4.2%) 0.925 1.24 [0.34-4.42] 
CMV 
syndrome 
All 54 (26.5%) 24 (16.9%) 0.049 0.57 [0.31-0.99] 
Mild 29 (53.7%) 18 (75%) 
0.213a - 
Moderate 19 (35.2%) 4 (16.7%) 
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Severe 6 (11.1%) 2 (8.3%) 
EBV 
(re)activation 
Detectable viral load 49 (24.0%) 25 (17.6%) 0.194 0.68 [0.38-1.19] 
Elevated viral load 15 (7.4%) 13 (9.2%) 0.686 1.27 [0.54-2.97] 
High viral load 5 (2.5%) 4 (2.8%) 1.000a 1.15 [0.22-5.46] 
BKV 
(re)activation 
Detectable viral load 108 (52.9%) 65 (45.8%) 0.229 0.75 [0.48-1.18] 
Elevated viral load 51 (25.0%) 25 (17.6%) 0.133 0.64 [0.36-1.13] 





Detectable viral load 17 (16.3%) 18 (20.0%) 0.636 1.28 [0.57-2.85] 
Elevated viral load 8 (7.7%) 7 (7.8%) 1.000 1.01 [0.30-3.35] 
High viral load 3 (2.9%) 2 (2.2%) 1.000a 0.77 [0.06-6.85] 
CMV 
syndrome 
All 24 (23.1%) 11 (12.2%) 0.076 0.47 [0.19-1.07] 
Mild 10 (41.7%) 6 (54.5%) 
0.741a - Moderate 12 (50.0%) 5 (45.5%) 
Severe 2 (8.3%) 0 (0.0%) 
EBV 
(re)activation 
Detectable viral load 13 (12.5%) 22 (24.4%) 0.049 2.26 [1.00-5.25] 
Elevated viral load 2 (1.9%) 7 (7.8%) 0.084a 4.27 [0.79-43.19] 
High viral load 1 (1.0%) 1 (1.1%) 1.000a 1.16 [0.01-91.65] 
BKV 
(re)activation 
Detectable viral load 49 (47.1%) 38 (42.2%) 0.590 0.82 [0.45-1.51] 
Elevated viral load 27 (26.0%) 18 (20.0%) 0.418 0.71 [0.34-1.48] 
High viral load 11 (10.6%) 7 (7.8%) 0.673 0.71 [0.22-2.13] 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees see Methods (2.7). With respect to severity of CMV syndrome, the percentage refers to the 
total number of CMV syndromes. 
BK virus (BKV), Cytomegalovirus (CMV),  95% Confidence interval (95% CI), Epstein-Barr virus (EBV), 
Odds ratio (OR). 
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8.2.3.5 Table S3E 
Differences in cytomegalovirus complications between strategy groups stratified for CMV risk 
constellation and sex 
Sex CMV risk constellation CMV event Severity 
Prophylactic 
strategy group  
Pre-emptive 






Detectable  18 (21.7%) 7 (36.8%) 0.235a 2.09 [0.60-6.82] 
Elevated  7 (8.4%) 6 (31.6%) 0.014a 4.9 [1.17-20.34] 
High  3 (3.6%) 3 (15.8%) 0.077a 4.89 [0.60-39.93] 
Syndrome 
 All 27 (32.5%) 6 (31.6%) 1.000 0.96 [0.27-3.07] 
 Mild 8 (29.6%) 5 (83.3%) 
0.028a -  Moderate 14 (51.9%) 0 (0.0%) 




Detectable  8 (9.8%) 20 (27.0%) 0.009 3.4 [1.31-9.63] 
Elevated  3 (3.7%) 6 (8.1%) 0.310a 2.31 [0.47-14.82] 
High  3 (3.7%) 3 (4.1%) 1.000a 1.11 [0.14-8.57] 
Syndrome 
 All 22 (26.8%) 18 (24.3%) 0.862 0.88 [0.40-1.92] 
 Mild 19 (86.4%) 13 (72.2%) 
0.423a -  Moderate 3 (13.6%) 4 (22.2%) 




Detectable  2 (5.6%) 1 (2.3%) 0.585a 0.40 [0.01-7.98] 
Elevated  0 (0.0%) 1 (2.3%) 1.000a Inf [0.02-Inf] 
High  0 (0.0%) 0 (0.0%) - - 
Syndrome 
 All 3 (8.3%) 0 (0.0%) 0.087a 0.00 [0.00-1.94] 
 Mild 2 (66.7%) 0 
1.000a -  Moderate 0 (0.0%) 0 




Detectable  12 (14.6%) 5 (17.2%) 0.768a 1.21 [0.30-4.20] 
Elevated  6 (7.3%) 3 (10.3%) 0.695a 1.46 [0.22-7.42] 
High  4 (4.9%) 2 (6.9%) 0.651a 1.44 [0.12-10.71] 
Syndrome 
 All 18 (22.0%) 6 (20.7%) 1.000 0.93 [0.27-2.84] 
 Mild 9 (50.0%) 4 (66.7%) 
0.467a - 
 Moderate 5 (27.8%) 0 (0.0%) 
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Detectable  13 (36.1%) 2 (25.0%) 0.695a 0.60 [0.05-4.01] 
Elevated  6 (16.7%) 0 (0.0%) 0.573a 0.00 [0.00-3.97] 
High  3 (8.3%) 0 (0.0%) 1.000 a 0.00 [0.00-11.54] 
Syndrome 
 All 16 (44.4%) 2 (25.0%) 0.439a 0.42 [0.04-2.81] 
 Mild 6 (37.5%) 1 (50.0%) 
1.000a -  Moderate 8 (50.0%) 1 (50.0%) 




Detectable  4 (7.3%) 15 (27.3%) 0.012 4.72 [1.36-21.05] 
Elevated  2 (3.6%) 7 (12.7%) 0.161a 3.82 [0.68-39.51] 
High  0 (0.0%) 2 (3.6%) 0.495a Inf [0.19-Inf] 
Syndrome 
 All 8 (14.5%) 9 (16.4%) 1.000 1.15 [0.36-3.75] 
 Mild 4 (50%) 5 (55.6%) 
1.000a -  Moderate 4 (50%) 4 (44.4%) 




Detectable  0 (0.0%) 0 (0.0%) - - 
Elevated  0 (0.0%) 0 (0.0%) - - 
High  0 (0.0%) 0 (0.0%) - - 




Detectable  9 (22.0%) 4 (16.7%) 0.753a 0.71 [0.14-3.00] 
Elevated  4 (9.8%) 2 (8.3%) 1.000a 0.84 [0.07-6.45] 
High  1 (2.4%) 0 (0.0%) 1.000a 0.00 [0.00-66.56] 
Syndrome 
 All 11 (26.8%) 2 (8.3%) 0.109a 0.25 [0.02-1.34] 
 Mild 5 (45.5%) 0 (0.0%) 
0.551a -  Moderate 5 (45.5%) 2 (100.0%) 
 Severe 1 (9.1%) 0 (0.0%) 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees see Methods (2.7). With respect to severity of CMV syndrome, the percentage refers to the 
total number of CMV syndromes. 
95% Confidence interval (95% CI), Cytomegalovirus (CMV), Seronegative donor and seronegative 
recipient (D-R-), Seropositive donor and seronegative recipient (D+R-), Infinity (Inf), Odds ratio (OR), 
Seropositive Recipient (R+). 
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8.2.3.6 Table S3F 
Differences in EBV (re)activations between strategy groups stratified for EBV risk constellation 
and sex 




strategy group  
Pre-emptive 





Detectable  3 (27.3%) 2 (25.0%) 1.000a 0.89 [0.06-10.71] 
Elevated  2 (18.2%) 2 (25.0%) 1.000a 1.47 [0.08-25.7] 
High  1 (9.1%) 1 (12.5%) 1.000a 1.40 [0.02-123.06] 
R+ 
(N=256) 
Detectable  37 (23.6%) 18 (18.2%) 0.387 0.72 [0.36-1.41] 
Elevated  10 (6.4%) 10 (10.1%) 0.398 1.65 [0.59-4.61] 
High  4 (2.5%) 3 (3.0%) 1.000a 1.19 [0.17-7.23] 
D-R- 
(N=5) 
Detectable  1 (33.3%) 0 (0.0%) 1.000a 0.00 [0.00-58.45] 
Elevated  0 (0.0%) 0 (0.0%) - - 
High  0 (0.0%) 0 (0.0%) - - 
Arm C 
(N=111) 
Detectable  22 (26.8%) 6 (20.7%) 0.685 0.71 [0.21-2.13] 
Elevated  7 (8.5%) 3 (10.3%) 0.719a 1.23 [0.19-5.92] 





Detectable  0 (0.0%) 1 (33.3%) 1.000a Inf [0.02-Inf] 
Elevated  0 (0.0%) 1 (33.3%) 1.000a Inf [0.02-Inf] 
High  0 (0.0%) 0 (0.0%) 1.000a Inf [0-Inf] 
R+ 
(N=144) 
Detectable  12 (14.6%) 14 (22.6%) 0.313 1.69 [0.66-4.4] 
Elevated  2 (2.4%) 4 (6.5%) 0.403a 2.74 [0.38-31.24] 
High  1 (1.2%) 0 (0.0%) 1.000a 0.00 [0.00-51.54] 
D-R- 
(N=4) 
Detectable  0 (0.0%) 1 (33.3%) 1.000a Inf [0.01-Inf] 
Elevated  0 (0.0%) 0 (0.0%) - - 
High  0 (0.0%) 0 (0.0%) - - 
Arm C 
(N=65) 
Detectable  6 (14.6%) 12 (50.0%) 0.005 5.65 [1.56-22.86] 
Elevated  1 (2.4%) 3 (12.5%) 0.138a 5.56 [0.42-306.72] 
High  0 (0.0%) 1 (4.2%) 0.369a Inf [0.04-Inf] 
Data are given in number (percentage). P value is calculated based on Pearson’s chi-square test or 
Fisher’s exact test (marked with a). Odds ratio and confidence intervals are given only for viral events 
that were significant different between the strategy groups. For the definition of (re)activation severity 
degrees see Methods (2.7).  
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95% Confidence interval (95% CI), Seronegative donor and seronegative recipient (D-R-), Seropositive 
donor and seronegative recipient (D+R-), Epstein-Barr virus (EBV), Infinity (Inf), Odds ratio (OR), 
Seropositive Recipient (R+).  
8.2.4 Figure S4 
Graft function dynamics of the prevention strategy groups 
 
Median eGFR (mL·min-1·1.73 m-2) of the prevention strategy groups is plotted for each protocol visit. 
The bars indicate the interquartile range. The numbers indicate the P value of the difference in eGFR 
between the prevention strategy groups, as calculated using the Mann-Whitney test. Day 0 is not 
shown, as it is pre-transplantation. 
8.2.5 Figure S5 
Graft function dynamics of the prevention strategy groups stratified according to sex, for 
patients with living donor 
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Median eGFR (mL·min-1·1.73 m-2) of the prevention strategy groups is plotted for each protocol visit. 
The bars indicate the interquartile range. The numbers indicate the p value of the difference in eGFR 
between the prevention strategy groups, as calculated using the Mann-Whitney test. Day 0 is not 
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Abstract
Background: Acute cellular rejection (ACR) is associated with complications after kidney transplantation, such as
graft dysfunction and graft loss. Early risk assessment is therefore critical for the improvement of transplantation
outcomes. In this work, we retrospectively analyzed a pre-transplant HLA antigen bead assay data set that was
acquired by the e:KID consortium as part of a systems medicine approach.
Results: The data set included single antigen bead (SAB) reactivity profiles of 52 low-risk graft recipients (negative
complement dependent cytotoxicity crossmatch, PRA < 30%) who showed detectable pre-transplant anti-HLA 1
antibodies. To assess whether the reactivity profiles provide a means for ACR risk assessment, we established a
novel approach which differs from standard approaches in two aspects: the use of quantitative continuous data
and the use of a multiparameter classification method. Remarkably, it achieved significant prediction of the 38 graft
recipients who experienced ACR with a balanced accuracy of 82.7% (sensitivity = 76.5%, specificity = 88.9%).
Conclusions: The resultant classifier achieved one of the highest prediction accuracies in the literature for
pre-transplant risk assessment of ACR. Importantly, it can facilitate risk assessment in non-sensitized patients
who lack donor-specific antibodies. As the classifier is based on continuous data and includes weak signals,
our results emphasize that not only strong but also weak binding interactions of antibodies and HLA 1 antigens
contain predictive information.
Trial registration: ClinicalTrials.gov NCT00724022. Retrospectively registered July 2008.
Keywords: Renal transplantation, Acute cellular rejection, Pre-transplantation risk assessment, Anti-HLA-1 antibodies,
Single HLA antigen bead assay, Immune signatures, Machine learning
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: m.orguil@biologie.hu-berlin.de
1Systems Immunology Lab, Department of Biology, Humboldt University
Berlin, Berlin, Germany
Full list of author information is available at the end of the article




The efficacy of immunosuppressive therapy in kidney
transplantation has steadily increased over the last dec-
ade. As a consequence, the incidence of acute rejection
(AR) episodes has decreased and short-term graft sur-
vival rates have improved [1, 2]. However, long-term
transplant outcomes are still poor and episodes of AR
are known to significantly exacerbate long-term out-
comes [2, 3]. AR is associated with long-term complica-
tions, such as graft dysfunction and reduced graft
survival and AR prevention continues to be a main focus
in the design of new therapeutic strategies for renal
transplantation [4–7]. The most common form of AR is
acute cellular rejection (ACR) [8]. ACR is a T cell cyto-
toxic immune response against the graft, leading to in-
flammatory cell infiltration with tubulitis and, eventually,
damage of the donor tissue [9, 10]. The positive outcome
of ACR if treated early, as well as its potentially irrevers-
ible damage, render it particularly relevant for prevention
research [10, 11]. Regarding non-invasive diagnostics, a
number of studies have obtained good results using tissue,
blood or urine markers [11–18]. For early risk assessment,
the large majority of models are donor-dependent, as they
either employ measurements from the early post-trans-
plantation period or utilize donor-derived data (e.g. from
crossmatch tests) [19–30]. The most common approach
for pre-transplant risk assessment relies on the
characterization of HLA antibodies in recipient serum
samples by solid phase single HLA antigen bead (SAB)
assay [24–29, 31]. The assay facilitates detection and iden-
tification of anti-HLA antibody specificities and provides a
method for monitoring the development of donor-specific
antibodies (DSA). The detection of DSA through SAB as-
says is a well-established method for antibody-mediated
rejection (ABMR) pre-transplantation risk assessment, but
not for ACR [24–30, 32].
Approaches for risk assessment of ACR do not employ
DSA for the prediction – as both patients with or without
DSA experience episodes of ACR – but other risk markers,
such as soluble CD30 levels or panel of reactive T cells [23,
33–35]. However, the inspection of SAB serum antibody
reactivity profiles (irrespective of DSA status) may provide
a means to an ACR risk assessment tool for two reasons:
(1) serum antibody binding profiles against antigen/protein
libraries are generally powerful in discriminating between
different health or disease conditions [36–39], and (2)
antibody-mediated mechanisms have been shown to be in-
volved in the T cell-mediated initiation, perpetuation, and
progression of graft injury [40, 41].
In this work, as part of an exploratory study, we present
a classifier achieving high-accuracy pre-transplant risk as-
sessment of ACR. Remarkably, this classifier is based on
continuous non-thresholded HLA 1 SAB data and does
not rely on donor-specific HLA typing.
Results
Characteristics of the graft recipients included in the
study
Pre-transplant HLA assay data were retrospectively ana-
lyzed as part of a systems medicine approach towards
early risk assessment of ACR [42, 43]. The investigated
study group comprised all kidney transplant recipients
enrolled in the Harmony trial (N = 615) who experienced
at least one ACR or borderline ACR event in the first
year (N = 77) and all transplant recipients who experi-
enced no serious adverse events (N = 80). Median time
to the first ACR event was 20.5 days (range = 4–373
days) (Additional file 1: Figure S1). Demographics and
clinical characteristics of the study groups are summa-
rized in Additional file 4: Table S1.
Pre-transplantation HLA-1 and HLA-2 MAB data
were available for N = 63 recipients of the ACR group
and N = 54 recipients of the control group (for demo-
graphic and clinical characteristics, see Additional file 5:
Table S2). Additionally, HLA-1 SAB data was measured
for all those patients who tested positive for HLA-1
MAB screening (21 ACR + 13 control) and a random
subset of patients who tested negative (13 ACR + 5 con-
trol). In total, pre-transplantation HLA-1 SAB data were
available for N = 34 recipients of the ACR group and N
= 18 of the control group. Due to the higher sensitivity
of SAB assay compared to MAB, the former assay was
considered a better candidate for ACR risk assessment.
Demographic and clinical characteristics of the SAB
ACR (N = 34) and the SAB control group (N = 18) were
compared and are summarized in Table 1. The majority of
patients was male, received their first kidney transplant
and had a deceased donor. There were no significant dif-
ferences between the study groups for the above men-
tioned characteristics as well as immunosuppressive
therapy. However, the mean age of patients in the ACR
group (54.9 ± 11.0) was significantly higher than for the
control group (51.6 ± 11.6; p = 0.04; Mann-Whitney U
test) as was the body mass index (27.7 ± 5.4 vs. 24.2 ± 4.2;
p = 0.01; Mann-Whitney U test). With respect to HLA
mismatches, a significant difference was found for
HLA-DR (p = 0.03; Pearson’s chi-squared test), with an el-
evated frequency of patients with two mismatches in the
ACR group (32.4% vs. 11.1%). No significant differences
were found for HLA-A or HLA-B. There were no signifi-
cant differences regarding PRA between the groups. There
was a near-significant difference in cold ischemia time
with longer times being observed for the ACR group (739
± 295 vs. 637 ± 302; P = 0.06; Mann-Whitney U test).
Conventional HLA SAB data analysis does not permit
pre-transplant risk assessment of ACR
To assess whether HLA-1 SAB reactivity profiles provide
a means for ACR risk assessment, we initially applied
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the conventional data analysis approach used in
HLA-diagnostics to our data set. Central to this ap-
proach is the conversion of the quantitative SAB
assay read-out data into qualitative binary data (1 =
presence of antibody-antigen reactivity, 0 = absence of
reactivity) based on a mean fluorescence intensity
(MFI) threshold. We performed all analyses for a
fixed threshold of 1000 MFI and an individually ad-
justed threshold in the range 253–1068 MFI (Add-
itional file 2: Figure S2). In both cases, there were no
statistically significant differences between the SAB
ACR and the SAB control group in any of the indi-
vidual reactivities (Additional file 6: Table S3 and
Additional file 7: Table S4). That is, there are no indi-
vidual HLA-1 antibody reactivities that allow for risk
assessment of ACR.
To assess whether there is a combination of reactivities
that allows for risk assessment of ACR, we extended the
conventional approach by applying a support vector
machine-based multiparameter classification method to
the binarized data (for details, see Material and Methods).
The resulting multiparameter classifiers did not achieve
significant classification performance (p > 0.1, Table 2).
Taken together, our results indicate that the conventional
HLA SAB data analysis approach does not permit
pre-transplant risk assessment of ACR.
A novel approach built on multiparameter classification
and quantitative data input allows for high accuracy
pre-transplant prediction of ACR
In spite of the widespread use of HLA SAB assays, the in-
terpretation of results obtained following the conventional
Table 1 Characteristics and medication details for the subset of patients included in the HLA class 1 SAB data seta
ACR Control p-value
Number of kidney transplant recipients 34 18 –
Age at time of transplantation (years) 57.9 ± 11.0 51.6 ± 11.6 0.04
Body mass index at time of transplantation (kg/m2) 27.7 ± 5.4 24.2 ± 4.2 0.01
Gender
Female 17 (50.0%) 7 (38.9%) nsb
Male 17 (50.0%) 11 (61.1%)
Type of donor
Living 7 (20.6%) 4 (22.2%) nsc
Deceased 27 (79.4%) 14 (77.8%)
Re-transplantation 3 (8.8%) 0 (0.0%) nsc
HLA-A Mismatchesd
0 11 (32.4%) 9 (50.0%) nsc
1 18 (52.9%) 8 (44.4%)
2 5 (14.7%) 1 (5.6%)
HLA-B Mismatchesd
0 3 (8.8%) 4 (22.2%) nsc
1 18 (52.9%) 11 (61.1%)
2 13 (38.2%) 3 (16.7%)
HLA-DR Mismatches
0 3 (8.8%) 7 (38.9%) 0.03c
1 20 (58.8%) 9 (50.0%)
2 11 (32.4%) 2 (11.1%)
PRA = 0% 31 (91.2%) 16 (88.9%) nsc
Therapeutic Arm
A 12 (35.3%) 6 (33.3%) nsc
B 10 (29.4%) 3 (16.7%)
C 12 (35.3%) 9 (50.0%)
Cold ischemia time: only deceased donors (min) 739 ± 295 637 ± 302 ns
aData are given as mean ± standard deviation for quantitative variables and as number (frequency) for categorical variables. P values for quantitative variables
were calculated by Mann-Whitney U test, for categorical variables either chi-squared (b) or Fisher’s exact test (c) were employed. (d) According to Fisher’s exact test,
there is also no statistically significant differences between the ACR and Control groups when HLA-A and HLA-B mismatches are combined into one group
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data analysis approach remains controversial [44]. A strict
MFI threshold consistently identifying clinically relevant
antibody-antigen reactivities is challenging to define [45].
Since it is likely that the choice of MFI threshold
compromises classification efforts, we applied a novel ap-
proach to the HLA-1 SAB data set that does not rely on
MFI thresholding. Key to this novel approach is the
rank-normalization of the continuous SAB assay read-out
data. Remarkably, a support-vector machine-based multi-
parameter classificator built on these data achieved highly
significant prediction performance with a balanced accur-
acy of 82.7% (Sens. = 76.5%, Spec. = 88.9%, p = 0.002,
Fig. 1a and Table 2). Receiver operating characteristic
(ROC) analysis further emphasizes that the prediction per-
formance was better than a random guess (area under the
curve [AUC] = 0.86) and illustrates the trade-off between
the probability of correctly predicting ACR (true positive
rate, sensitivity) and the probability of incorrectly predict-
ing ACR (false positive rate, specificity) (Fig. 1b). Import-
antly, we found that prediction performance was
independent of a patient’s MAB screening test result, as
patients who tested positive or negative for HLA-1 anti-
bodies are predicted equally well (Fig. 1a). Moreover, the
performance of the continuous data classifier was not due
to age, BMI or HLA-DR mismatch frequency as con-
founding factors; significant classification was not
achieved when HLA class 1 SAB continuous data were
grouped according to either of those factors (≤50 y vs. >
50 y, ≤25 BMI vs. > 25 BMI, or no-mismatch vs. 1–2 mis-
matches). In addition, median-centered bead MFIs did not
show any association with age or BMI (mean Spearman
correlation coefficient r = 0.019 ± 0.129 and r = 0.009 ±
0.133, respectively). Taken together, our results show that
continuous, rank-normalized HLA-1 SAB reactivity pro-
files provide a means of high-accuracy risk assessment of
pre-transplant ACR.
Diagnostics based on HLA antibody detection assays may
generally benefit from the novel approach
The fact that continuous HLA-1 SAB reactivity data out-
performed MFI-thresholded binary data in terms of
pre-transplant prediction of ACR (Table 2) led us to the
conjecture that the conventional approach entails a loss
of information that may compromise HLA-diagnostics
classification efforts in general. To substantiate this
claim, we performed additional analyses on the MAB
screening data (63 ACR + 54 controls). Conventional
MFI-threshold based data analysis revealed no statistical
Table 2 Multiparameter pre-transplant prediction of ACR
Data set Data analysis approach MFI-treshold BACC [%] Sens. [%] Spec. [%] p-value
HLA-1 SAB Conventional, binary data input [0, 1] 1000 62.1 35.3 88.9 ns (p > 0.1)
Conventional binary data input [0, 1] Individually adjusted [253–1068] 70.9 52.9 88.9 ns (p > 0.1)
Novel, continuous data input – 82.7 76.5 88.9 0.002
MAB Novel, continuous data input – 63.9 55.6 72.2 0.040
Fig. 1 Predictive performance of the multiparameter ACR risk assessment classifier based on rank-normalized continuous pre-transplant HLA-1
antibody reactivity profiles. a Output of the classifiers decision function for each patient. The decision threshold is indicated by a dashed
horizontal line. Patients with a decision value > 0 are classified as ACR, patients with a decision value < 0 are classified as control. Colors indicate
whether patients tested positive (black) or negative (grey) for the presence of serum HLA-1 antibodies during MAB screening. b ROC curve of the
multiparameter classifier
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differences between the two study group as to the preva-
lence of HLA class 1 and/or HLA class 2 antibodies
(Fig. 2). A multiparameter classifier based on the
continuous rank-normalized data, however, achieved sta-
tistically significant prediction of the patients who ex-
perience ACR (p = 0.04, Table 2 and Additional file 3:
Figure S3). Even though the accuracy of the classifier
was low and not sufficient for routine risk assessment
(BACC = 63.9%, Sens. = 55.6%, Spec. = 72.2%), the fact
that it was significant emphasizes that the use of con-
tinuous non-thresholded antigen bead assay data favor-
ably affects classification performance.
Discussion
The current study shows that pre-transplant HLA class 1
SAB signatures predict the risk of acute cellular rejection
(ACR) with high accuracy. Importantly, it demonstrates
that HLA antibody signatures contain information on
cell-mediated events to come.
In contrast to the vast majority of existing pre-trans-
plant risk assessment models [24–29, 31], our model
does not rely on DSA reactivity data. The key advantages
of this approach are that i) it facilitates risk assessment
for non-sensitized patients lacking DSA and ii) it can be
carried out independently of donor assignment.
HLA SAB data usually feed into prediction models in
the form of binary data derived from MFI thresholding
– the focus lying on strong binding interactions. Strik-
ingly, our study emphasizes that such an approach en-
tails a loss of information and ultimately results in loss
of or suboptimal prediction performance. The fact that
continuous HLA reactivity data outperform thresholded
binary data (Table 2) indicates that weak binding interac-
tions hold high-value information for risk assessment of
ACR. This is further emphasized by our finding that our
risk assessment tool performs equally well for patients
who tested positive or negative for the presence of HLA-1
antibodies during MAB screening. There is indeed suffi-
cient evidence in the literature to show that weak binding
events are of great importance to biological systems, e.g.
protein-peptide interactions [46], virus-cell interactions
[47], cell adhesion, and cell-cell interactions [48–51]. Our
data suggest that HLA SAB based diagnostics will profit
from inclusion of weak interactions by feeding predic-
tion models with non-thresholded continuous data. A
further advantage of prediction models based on
non-thresholded MFI data is that they are not af-
fected by the prevailing uncertainties regarding the
right choice of the threshold MFI level and by the yet
missing internationally agreed standards [44, 52].
But why is the pre-transplant signature of serum anti-
bodies against HLA-1 SAB predictive for the risk of T
cell mediated rejection? There is evidence in the litera-
ture for an association between anti-HLA serum anti-
bodies and ACR. Crosslinking of HLA-1 antigens
expressed on the surface of donor cells by HLA class 1
antibodies has been shown to trigger the classical com-
plement pathway through binding of C1q. The subse-
quent release of the complement peptides C3a and C5a
then leads to enhanced allo-T cell responses and leuco-
cyte recruitment [53]. That is, pre-transplant HLA class
1 antibodies may be involved in the initiation and
Fig. 2 Conventional MFI-thresholded binary MAB screening data do not allow for pre-transplant risk assessment of ACR. Illustrated are the results
of the MAB screening data of the cohort (117 graft recipients, 63 ACR + 54 controls; for demographics and clinical characteristics, see Additional
file 5: Table S2).). Analyses were carried out on MFI-thresholded binary HLA MAB screening data (conventional approach); according to Fisher’s
exact test, differences with respect to the prevalence of HLA antibodies are not significant (p > 0.05)
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perpetuation of ACR by boosting adaptive T cell activities
after graft transfer. HLA class 1 antibodies have also been
shown to be directly involved in mechanisms that cause
severe graft injury such as endothelial cell activation or
NK cell related FcγR-dependent processes [53]. However,
these mechanisms usually result in histological manifesta-
tions strongly associated with ABMR [53]. Since our study
cohort did not show such manifestations, these processes
are unlikely to be relevant to the predictive value of our
pre-transplant HLA 1 antibody signatures.
The HLA MAB and SAB data used in this study are
part of a large multi-parameter database set up by the
e:KID consortium that seeks to establish a systems
medicine approach to personalized immunosuppressive
treatment at an early stage after kidney transplantation
(http://www.sys-med.de/en/consortia/ekid/). e:KID re-
corded a total of 478 parameters including, among
others, gene expression, cytokine profile, epigenetics,
metabolomics and viral load data as well as common
clinical variables such as renal function or acute phase
proteins. Evaluation of clinical parameters failed to iden-
tify any markers or combinations thereof which are pre-
dictive of ACR [4]. Additionally, no other single
parameter or multiparameter set, other than HLA class
1 SAB signatures, achieved high accuracy pre-transplant
prediction performance. This emphasizes the vast poten-
tial of serum antibodies in diagnostics in general, and, in
particular, for diseases where the antigens are unknown.
The comparison of predictive performances between
our classifier and classifiers in the literature underlines
its relevance to pre-kidney transplant risk assessment
(Additional file 8: Table S5). Its accuracy of 82.7% is i)
one of the highest among all donor-independent risk as-
sessment models [19, 22, 27, 34, 54], ii) comparable to
any AR models [19–24, 26–30, 34, 35, 54, 55] and iii)
comparable to any SAB data based models for ABMR
[24, 26–30]. Furthermore, our classifier is based on SAB,
an established diagnostics laboratory tool, thereby facili-
tating its further use for ACR risk assessment.
Conclusions
Our study establishes a novel tool for pre-transplant risk
assessment of acute cellular rejection. Once externally
validated, patients classified as high risk by our model
will benefit from its implementation through modified
immunosuppression as well as closer monitoring leading
to earlier detection of rejection onset and initiation of
treatment. Consequently, the prognosis and survival rate
of the graft will improve.
Methods
Study aim
The aim of this study is to determine whether SAB serum
antibody reactivity profiles of renal transplantation
recipients can be used for the prediction of ACR during
the first post-transplantation year. For this goal,
pre-transplant HLA assay data were retrospectively ana-
lyzed as part of a systems medicine approach.
Patient population and monitoring
Six hundred fifteen adult kidney transplant recipients
were enrolled in the randomized, multicenter diagnostic
trial Harmony (EudraCT-Nr. 2007–006516-31) [4]. Pa-
tients were treated with a quadruple (arm A) or triple
(arms B and C) immunosuppressive therapy as described
before [4]. The immunosuppressive therapy included in-
duction with either monoclonal IL-2R antibody basilixi-
mab (arms A and B) (Simulect®, Novartis) or rabbit ATG
(arm C) (Thymoglobulin®, Sanofi). Maintenance im-
munosuppression consisted of tacrolimus (Advagraf®,
Astellas) and mycophenolate mofetil (MMF) with (arm
A) or without steroids (arms B and C) [4]. All transplan-
tations were of low immunological risk, with recipient
PRA scores ≤30% and no detectable DSA prior to trans-
plantation (complement-dependent cytotoxicity cross-
match) [4]. Further inclusion and exclusion criteria can
be found in Thomusch et al. [4]. Suspected episodes of
acute rejection were confirmed through biopsy accord-
ing to the Banff criteria of 2005 [56]. For the e:KID pro-
ject, which aims at early risk assessment of ACR by
following a systems medicine approach [42, 43], 157 re-
cipients were retrospectively monitored for the presence
of HLA antibodies in blood serum on day 0 (pre-trans-
plantation). All patients who experienced ACR (border-
line or Banff class 1 or higher) in the first year were
assigned to the ACR group (N = 77). The control group
included all patients who neither experienced a rejection
episode nor other serious adverse events (N = 80).
HLA antibody detection by Luminex multiplex bead assay
Screening for HLA class 1 and class 2 antibodies was
performed using a MAB assay (LABScreen® Mixed Kit,
One Lambda, Canoga Park, CA, USA). All sera that
tested positive and a random subset of negative sera
were subject to SAB assays to identify antibody specific-
ities (LABScreen Single Antigen HLA Class I kit and/or
LABScreen Single Antigen HLA Class II kit, One
Lambda). Both MAB and SAB were performed accord-
ing to the manufacturer’s instructions. Briefly, following
heat-inactivation at 56 °C for 30 min and clearance from
debris (0.22 μm filter), 20 μl of undiluted serum was
added to 3 μl of the LABScreen bead mix and incubated
for 30 min in the dark at room temperature. After a
washing step in 1x LABScreen wash buffer, the bead mix
was incubated with 100 μl of a 1:100 dilution of the
PE-conjugated goat anti-human IgG detection antibody
for 30 min in the dark at room temperature. After a final
washing step in 1x LABScreen wash buffer, data
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acquisition was performed using a FLEXMAP3D Ana-
lyser in combination with xPONENT software version
4.1 (Luminex Corporation, Texas, USA).
Conventional HLA data processing and analysis
Key to the conventional method for HLA data process-
ing is the binarization of the continuous xPONENT me-
dian fluorescence intensity (MFI) raw data by means of a
MFI threshold (1 = presence of reactivity, 0 = absence of
reactivity). For generation of binary data, raw MFI data
were normalized to an in-house negative control serum
(MAB) or the One Lambda negative serum OLI.NS
(SAB). In case of MAB data, a bead was considered posi-
tive if its normalized background ratio exceeded 3. For
binarization of SAB data, we used both a fixed threshold
of 1000 MFI and an individually adjusted MFI threshold.
In case of the latter, a bead was considered positive
when its baseline normalized MFI exceeded 30% of the
MFI of the bead showing the highest strength in reac-
tion. Single parameter prediction performance of binar-
ized HLA class I SAB data was assessed using Fisher’s
exact test. In the case of binarized HLA class reactivity
screening data (MAB), study groups were compared
using Fisher’s exact test.
Experimental design and statistical rationale: novel
strategy for HLA data processing and analysis
In this work we applied a novel approach to the HLA data
sets that does not rely on MFI- thresholding. Key to it is
the use of non-thresholded unprocessed continuous data,
that is unprocessed raw MFI data given out by the FLEX-
MAP3D Analyser in combination with the xPONENT
software. In contrast to the conventional approach, re-
activity may take any value and is not limited to a binary
set of values (reactivity/no reactivity). For downstream
analyses these raw data are rank-transformed; they are not
processed in any other way or form. To assess the predict-
ive potential of the rank-normalized data, we performed
multiparameter classification using an non-public R im-
plementation of the Potential Support Vector Machine
(P-SVM) algorithm [57]. An equivalent public release that
can be run via command line or MatLab interface is pro-
vided under: https://ml.jku.at/software/psvm/. To assess
the predictive performance of the classifier, we followed a
leave-one-out cross-validation approach. The latter pro-
vides a well-established solution to assess a classifier’s pre-
dictive performance for high-dimensional, low sample size
data sets as ours [58]. To rate predictive performance, we
used the statistical measures sensitivity (Sens.), specifi-
city (Spec.) and balanced accuracy (BACC). To assess the
statistical significance of the predictive performance, we
used random class label-permutation testing. The signifi-
cance level was set at p < 0.05. Training of the P-SVM
classifier was performed using the function psvm(),
providing the matrix of training data, the class labels of
the training data, the cost parameter C, the regularization
parameter ε and the parameter epsitol as arguments. In
case of classification of SAB data, we performed grid
search for the hyperparameter space ε = {0.25, 0.5, 0.75, 1}
and C = {1, 6}; the hyperparameter space for MAB
data-based classification was ε = {8, 9, 10, 11} and C = {1,
6}. The parameter epsitol was set to 0.05 for all analyses.
To predict the class labels of test data, we called the func-
tion predict() with the arguments object and x set to the
trained classifier and the test data that is to be predicted,
respectively. True classification and p-value estimation
were always carried out for the same grid of hyperpara-
meters. To further specify the performance of classifica-
tors, receiver operating characteristic (ROC) curve
analysis was performed. The numerical scores (decision
values) that form the basis of P-SVM class identity label
assignment were extracted by setting the argument deci-
sion.values of the predict() function to TRUE. After sort-
ing the decision values in increasing order they were used
as decision boundaries. For each boundary, both sensitiv-
ity and specificity were estimated. AUC was calculated
based on Mann-Whitney U statistics [59].
Statistical analyses
To assess whether the two study groups (control/ACR)
differed in any of the baseline population characteristics,
Mann-Whitney U test (metric variables), Pearson’s
chi-squared or Fisher’s exact test (categorical variables)
were applied. A p-value < 0.05 was considered statistically
significant. Variables are described with mean ± standard
deviation or median [interquartile range (IQR)].
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9.2 Supplementary materials 
9.2.1 Figure S1 
Cumulative frequency of ACR through the first post-transplantation year 
 
Frequency of patients in the ACR group who experienced at least one ACR event at different time 
points post-transplantation. At week 2 and month 3, 34% and 79% of patients in the ACR group had 
experienced an ACR event.  
9.2.2 Figure S2 
Distribution of MFI cutoffs for generation of binary HLA class 1 SAB data 
 
Illustrated are the MFI cutoff values of the 52 pre-transplant serum samples (control group = 18; ACR 
group, Rej = 34) of the binary HLA class 1 SAB data (1: presence of reactivity = above the MFI cutoff). 
9.2.3 Figure S3 
Predictive performance of multiparameter ACR classification based on rank-normalized 
continuous pre-transplant MAB screening data. 
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(A) Output of the classifiers decision function for each patient. The decision threshold is indicated by 
a dashed horizontal line. Patients with a decision value > 0 are classified as ACR, patients with a 
decision value < 0 are classified as control. Colors indicate whether patients tested positive (black) or 
negative (grey) for the presence of serum HLA-1 antibodies during MAB screening. (B) ROC curve of 
the multiparameter classifier. 
9.2.4 Table S1 
Study population characteristics and medication details of the Harmony cohorta 
 
ACR  Control p-value 
Number of kidney transplant recipients 77 80 - 
Age at time of transplantation (years) 54.9 ± 12.1 49.5 ± 12.6 0.005 
Body mass index at time of transplantation (kg/m2) 27.0 ± 5.3 25.6 ± 4.6 0.09 
Gender Female 31 (40.3%) 29 (36.2%) nsb 
Male 46 (59.7%) 51 (63.8%) 
Type of donor Living 10 (13.0%) 19 (23.8%) 0.13b 
Deceased 67 (87.0%) 61 (76.2%) 
Re-transplantation 5 (6.5%) 1 (1.3%) 0.11c 
HLA-A Mismatches 0 25 (32.5%) 33 (41.3%) 0.18b 
1 38 (49.4%) 40 (50.0%) 
2 14 (18.2%) 7 (8.7%) 
HLA-B Mismatches 0 13 (16.9%) 24 (30.0%) 0.09b 
1 39 (50.6%) 39 (48.7%) 
2 25 (32.5%) 17 (21.3%) 
HLA-DR Mismatches 0 16 (20.8%) 28 (35.0%) 0.03b 
1 39 (50.6%) 41 (51.2%) 
2 22 (28.6%) 11 (13.8%) 
PRA = 0%  70 (90.9%) 75 (93.4%) nsc 
Therapeutic  Arm A 25 (32.5%) 33 (41.3%) nsb 
B 29 (37.7%) 21 (26.2%) 
C 23 (29.9%) 26 (32.5%) 
Cold ischemia time: only deceased donors (min) 704 ± 290 718 ±275 0.06 
 
aData are given as mean±standard deviation for quantitative variables and as number (frequency) for 
categorical variables. P values for quantitative variables were calculated by Mann-Whitney U test, for 
categorical variables either chi-squared (b) or Fisher’s exact test (c) were employed.  
ACR: acute cellular rejection; ns: non-significant; PRA: panel reactive antibody. 
9.2.5 Table S2 
Study population characteristics and medication details of the patients with HLA MAB dataa 
 
ACR  Control p-value 
Number of kidney transplant recipients 63 54 - 
Age at time of transplantation (years) 55.8 ± 11.3 49.7 ± 12.6 0.007 
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Body mass index at time of transplantation (kg/m2) 26.8 ± 5.3 25.1 ± 4.4 0.09 
Gender Female 26 (41.3%) 16 (29.6%) nsb 
Male 37 (58.7%) 38 (70.4%) 
Type of donor Living 8 (12.7%) 12 (22.2%) nsb 
Deceased 55 (87.3%) 42 (77.8%) 
Re-transplantation 4 (6.3%) 0 (0.0%) 0.12c 
HLA-A Mismatches 0 20 (31.7%) 20 (37.0%) nsb 
1 30 (47.6%) 29 (53.7%) 
2 13 (20.6%) 5 (9.3%) 
HLA-B Mismatches 0 9 (14.3%) 12 (22.2%) nsb 
1 34 (54.0%) 29 (53.7%) 
2 20 (31.7%) 13 (24.1%) 
HLA-DR Mismatches 0 10 (15.9%) 20 (37.0%) 0.009b 
1 35 (55.6%) 28 (51.9%) 
2 18 (28.6%) 6 (11.1%) 
PRA = 0%  59 (93.7%) 51 (94.4%) nsc 
Therapeutic  Arm A 22 (34.9%) 20 (37.0%) nsb 
B 21 (33.3%) 17 (31.5%) 
C 20 (31.7%) 17 (31.5%) 
Cold ischemia time: only deceased donors (min) 710 ± 292 729 ±293 0.10 
 
aData are given as mean±standard deviation for quantitative variables and as number (frequency) for 
categorical variables. P values for quantitative variables were calculated by Mann-Whitney U test, for 
categorical variables either chi-squared (b) or Fisher’s exact test (c) were employed.  
ACR: acute cellular rejection; ns: non-significant; PRA: panel reactive antibody. 
9.2.6 Table S3 
Single parameter pre-transplant prediction of ACR based on binarized HLA class 1 single 
antigen bead (SAB) data (fixed MFI threshold of 1000 MFI).  






















B13  0.682 
B18  0.285 
B27  0.543 
B35  1.000 
B37  1.000 
B38  0.543 
B39  1.000 
B41  1.000 
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B42  1.000 
B44  1.000 
B45  1.000 
B46  0.602 
B47  1.000 
B48  0.150 
B49  0.543 
B50  0.538 
B51  0.399 
B52  0.081 
B53  1.000 
B54  NA 
B55  0.538 
B56  1.000 
B57  0.300 
B58  0.698 
B59  0.285 
B60  0.543 
B61  0.543 
B62  1.000 
B63  0.285 
B64  NA 
B65  NA 
B67  0.538 
B7 B 0.648 
B71  1.000 
B72  0.543 
B73  1.000 
B75  0.648 
B76  0.327 
B77  0.543 
B78  1.000 
B8 B 0.648 
B81  0.648 
















*P-values are not corrected for multiple testing. 
ACR: acute cellular rejection; SAB: single antigen bead screening; NA: not applicable. 
9.2.7 Table S4 
Single parameter pre-transplant prediction of ACR based on binarized HLA class 1 single 
antigen bead (SAB) data (individually adjusted MFI threshold).  






















B13  0.236 
B18  0.543 
B27  0.543 
B35  0.648 
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B37  0.538 
B38  0.538 
B39  0.538 
B41  0.538 
B42  1.000 
B44  1.000 
B45  1.000 
B46  1.000 
B47  1.000 
B48  0.081 
B49  0.285 
B50  0.538 
B51  0.648 
B52  0.150 
B53  0.648 
B54  1.000 
B55  0.543 
B56  0.538 
B57  0.425 
B58  1.000 
B59  0.543 
B60  0.285 
B61  0.543 
B62  0.543 
B63  0.285 
B64  1.000 
B65  1.000 
B67  0.538 
B7 B 0.285 
B71  0.543 
B72  0.285 
B73  NA 
B75  0.150 
B76  1.000 
B77  0.285 
B78  0.543 
B8 B 0.538 
B81  0.285 

















*P-values are not corrected for multiple testing. 
ACR: acute cellular rejection; SAB: single antigen bead screening; NA: not applicable. 
9.2.8 Table S5 
Summary of existing AR prediction models 













100 87 93.5 HLA-2 DSA SAB Yes No 
5 ABMR (2 
Mixed 
ABMR+ACR) vs. 
22 No ABMR (4 
ACR) 




93.3 89 91.15 Urinary CXCL9  No - 
15 AR (14 ACR, 
1 ABMR) vs. 54 
No AR 




87.1 91.8 89.45 sCD30 No - 
49 AR vs. 182 
No AR 
Lefaucheur 
et al. 2010 
2063429
7 
90.6 85.4 88 HLA DSA SAB  Yes No 
32 ABMR vs. 
370 No ABMR 
(18 ACR) 




82 90 86 
Expression levels 
of Perforin and 
Granzyme B 
No - 
17 AR vs. 50 No 
AR 
Shaikhina et 
al. 2017 - 81.8 88.9 85.35 
DSA HLA + IgG4 








et al. 2019 
3102908
6 76.5 88.9 82.7 
Quantitative 
HLA-1 SAB Yes Yes 
34 ACR vs. 18 
No AR 
Riethmüller 
et al. 2010 
2065876
0 





Mixed) vs. 29 
No ABMR (10 
ACR) 




86 78 82 
Elispot Panel of 
Reactive Cells 
Yes Yes 
7 ACR (1 Mixed 
ABMR+ACR) vs. 





70 93 81.5 HLA DSA SAB  Yes No 
10 ABMR vs. 14 






87.5 73.4 80.45 
Proportion of 
CD95+ CD8+ T 
Cells 
Yes Yes 
14 AR (2 
ABMR) vs. 65 
No AR 








PD1 Expression T 
cells 
Yes Yes 
9 AR (1 ABMR) 
vs. 17 No AR 
Malheiro et 
al.  2015 
2566187
3 
85.7 73.1 79.4 HLA DSA SAB  Yes No 




26 No ABMR (2 
ABMR) 








15 ACR vs. 35 
No AR 
Vondran et 
al.  2014 
2493103
1 
75 69.2 72.1 
sCD25, sCD30 and 
sCD44 
Yes Yes 
7 ACR vs. 18 
No AR (5 
Borderline) 




70 71.7 70.85 sCD30 No - 
23 AR vs. 180 
No AR 
*Calculated by the authors of this study as the average of specificity and sensitivity.
** Not shown in the publication; calculated by the authors of this study. 
ABMR: antibody-mediated rejection; ACR: acute cellular rejection; AR: acute rejection; BACC: balanced 
accuracy; Donor-ind: donor-independent marker; DSA: donor-specific antibodies; SAB: single antigen bead 
screening; Sens: sensitivity; Spec: specificity; NA: not applicable; PMID: PubMed Identifier; Pre-Tx: pre-
transplantation marker. 
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Abstract
BK virus (BKV) associated nephropathy affects 1–10% of kidney transplant recipients, lead-
ing to graft failure in about 50% of cases. Immune responses against different BKV antigens
have been shown to have a prognostic value for disease development. Data currently sug-
gest that the structural antigens and regulatory antigens of BKV might each trigger a differ-
ent mode of action of the immune response. To study the influence of different modes of
action of the cellular immune response on BKV clearance dynamics, we have analysed the
kinetics of BKV plasma load and anti-BKV T cell response (Elispot) in six patients with BKV
associated nephropathy using ODEmodelling. The results show that only a small number of
hypotheses on the mode of action are compatible with the empirical data. The hypothesis
with the highest empirical support is that structural antigens trigger blocking of virus produc-
tion from infected cells, whereas regulatory antigens trigger an acceleration of death of
infected cells. These differential modes of action could be important for our understanding
of BKV resolution, as according to the hypothesis, only regulatory antigens would trigger
a fast and continuous clearance of the viral load. Other hypotheses showed a lower degree
of empirical support, but could potentially explain the clearing mechanisms of individual
patients. Our results highlight the heterogeneity of the dynamics, including the delay
between immune response against structural versus regulatory antigens, and its relevance
for BKV clearance. Our modelling approach is the first that studies the process of BKV clear-
ance by bringing together viral and immune kinetics and can provide a framework for per-
sonalised hypotheses generation on the interrelations between cellular immunity and viral
dynamics.
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Author summary
BK virus (BKV) is the cause of a kidney disease affecting 1–10% of kidney transplant
recipients, which leads to transplantation failure in about 50% of the cases. This disease
is not well understood, but there are indications that markers of the immune response
against BKV can be used to predict the outcome. Since the immune response can act
through different modes of action, we have studied the dynamics between immune
response and virus to determine which modes of action play an important role in the fight
against BKV. We have analysed immune and viral kinetics in six kidney transplantation
patients and developed a mathematical model to integrate the data and better understand
the interactions between virus and immune response to different BKV antigens. Our
results allow for discarding the majority of action modes hypotheses. The most supported
hypothesis is: structural proteins trigger the blocking of virus production by infected cells,
whereas non-structural proteins trigger the acceleration of infected cells death. This differ-
ence could be central for disease outcome, as under this hypothesis only the latter would
trigger a fast and continuous BKV clearance.
Introduction
In the last years, BK virus-associated nephropathy (BKVN) has become the most challenging
infectious cause of renal graft dysfunction in kidney transplant, leading to graft failure in over
50% of cases [1,2]. The rise in BKVN incidence has been attributed, at least to some degree, to
the increased potency of immunosuppressive drugs [3,4]. Given the absence of specific antivi-
ral treatments, BKVN is handled by changing the immunosuppressive regimes of the patients,
enabling the development of a specific antiviral immune response [3–5]. Diagnosis of BKVN
is performed through renal biopsy [3,6–8] as progression of the illness occurs without clinical
signs, except for an increase in serum creatinine concentrations [1]. In the absence of medical
intervention, BKVN can cause extensive fibrosis and tubular atrophy in the allograft, leading
to transplant loss [1,3,7]. This progression is accompanied by a high BK virus (BKV) plasma
load. Therefore, screening of plasma BKV viral load is currently recommended for the moni-
toring of BKVN [8,9].
BKV is a non-enveloped virus with an icosahedral capsid and a small circular double-
stranded DNA genome (~5kb), which encodes for the early regulatory proteins: small tumor
antigen (st) and large tumor antigen (LT) (here collectively referred to as sLT antigens), the
late structural viral proteins 1–3 (VP1, VP2 and VP3) (here referred to as VP antigens) and the
agnoprotein [3,10]. Latent BKV infection is very common among the healthy population, with
a prevalence above 80% [3,11–13].
In spite of a high frequency of self-limited BKV reactivation in kidney transplant recipients
[12,14,15], only 1–10% [2] of transplant recipients do actually develop BKVN. To determine
the factors leading to BKVN, much emphasis has been placed on the immune reaction against
BKV antigens. sLT and VP antigens (but not the agnoprotein) have been demonstrated to elicit
a T cell response, as we previously showed in our studies [16–18]. Our data suggest that cellular
immune reaction has a prognostic value for BKVN evolution [16]. However, T cell response
can act through a number of mechanisms—killing of infected cells, blocking virus production
or infection, among others—which should have different impacts on viremia control.
Although our data [16] suggest that VP and sLT antigens trigger substantially different
immune responses, the experimental data alone do not allow to determine the relation
between antigens, immune mechanisms and clearance. Sophisticated instruments, such as
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mathematical models tailored for data analysis of this particular question, are required to for-
malise and analyse whether different antigens trigger different immune mechanisms and what
these modes of action are.
The most widely used method for modelling viral dynamics is ordinary differential equa-
tions (ODE). It has, for instance, helped elucidate the dynamics of HIV-1, hepatitis and
opportunistic viruses in transplant recipients [19]. It has also been used for the study of BKV,
simulating the dynamics of viral production, predicting cytopathic effects of the virus and
explaining the interactions between viral reactivation in tubular epithelial cells, urothelial cells,
viremia and viruria [20,21]. However, to our knowledge, no model exists that incorporates the
activation of the immune response with viral clearance dynamics.
Therefore, in this study we have retrospectively analysed the data of BKV plasma load kinet-
ics and T cell responses against BKV antigens in six patients with biopsy-proven BKVN [16].
The objective of the analysis was to determine the dominant modes of action of the observed
immune responses. For this, a tailor-made ODE model was generated, allowing for the forma-
lisation of different hypotheses on the dominant modes of action of the immune response
against BKVN.
To accomplish our goal, we pursued the following strategy: Firstly, we obtained a continu-
ous curve that fits the time course of the T cell response data (Elispot) for each patient and
antigen. Secondly, we designed an ODE model for the viral load clearance dynamics depen-
dent on the T cell response curves. This model uses the former curves as input and simulates
the dynamics of three variables: number of healthy cells, number of infected cells and BKV
viral load. It incorporates three mechanisms of the immune system in viral clearance, allowing
for the simulation of nine different hypotheses about dominant modes of action. Lastly, we
evaluated all hypotheses for their capacity to reproduce the viral clearance data. Our results
allowed for the discarding of most hypotheses and suggested that the anti-VP response induces
the blocking of virus production while anti-sLT responses induces killing of infected cells.
This difference in modes of action could be central for disease outcome, since only the sLT
responses would trigger a fast and continuous BKV clearance under this hypothesis. These
results could therefore have implications in the development of new immunotherapies against
BKVN.
Results
Patient characteristics and clinical data
The study involved six renal transplant patients analysed in our previous study [16]. These six
patients (called Patient A to F in the following) received renal transplants between 12/2004
and 05/2009 and developed severe BKV reactivation in follow-up. The patients were moni-
tored for BKV viral load by quantitative polymerase chain reaction (qPCR). Cellular adaptive
immune response against the BKV antigens (VP1, VP2, VP3, st and LT) was monitored by
Interferon gamma (IFN-γ) Enzyme-Linked ImmunoSpot (Elispot), measured in spot forming
units (SFU) per 106 peripheral blood mononuclear cells (PBMC). Elispot read-outs are known
to accurately quantify antigen-specific T cell responses for BKV [22].
All patients had biopsy-proven BKVN and were initially treated with a tacrolimus-based
immunosuppressive regimen. Tacrolimus is a calcineurin inhibitor. It inhibits T cell activation
but does not have cell-depleting effects [23]. It is associated with significantly higher incidence
of BKVN compared to cyclosporine A, a less potent calcineurin inhibitor [24]. Upon BKV
reactivation and diagnosis of BKVN, tacrolimus was replaced by cyclosporine A. This immu-
nosuppressant switch is a commonly used protocol against BKVN, as cyclosporine A is known
to allow the onset of a T cell response against BKV [16,25]. Patients were monitored for BKV
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viral load during the complete evolution of the illness. The immune response was measured at
the latest from the point of immunosuppressant switch until BKV clearance (Fig 1).
Description of viral load and Elispot experimental data
We observed a considerable diversity in the times needed to reach viremia clearance for each
patient, ranging from 117 days after viremia onset for Patient F to 1744 days (~4 years) for
Patient A. However, some common patterns could be observed. The immune response came
generally in two waves, the first with an anti-VP immune response (red, pink and yellow lines
in Fig 1) and the second, targeted against sLT antigens (light and dark green). Importantly, the
immune response against VP was triggered for all but patient C within a relatively short span
of time (< 70 days) after immunosuppressant switch. On the other hand, immune response
against the sLT antigens was observed in only five patients. Again patient C did not show any
Fig 1. Viral load and immune response data of the patients. For each patient, the time course of viral load (black) and the Elispot read-out for each immunogenic
BKV antigen (coloured) are plotted. The change of immunosuppressant therapy is marked as a dashed blue line. This change in immunosuppressant therapy is
known to foster the development of an immune response against BKV. On the upper row the patients that had not cleared within 700 days after transplantation are
shown, while those that achieved clearance in a shorter time appear in the lower row. Please note the difference of time scales between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g001
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immune response against either sLT antigen. Based on the delay between the VP and the sLT
immune responses, patients could be grouped in two categories: Patients D, E and F showed a
short delay of approximately 30 days, while patients A and B showed a much longer delay of
over 180 days.
The triggering of cellular immune responses against the BKV antigens occurred after the
immunosuppressant switch. This immune response led to a progressive decrease of viral load
until viral clearance was achieved. This decreasing phase took place for hundreds of days on
most cases. In the five patients showing an anti-sLT immune response, the emergence of this
response was tied to a substantially faster viral load decrease. This strongly suggests that the
kind of immune response triggered by the sLT antigens is inherently different from the one
triggered by VP antigens.
Fitting of a model of the immune response against BKV to obtain
continuous curves describing the T cell response
With the goal of using the immune response data as an input for the viral load clearance
dynamics model, we developed a simple curve based on one or more logistic functions to
describe the experimentally observed T cell response. The use of logistic functions to describe
T cell dynamics of antigen specific populations was chosen due to their simplicity and capacity
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antia(t) is the T cell response for an antigen, where a represents the antigen that elicits the
response. For the definition of parameters see Table 1. We chose the activation time ta as a free
parameter because the T cell response may start at different points in time for every antigen.
As it is possible that an immune response presents multiple boosting episodes, we considered
the possibility that at a second time point ta2 the parameters of the curve are replaced by a sec-
ond set of parameters. We fitted this function to the BKV specific immune response against
each of the five antigens (VP1, VP2, VP3, st and LT).
t = 0 was defined at a day for which there are both Elispot and viral load data and the viral
load is maximum compared to all later measurements. This was defined as follows: Patient A,
day 1363 after transplantation; B, day 412; C, day 538; D, day 175; E, day 235; and F, day 530.
Simulations were performed until the time point viral load becomes undetectable or there are
no further Elispot measurements. This time point was chosen because we aim to model only
the clearance process. The objective function used for the fitting takes the form of vertical
Table 1. Immune function curve parameters.
Name Meaning Unit
ta Activation time of immune response Days
ra Immune response growth rate Days-1
maxantia Maximum immune response SFU   10−6 PBMC
deca Maximum response decay rate Days-1
Definition of the parameters of the immune function curve (Eq 1)
https://doi.org/10.1371/journal.pcbi.1005998.t001
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where  yÖt; aÜ is the experimental value of the Elispot read-out at time t for antigen a. y(t,a,p)
is the calculated Elispot read-out for a given parameter set p.N is the total number of measure-
ments and A is the number of screened antigens. The results of the parameter estimation are
shown in S1 Table and Fig 2. As depicted in Fig 2, Eq 1 was sufficient to reproduce the immune
response time courses of all six patients. For the immune response to the structural antigens of
Patient A, a time point ta2 with a second parameter set was employed to achieve a minimum
value for the objective function of (4.16 10−2), instead of the minimum achieved for only one
parameter set (2.24 10−1) (see S1 Fig).
In order to study the differences in the mechanisms of the immune responses against struc-
tural (VP1, VP2, VP3) and regulatory (st, LT) antigens, the results of the fitting were summarised
Fig 2. Fitting of immune response data. The calculated values for the immune response (lines) are plotted against the observed values (plus sign). Note the
difference of time scales between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g002
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in a VP function and a sLT function. These functions are employed in the model of BKV viral
load clearance as an input, to model the influence of each immune response against BKV.
VPÖtÜ à maxÖantiVP1ÖtÜ; antiVP2ÖtÜ; antiVP3ÖtÜÜ   1
sLTÖtÜ à maxÖantistÖtÜ; antiLTÖtÜÜ   1 Ö3Ü
The maximum value is taken under the assumption that the effects of the antigens are not
additive, but that there is some degree of saturation. The functions are subtracted by one unit
because 1 is the baseline value of the logistic curve antia(t).
Model of BKV viral load clearance in dependence on immune response
time course
The evolution of BKV viral load clearance was described using a modified version of a basic
model of viral dynamics [29], such that
d
dt
C tÖ Ü à g   C tÖ Ü   1  CÖtÜ á IÖtÜ
maxc
✓ ◆
  d   C tÖ Ü   b   C tÖ Ü   V tÖ Ü   1  nÖtÜÖ Ü
d
dt
I tÖ Ü à b   C tÖ Ü   V tÖ Ü   1  nÖtÜÖ Ü   d   k   I tÖ Ü   1ám   mÖtÜÖ Ü
d
dt
V tÖ Ü à p   I tÖ Ü   1  ✏ÖtÜÖ Ü   c   V tÖ Ü Ö4Ü
This model contains three variables: number of healthy cells (C), number of infected cells
(I) and BKV viral load in copies  mL-1 (V). Healthy cells proliferate at a rate proportional to g;
this rate is limited bymaxc, which represents total number of cells (including both healthy and
infected). Healthy cells die at a rate d and are infected in presence of virus at a rate β. Infected
cells die at a rate d   k, where k is virus-associated cytopathicity. Viruses are produced by the
infected cells at a rate p and get cleared by the excretory system at a rate c. For a schematic
representation of the model, see Fig 3. For a further definition of the parameters, see Table 2.
The three model variables (C, I and V) depend on the T cell response curves as defined in
previous section. To study the mode of action of T cell responses, we consider that T cells can
act via three mechanisms: (1) virus production blockage (described by function ε(t)), (2) kill-
ing of the infected cells (described by function μ(t)) and (3) infection blockage (described by
function υ(t)). ε(t), μ(t) and υ(t) take the form of the sum of Hill functions, a standard form for
describing a saturating function, with a maximum value of 1, such that
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Fig 3. Schematic representation of the ODEmodel.Healthy cells produce other healthy cells (rate proportional to g) and die at rate d. The virus triggers
the conversion of healthy cells into infected cells (rate β). Infected cells die at rate d k and produce the virus at rate p, which is cleared at rate c. The immune
system can intervene through three different mechanisms: blocking virus production (ε(t)), enhancing infected cell death (μ(t)) and blocking infection
(ν(t)).
https://doi.org/10.1371/journal.pcbi.1005998.g003
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where ε(t), μ(t) and υ(t) depend on the VP(t) and the sLT(t) immune responses, as defined in
Eq 3.
Hypotheses on immune modes of action on the BKV viral load clearance
model
The objective of our work is to find the dominant modes of action responsible for viral load
clearance. Therefore, we assume for the model that each one of the two immune responses
(VP(t) and sLT(t)) acts through only one mode of action, either ε(t), μ(t) or υ(t) (Eq 5). As
these are three modes of action and two antigen-specific responses, nine different hypotheses
on the relationship between dominant modes of action and immune response are possible.
These nine hypotheses are referenced here following this convention: For example, the
hypothesis that anti-VP triggers a μ(t) response (accelerated killing) and anti-sLT triggers a
υ(t) response (infection blockage) is named VPμ-sLTυ hypothesis. For the definition and
description of all nine hypotheses, see S2 Table.
Testing of hypotheses for dominant modes of action of the immune system
in BKV clearance
To evaluate the feasibility of the hypotheses for dominant modes of action of the immune sys-
tem, the model was fitted against the BKV clearance data for all nine hypotheses. The parame-
ters c, g, d, β and p were estimated based on previous publications. Parameter k was estimated
for each hypothesis based on one particular patient, while the remainder of the parameters
were estimated individually for each patient and hypothesis.
The rate constant c for virus clearance was fixed to the value calculated by Funk et al. [30].
In the case of g, which is the maximum replication capacity for C(t) + I(t)<<maxc, cell culture
results show a maximum duplication rate of approximately one day for renal foetal kidney
cells [31]. Therefore, for the sake of simplicity we assigned a value of 1 days-1 for g. For the cell
death rate of healthy cells d, a value of 0.01 days-1 was used on a model of similar structure for
Hepatitis C virus [32] and it was deemed to be reasonable estimation here. The value of the
virus production rate p was calculated in the same model to be 100 copies  mL-1   cells-1  
days-1 [32]. Given that BKV is a less aggressive infection, we deemed it reasonable to assume
a value of 15 copies  mL-1  cells-1   days-1. This has the property that, for I(t) = V(t) and no
immune reaction, the viral load is in a steady state. Likewise, as the cell infection rate β for
the Hepatitis C virus was estimated to be 3 10−7 copies-1  mL   days-1 [32], a value of 3 10−8
copies-1  mL   days-1 for BKV was assumed. Patient C had the slowest progression of viral
Table 2. Viral load clearance model parameters.
Name Meaning Unit
g Self-regeneration of healthy cells rate Days-1
maxc Maximum number of total cells Cells
d Cell death independent of viral cytotoxicity rate Days-1
β Cell infection rate Copies-1  mL   days-1
k Viral cytopathicity factor Unitless
p Virus production rate Copies  mL-1   cells-1   days -1
c Virus clearing rate Days-1
m Maximum value of accelerated killing with μ(t) Unitless
Definition of the parameters of the viral load clearance model (Eq 4)
https://doi.org/10.1371/journal.pcbi.1005998.t002
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clearance, which suggests that immune cytotoxic effects were relatively low. Therefore, we esti-
mated the viral cythopathic factor (k) for all patients using data obtained from Patient C. The








which takes the form of vertical least-squares. N is the total number of measurements,  yÖtÜ is
the viral load at the time t, y(t, p) is the simulated viral load for a parameter set p and time t.
The initial conditions for all cases were
For t = 0:
C 0Ö Ü à maxc  
c
p
  V 0Ö Ü
I 0Ö Ü à c
p
  V 0Ö Ü
VÖ0Ü à VÖ0Ü Ö7Ü
so that, at time t = 0 and no immune response, viral load is in steady state. V(0) is defined as
the observed viral load at t = 0. t = 0 was defined as above. The results obtained for the fittings,
as well as the model selection criterion (see Materials and methods) for each hypothesis and
patient, are shown in Table 3.
The results in Table 3 were interpreted to discard hypotheses based on the ΔBIC score and
the value of the objective function. Accordingly, there is good empirical support to generally
discard hypotheses VPν-sLTν and VPν-sLTε as probable mechanisms for viral clearance.
Table 3. Results of the model fitting for the hypotheses on dominant immune modes of action.
Patient Measurement VPε-sLTε VPε-sLTμ VPε-sLTν VPμ-sLTε VPμ-sLTμ VPμ-sLTν VPν-sLTε VPν-sLTμ VPν-sLTν
Number parameters 7 6 5 6 7 6 5 6 7
A f 0.11957 0.03090 0.06613 0.05490 0.04409 0.06091 0.14584 0.05053 1.88160
ΔBIC 11.4180 0.0000 3.3800 4.0233 4.4336 4.7510 8.9165 3.4425 30.7098
B f 0.06843 0.01120 0.06046 0.03153 0.02190 0.02233 0.06159 0.01994 0.06227
ΔBIC 14.6151 0.0000 9.8562 7.2449 6.6399 4.8297 9.9857 4.0387 13.9550
C f 0.01280 0.01030 0.01230 0.01070 0.01070 0.01070 0.01050 0.01050 0.01020
ΔBIC 5.6813 0.0000 2.48438 0.5334 3.1725 0.5334 0.2692 0.2692 2.5025
D f 0.00005 0.00044 0.10923 0.01080 0.18563 0.15925 0.01870 0.13048 2.33900
ΔBIC 0.0000 7.2157 27.9327 20.0636 32.8264 30.8273 20.8732 30.0301 42.9616
E f 0.17314 0.05591 0.25664 0.05083 0.08718 0.11018 3.03501 0.28754 2.40041
ΔBIC 11.8850 0.7632 10.8748 0.0000 6.3957 6.1895 30.6372 13.8637 32.9195
F f 1.25703 0.15598 1.31113 0.24925 0.21315 0.12060 1.31455 0.12063 4.25438
ΔBIC 10.7624 1.0289 8.1584 2.9039 3.6644 0.0000 8.1688 0.0008 15.6392
fSUM 1.63101 0.26472 1.81587 0.40800 0.56264 0.48397 4.58619 0.61961 10.94786
Median ΔBIC 11.0902 0.3816 9.0073 3.4636 5.4146 4.7903 9.4511 3.7406 23.1745
The results for the objective function f (Eq 6) and ΔBIC (Eqs 8 and 9) are shown for each one of the hypotheses and patients. The sum of the objective functions over all
patients is shown as fSUM. In bold are highlighted: The lowest per patient values for f, as well as the scores of ΔBIC within the range of substantial empirical support (<2).
The definitions of the hypotheses are shown in S2 Table. Detailed results of the model selection criteria are shown in S3 Table. S2 Fig shows the results of the fittings for
each hypothesis, compared to the best-performing hypothesis.
https://doi.org/10.1371/journal.pcbi.1005998.t003
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Hypotheses VPμ-sLTν, VPε-sLTν, VPε-sLTε, VPμ-sLTμ and VPν-sLTμ can only be consid-
ered as possible mechanisms for individual patients but not for the entire patient cohort.
Hypothesis VPμ-sLTε cannot be discarded but does not show the highest degree of empirical
support.
The hypothesis VPε-sLTμ has the lowest median ΔBIC and thus the highest empirical sup-
port. For five out of six patients, this hypothesis was within the range of substantial empirical
support (ΔBIC<2) [33], while no other hypothesis had comparable support for more than two
patients. This hypothesis associates an anti-VP response with virus production blockage and
an anti-sLT response with accelerated killing of infected cells. The hypothesis VPε-sLTμ is
shown compared to the other alternative hypotheses in S2 Fig.
Results of the parameter estimation, confidence intervals and the objective function for
the VPε-sLTμ hypothesis are shown in Table 4. The fitted model for each patient is shown on
Fig 4.
In spite of the good results of the fitting, the estimated values of the parameters should be
taken with caution. The results show heterogeneity between patients, especiallymaxc, hillε and
θε, with a range of around 3 orders of magnitude. This could be partly caused by parameter
uncertainty, as supported by the 95% confidence intervals, which for some parameters range
over 2 orders of magnitude. However, the variation of parameters between patients is larger
than the confidence intervals for each patient, confirming that the high variation is not solely a
Table 4. Parameter for the viral load clearance model under hypothesis VPε-sLTμ.
Patients
Parameter Type A B C D E F
g Fixed value 1.00
d Fixed value 1.00 10−2
p Fixed value 15.00
β Fixed value 3 10−8
c Fixed value 15.00
k Fixed value 1.02
maxc Estimated value 5.52 105 6.91 105 3.39 105 1.91 108 3.78 106 1.17 107
95% Confidence
interval





m Estimated value 48.3 4.27 - 15.8 25.9 24.9
95% Confidence
interval
[47.3, 55.9] [4.21, 4.86] - [13.2, 18.5] [16.4, 41.6] [11.5, 86.5]













θε Estimated value 1.08 102 1.16 102 1.48 102 3.15 10−1 61.0 78.7
95% Confidence
interval




[5.93, 89.4] [3.07 10−4, 1.68 108]
hillμ Estimated value 1.30 102 1.34 102 - 98.6 1.36 102 1.13 102
95% Confidence
interval
[1.29 102, 1.30 102] [1.28 102, 1.34 102] - [47.5, 1.49 102] [38.8, 1.74 102] [19.5, 1.49 102]
θμ Estimated value 2.04 102 2.00 102 - 22.7 87.3 2.10 102
95% Confidence
interval
[2.03 102, 2.04 102] [1.99 102, 2.00 102] - [22.2, 29.2] [50.0, 1.19 102] [1.37, 3.28 102]
f Obj. Function 3.10 10−2 1.12 10−2 1.03 10−2 4.40 10−3 5.60 10−2 1.56 10−1
Results of the fitting for the viral clearance model (Eqs 3–5) under hypothesis VPε-sLTμ (S2 Table) for all six patients. The last row indicates the value of the objective
function (Eq 6).
https://doi.org/10.1371/journal.pcbi.1005998.t004
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product of parameter uncertainty. This is not surprising, as there is a very high degree of varia-
tion in the clearing time courses of the patients.
Note that the fitted parameters summarise complex biological processes, as opposed to
reflecting fundamental mechanisms, rendering it difficult to interpret parameter variations.
Nevertheless, fundamental biological variation between patients is conceivable. A clear case is
patient F. This patient had a simultaneous activation of the anti-VP and anti-sLT immune
response, and the extremely low estimate for hillε and very broad confidence intervals hillε and
θε, suggest that the anti-sLT immune response through the μmode of action could have a satu-
rating effect over the anti-VP immune response. In fact, assuming only an anti-sLT response
for patient F led to an increase of f of less than 5% in comparison to the original VPε-sLTμ,
with substantially lower BIC values (see S3 Table). This result supports the possibility of a satu-
rating anti-sLT response for this patient.
Fig 4. Modelled time course of BKV viral load clearance for hypothesis VPε-sLTμ. The results of the model (Eqs 3–5) under hypothesis VPε-sLTμ (S2 Table)
using the parameters in Table 4 are plotted: viral load (V(t)) is shown as a black line, the immune responses virus production blockage (ε(t)) and accelerated killing
of infected cells (μ(t)) are shown in green and red, respectively. Observed viral load values are shown as black plus signs. Please note the difference of time scales
between the rows.
https://doi.org/10.1371/journal.pcbi.1005998.g004
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Sensitivity analysis of the model
To analyse the impact of the chosen values for the fixed parameters g, d, p, β and k on the
behaviour of the model, a sensitivity analysis was performed. The goal was to analyse whether
the same quality of fitting and qualitative behaviour of the model can be achieved for different
values of these parameters. The analysis was performed following the principle of one-factor-
at-a-time. The value of a single parameter was modified over a span ranging from a factor 0.1
of the original value up to 10; for each new value of the parameter a fitting was performed to
minimise the value of the objective function (Eq 6). The detailed results of the sensitivity analy-
sis are shown in S4 Table, the results for the extreme values (factors 0.1. and 10) are plotted in
S3 Fig.
Briefly, the results show that the model VPε-sLTμ can robustly simulate the viral clearance
dynamics of the six patients and is not sensitive to variations of the fixed parameters: For the
extreme values (factors 0.1 and 10), fittings with fSUM < 0.4 were achieved in all cases. This is
especially relevant when comparing the results with those for the mode of action hypotheses
(Table 3), where the best alternative hypothesis had a fSUM = 0.40800. Taken together, the
results of the analysis reinforce the relevance of the hypothesis VPε-sLTμ, demonstrating that
it is able to fit the viral dynamics better than the other hypotheses, even when modifying the
fixed parameters across two orders of magnitude.
Discussion
In this work we have created the first model that provides evidence of the dominant modes of
action involved in the clearance of BKV. It is the first model that covers the process of BKV
clearance harmonising the viral and immune dynamics and formalising different modes of
action of the immune system and their influence on the viral dynamics. It incorporates the
influence of the adaptive immune system on the clearance of BKV reactivation in a patient-to-
patient basis by considering multiple antigens and immune reactions against the same viral
infection and highlighting certain patterns of the process of immunological re-arming against
BKV after immunosuppressant switch. Our results show that immune modes of action can be
captured by acquisition of time series of blood markers not directly related to mechanistic
observations. Taken together, our work can be used as a tool for personalised hypothesis gen-
eration and evaluation of the modes of action through which the immune system successfully
fights against BKVN.
Our model suggests that for VP-specific cellular immune response, the dominant mode of
action is reducing the rate of virus production, while the mode of action triggered by sLT-anti-
gen specific T cells is an increased death rate of infected cells. This remarkable feature would
be central for BKV clearance: the VP-triggered immune response would cause an initial drop
in the viral load, leading to a plateau, where reduction of the viral load is slower than 0.5
log10(virus mL-1) every 100 days. Only the acceleration of death of infected cells, triggered by
the sLT antigens, would lead to a fast and continuous clearance of the viral load. It further sug-
gests that in cases of simultaneous anti-VP and anti-sLT response, the latter response would
play the central role in viral clearing.
This hypothesis, VPε-sLTμ, achieved substantial empirical support for five out of six
patients, while none of the alternative hypotheses on dominant modes of action had substan-
tial empirical support for more than two patients. Even though one alternative hypothesis
could be used to fit the viral dynamics of the patients satisfactorily, the VPε-sLTμ hypothesis
achieved the lowest total value for the objective function.
The suggested VP-triggered blockage of virus production can be linked mechanistically to
the action of some cytokines, such as type I-interferons; while sLT-triggered accelerated
Differential T cell response and BK virus dynamics in renal transplantation
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 13 / 20
134
killing can be associated with cytotoxic cells. This qualitatively different role of both antigen
groups is in agreement with biological evidence provided by a previous flow cytometry-
based study on VP1- and LT-specific CD4+ and CD8+ T-cells in patients with BKV reactiva-
tion [34]. In this work, VP1 elicited a significantly higher response in CD4+ T-cells than in
CD8+ T-cells. In the case of the LT antigen, even though there was no significant difference
between the magnitude of the CD4+ and the CD8+ T-cell responses, CD8+ cells were signifi-
cantly more likely to respond against LT than VP1. The agreement between the hypothesis
with the highest empirical support and the cited study highlights, in our opinion, the capabil-
ities of using our model as an instrument for hypothesis generation on the physiological
background of BKV clearance.
Interestingly, our model highlights a feature of heterogeneity among patients, the delay
between anti-VP and anti-sLT immune response, as central for BKV dynamics, linking it to
the previously presented division of patients into two groups—with a first group (upper row in
Fig 4) clearing the infection after over 300 days and a second group (lower row) clearing the
infection in around 100 days after immunosuppressant switch—in terms of an increased clear-
ance speed associated with anti-sLT immune response. Our model highlights the close rela-
tionship between viral clearance and this delay, underscoring that anti-sLT specific T cells are
needed for clearance. A delay between VP and sLT responses has been observed in two previ-
ous studies [16,34]. However, in spite of having been observed repeatedly, there is to our
knowledge at present no discussion in the literature on this striking factor. Possible causes
could be related to the different ways of VP and sLT antigen presentation or to the effects of
immunosuppression. Based on the results of our model, we would welcome more profound
experimental and theoretical research on the reasons underlying the delay.
Moreover, our results suggest that heterogeneity is not confined to the delay between
immune responses but is a central feature of the BKV clearing dynamics: For certain individ-
ual patients, hypotheses other than VPε-sLTμmight be specifically suitable to explain their
viral clearance dynamics. There is also a high degree of variation in the estimated values of the
parameters between individuals for each hypothesis. A part of this variation may stem from
physiological differences. For example, in the case of patient F, for whom particularly extreme
values for some parameters were found, this can be linked to this patient being the only one
with simultaneous activation of anti-VP and anti-sLT immune responses: Analyses suggested
that the latter response could have a saturating effect, rendering the former irrelevant for the
viral dynamics.
A relevant aspect of the model is that the dynamics of the immune response and their
dependence on viral load were not explicitly modelled. The influence of the immune response
on viral load is taken into account but the hypothetical contribution of BKV viral load to the
building of an immune reaction is not addressed. This approach was chosen due to the high
complexity and heterogeneity of the dynamics of immune reaction after immunosuppressant
switch—especially the VP-sLT delay. Given that the mechanisms underlying this delay are cur-
rently unknown, we consider it to be highly unlikely that using currently available knowledge
the immune response can be predicted from viral load.
The findings of our work on immune modes of action are especially relevant for future
immunotherapeutic approaches against BKVN, since they suggest that the immune response
against regulatory sLT antigens is central for BKV clearance. The use of T cells specific for
BKV regulatory antigens is an interesting clinical approach, which has recently been shown to
be technically possible [35]. In this study, the authors established a protocol for the ex-vivo
generation of T cells specific for the antigens VP1 and LT, offering evidence of the specificity
and safety of these cells [35].
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Our BKV clearance modelling approach provides a framework for the hypothesis genera-
tion on the interrelations between cellular immunity and viral load at a personalised basis. Fur-
ther research with the model could help us to improve therapeutic approaches in patients with
BKVN, with the final aim of preventing kidney graft failure. The results of our model strongly
suggest a general association between different target antigens and distinct mechanisms of the
cellular immune system, linking structural VP antigens with the blockage of viral production
and regulatory sLT antigens with cytotoxic effects. It further highlights the essential role of
anti-sLT antigen response in clearance. These results should serve as a stimulus for further
research on the differences between anti-VP and anti-sLT responses, particularly on their
mechanisms, exploring possible physiological differences between patients in this respect. A
suggested method could involve complementing the Elispot analysis with flow cytometry anal-
ysis of different cell populations reacting to each antigen (e.g. CD4+, CD8+, T helper 17, T reg-
ulatory) at all time points of the clearance process, with a special emphasis on the differences
between the early- and late-stage responses. The knowledge gained through these experiments,
as well as further implementations of our model, could open the door to the use of immuno-
therapy in the treatment, and perhaps prevention, of BKVN. Modelling approaches built upon
our work could then be used in a personalised basis to tailor the therapy according to the char-
acteristics of their viral and immune dynamics.
Materials andmethods
Ethics statement
This study was approved by our local ethical review committee in compliance with the declara-
tion of Helsinki. Informed consent was obtained from all patients (Ethic Committee Charité
University Medicine, Berlin, Germany, 126/2001, 07/30/2001).
Monitoring of BKVN patients
Patients were monitored for serum BKV viral load from 4/2006 to 9/2012 and for BKV specific
immune response against VP and sLT from 01/2008 to 07/2010 as described in our previous
study [16]. Screening for viral load was performed monthly over the first six months after
kidney transplantation, then every three months, and again monthly during active BKV reacti-
vation, while screening for specific immune response with Elispot was performed monthly
since approximately the change of immunosuppressive therapy, until BKV clearance (<3000
copies mL-1). A total of 167 viral load samples and 98 Elispot samples were collected. BKVN
was confirmed by histological examination of the graft biopsy.
Screening of BKV viral load
BKV viral load was measured by qPCR as described previously [15]. Briefly, BKV viral load
was measured with TaqMan Real Time PCR. DNA was isolated from serum using a QIAamp
DNAMini Kit (Qiagen Corp., Hilden, Germany) according to the instructions of the manu-
facturer. PCR was performed with the TaqMan platform (ABI). PCR amplifications were set
up in a reaction volume of 25 u/μL using primer and probe at final concentrations of 900 nM
and 5 μM, respectively, amplifying the VP1 region of BKV. A plasmid standard containing the
VP1 coding region of respective virus was used to determine the copy number per millilitre.
Thermal cycling was begun with an initial denaturation step at 95˚C for 10 min that was fol-
lowed by 40 cycles at 95˚C for 15 s and 60˚C for 1 min.
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Screening of anti-BKV immune reaction
BKV-specific T cell immune response was determined by IFN-γ Elispot upon stimulation of
PBMC with 5 different BKV proteins (VP1, VP2, VP3, st and LT) as described in our previ-
ous study [16]. Briefly, PBMC were isolated from 10–20 mL of heparinised blood using the
standard Ficoll Hypaque density gradient centrifugation technique. For the Elispot assay,
96-well multiscreen filter plates (MAIPS 4510, Millipore, Billerica, MA, USA) were coated
with 100 μL of primary IFN-γmonoclonal antibody (mAb) at a concentration of 3 μg/mL
(IFNGM700A, Endogen, Woburn, MA, USA) and incubated overnight at 4˚C. A standard-
ised responder T-cell number of 2.5 × 105 PBMC per well was added in quadruple or at least
triplicate wells with one of the five stimulating peptides (1 μg/mL). Staphylococcus entero-
toxin B (SEB; Sigma, Munich, Germany, 1 μg/mL) was used as positive control and negative
controls were run in parallel using responder cells plus medium alone. Probes were incu-
bated for 24 hours at 37˚C. The detection of IFN-γ took place after an overnight incubation
at 4˚C with 100 μL (1 μL/mL) biotinylated detection IFN-γ antibody (IFNG-M701-B Biotin,
Endogen). After adding streptavidine (1 μg/mL) for 2 hours at room temperature, spots were
developed by adding 200μL visualization solution, AEC (3-amino-9-ethylcarbazole, Sigma)
in acetate buffer supplemented with H2O2 30% for 3–5 min. Resulting spots were counted
using a computer-assisted Elispot reader (Immunospot, Cellular Technologies, Ltd., Cleve-
land, OH, USA). The number of SFU 10−6 PBMC was calculated by adding spot counts from
each well.
Parameter estimation of the mathematical models
The models were fitted using the function fminsearch of the mathematical open-access soft-
ware Scilab, which employs the Nelder-Mead algorithm [36]. To ensure that the minimum
of the objective function is reached, several replications (> 100) of the estimation were per-
formed, using vastly different (> 2 orders of magnitude in some cases) starting parameter sets.
The objective functions for the immune dynamics and the viral dynamics, which take the form
of vertical least-squares, are defined in the Results section (Eqs 2 and 7).
To avoid overestimating the degrees of freedom of each hypothesis, parameters appearing
only as the product of two free parameters are considered as only one free parameter. This is
the case for model VPμ-sLTμ, wherem maxμ andm maxM are estimated as two parameters,
instead of three parameters.
Model selection
Bayesian Information Criterion (BIC) differences were employed as the model selection crite-
rion. Additionally, the Akaike’s Information Criterion (AIC) was also calculated. The cor-
rected Akaike’s Information Criterion (AICc) was not used, as its value was not calculable for
certain patient/hypotheses combinations. BIC and AIC were estimated for each patient i and
hypothesis h under the assumption of independent, normally distributed errors
BICih à Ni ln fih á Kih ln Ni
AICih à Ni ln fih á 2Kih Ö8Ü
where Ni is the total number of measurements per patient i, Kih is the number of parameters
for patient i and hypothesis h, and fih is the objective function for patient i and hypothesis h as
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defined in Eq 6. [33] AIC and BIC differences were calculated as
DBICih à BICih  minÖBICi Ü
DAICih à AICih  minÖAICi Ü Ö9Ü
where the function min denotes the lowest AIC or BIC achieved for a patient. A difference in
the range [0, 2] for ΔBICih is considered to give substantial empirical support for the hypothesis
h in patient i [33].
Estimation of 95% confidence intervals
95% confidence intervals were estimated using bootstrapping, as described in Banks et al. [37].
Briefly, for each of the six patients the dynamics were simulated with the best-performing
hypothesis (VPε-sLTμ) and the best-fitting parameter set (Table 4). Residuals for the viral
load were calculated as the difference between predicted and observed viral load for each time
point. The residuals of each patient (excluding the first residual, which is zero by definition)
were randomly resampled with replacement 1000 times, constructing 1000 artificial data sets
for each patient, each with the same number of measurements as the patient. These artificial
data sets were subject to fitting using as initial parameter values those in Table 4. The obtained
distribution of estimated parameters for each patient was employed to calculate the 95% confi-
dence intervals: for a normal distribution of parameter values for a patient, the confidence
intervals were calculated as the mean ± 1.96   standard deviation; for skewed distributions
(absolute value of skewness or kurtosis higher than 2), the 95% confidence intervals were cal-
culated directly from the 25th and 975-th entries in the set of ordered parameter estimates.
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S2 Table. Hypotheses on the dominant modes of action of the immune system as defined
by the model.Description of the possible hypotheses on the dominant modes of action of the
immune response against VP and sLT antigens, as defined by the model (Eqs 3–5).
(PDF)
S3 Table. Detailed results for the model comparison criteria of the fittings for the nine
hypotheses. The results for patient F and hypothesis VPε-sLTμ are shown additionally under
the special assumption of a saturating sLT response.
(PDF)
S4 Table. Results of the sensitivity analysis for the fixed parameters.
(PDF)
S1 Fig. Comparison of anti-VP responses fittings for patient A. Results of the fitting assum-
ing only one activation event, compared to the fitting for two activation events.
(TIF)
S2 Fig. Comparison of the fittings of the hypotheses to the best-performing hypothesis.
The hypotheses are shown in order of increasing fSUM
(PDF)
Differential T cell response and BK virus dynamics in renal transplantation
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 17 / 20
138
S3 Fig. Plotting of the sensitivity analysis results for the extreme parameter values. Note
that for k only k = 10.7 was plotted, as k = 0.107 is not biologically meaningful.
(PDF)
Author Contributions
Conceptualization: Arturo Blazquez-Navarro, Ulrik Stervbo, Edda Klipp, Avidan U. Neu-
mann, Michal Or-Guil.
Data curation: Arturo Blazquez-Navarro, Ulrik Stervbo, Avidan U. Neumann.
Formal analysis: Arturo Blazquez-Navarro.
Funding acquisition: Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Investigation: Thomas Schachtner, Anett Sefrin, Maik Stein, Timm H. Westhoff, Petra
Reinke, Nina Babel.
Methodology: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Project administration: Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Resources: Petra Reinke, Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Software: Arturo Blazquez-Navarro.
Supervision: Edda Klipp, Nina Babel, Avidan U. Neumann, Michal Or-Guil.
Validation: Arturo Blazquez-Navarro.
Visualization: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Writing – original draft: Arturo Blazquez-Navarro, Avidan U. Neumann, Michal Or-Guil.
Writing – review & editing: Thomas Schachtner, Ulrik Stervbo, Anett Sefrin, Maik Stein,
Timm H. Westhoff, Petra Reinke, Edda Klipp, Nina Babel.
References
1. Ramos E, Drachenberg CB,Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropa-
thy: state of affairs. Transplantation. 2009; 87: 621–630. https://doi.org/10.1097/TP.
0b013e318197c17d PMID: 19295303
2. Comoli P, Binggeli S, Ginevri F, Hirsch HH. Polyomavirus-associated nephropathy: update on BK virus-
specific immunity. Transpl Infect Dis. 2006; 8: 86–94. https://doi.org/10.1111/j.1399-3062.2006.00167.
x PMID: 16734631
3. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003; 3: 611–623. PMID: 14522260
4. Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis. 2005; 41: 354–360. https://doi.org/
10.1086/431488 PMID: 16007533
5. Rinaldo CH, Hirsch HH. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti
Infect Ther. 2007; 5: 105–115. https://doi.org/10.1586/14787210.5.1.105 PMID: 17266458
6. Purighalla R, Shapiro R, McCauley J, Randhawa P. BK virus infection in a kidney allograft diagnosed by
needle biopsy. Am J Kidney Dis. 1995; 26: 671–3. PMID: 7573026
7. Trofe J, Gordon J, Roy-Chaudhury P, Koralnik IJ, AtwoodWJ, Alloway RR, et al. Polyomavirus
nephropathy in kidney transplantation. Prog Transplant. 2004; 14: 130–140. PMID: 15264457
8. Nickeleit V, Singh HK, Mihatsch MJ. Polyomavirus nephropathy: morphology, pathophysiology, and
clinical management. Curr Opin Nephrol Hypertens. 2003; 12: 599–605. PMID: 14564196
9. Bennett WM, Meyer L, Ridenour J, Batiuk TD. Surveillance and modification of immunosuppression
minimizes BK virus nephropathy. Am J Nephrol. 2010; 32: 10–2. https://doi.org/10.1159/000313888
PMID: 20484894
10. Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus—immune system
interplay. Nat Rev Nephrol. 2011 May 24; 7(7): 399–406. https://doi.org/10.1038/nrneph.2011.59
Differential T cell response and BK virus dynamics in renal transplantation
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 18 / 20
139
11. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, et al. Prevalence of Polyomavirus BK and
JC Infection and Replication in 400 Healthy Blood Donors. J Infect Dis. 2009; 199: 837–846. https://doi.
org/10.1086/597126 PMID: 19434930
12. Hirsch HH, KnowlesW, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of
polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;
347.
13. Egli A, Binggeli S, Bodaghi S, Dumoulin A, Funk GA, Khanna N, et al. Cytomegalovirus and polyomavi-
rus BK posttransplant. Nephrol Dial Transplant. 2007; 22: viii72–viii82. https://doi.org/10.1093/ndt/
gfm648 PMID: 17890268
14. Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in
de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized,
multicenter study. Am J Transplant. 2013; 13: 136–145. https://doi.org/10.1111/j.1600-6143.2012.
04320.x PMID: 23137180
15. Babel N, Fendt J, Karaivanov S, Bold G, Arnold S, Sefrin A, et al. Sustained BK viruria as an early
marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum sam-
ples. Transplantation. 2009; 88: 89–95. https://doi.org/10.1097/TP.0b013e3181aa8f62 PMID:
19584686
16. Schachtner T, Müller K, Stein M, Diezemann C, Sefrin A, Babel N, et al. BK virus-specific immunity
kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant.
2011; 11: 2443–52. https://doi.org/10.1111/j.1600-6143.2011.03693.x PMID: 21831150
17. Trydzenskaya H, Sattler A, Müller K, Schachtner T, Dang-Heine C, Friedrich P, et al. Novel approach
for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immu-
nity. Transplantation. 2011; 92: 1269–77. https://doi.org/10.1097/TP.0b013e318234e0e5 PMID:
22124284
18. Mueller K, Schachtner T, Sattler A, Meier S, Friedrich P, Trydzenskaya H, et al. BK-VP3 as a New Tar-
get of Cellular Immunity in BK Virus Infection. Transplantation. 2011; 91: 100–107. https://doi.org/10.
1097/TP.0b013e3181fe1335 PMID: 21452414
19. Perelson AS. Modelling viral and immune system dynamics. Nat Rev Immunol. 2002 Jan; 2(1): 28–36.
20. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH. Polyomavirus BK replication dynamics in vivo and
in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant. 2008; 8:
2368–77. https://doi.org/10.1111/j.1600-6143.2008.02402.x PMID: 18925904
21. Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients.
J Infect Dis. 2006; 193: 80–87. https://doi.org/10.1086/498530 PMID: 16323135
22. Chakera A, Bennett S, Lawrence S, Morteau O, Mason PD, O’Callaghan CA, et al. Antigen-specific T
cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide
immunosuppression following renal transplantation. Clin Exp Immunol. 2011; 165: 401–409. https://doi.
org/10.1111/j.1365-2249.2011.04429.x PMID: 21671906
23. Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016; 11: 332–343. https://doi.
org/10.2215/CJN.08570814 PMID: 26170177
24. Renner FC, Dietrich H, Bulut N, Celik D, Freitag E, Gaertner N, et al. The risk of polyomavirus-associ-
ated graft nephropathy is increased by a combined suppression of cd8 and cd4 cell-dependent immune
effects. Transplant Proc. Elsevier Inc.; 2013; 45: 1608–1610. https://doi.org/10.1016/j.transproceed.
2013.01.026 PMID: 23726630
25. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of Polyomavirus Infec-
tion in Kidney Transplant Recipients: A Systematic Review. Transplantation. 2010; 89: 1057–1070.
https://doi.org/10.1097/TP.0b013e3181d0e15e PMID: 20090569
26. Cappuccio A, Elishmereni M, Agur Z. Cancer immunotherapy by interleukin-21: Potential treatment
strategies evaluated in a mathematical model. Cancer Res. 2006; 66: 7293–7300. https://doi.org/10.
1158/0008-5472.CAN-06-0241 PMID: 16849579
27. Perelson AS, Nelson PW. Mathematical Analysis of HIV-1 Dynamics in Vivo. SIAMRev. 1999; 41: 3–
44. https://doi.org/10.1137/S0036144598335107
28. Huang Y, Rosenkranz SL,Wu H. Modeling HIV dynamics and antiviral response with consideration of
time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci. 2003; 184: 165–186.
https://doi.org/10.1016/S0025-5564(03)00058-0 PMID: 12832146
29. Wodarz D, NowakMA. Mathematical models of HIV pathogenesis and treatment. BioEssays. 2002; 24:
1178–1187. https://doi.org/10.1002/bies.10196 PMID: 12447982
30. Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients.
J Infect Dis. 2006; 193: 80–87. https://doi.org/10.1086/498530 PMID: 16323135
Differential T cell response and BK virus dynamics in renal transplantation
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 19 / 20
140
31. Kim S-S, Gwak S-J, Han J, Park MH, Song KW, Kim B-S. Regeneration of kidney tissue using in vitro
cultured fetal kidney cells. Exp Mol Med. 2008; 40: 361–369. https://doi.org/10.3858/emm.2008.40.4.
361 PMID: 18779648
32. Neumann AU, Lam NP, Dahari H, Gretch DR,Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in
vivo and the antiviral efficacy of interferon-therapy. Science (80-). 1998; 282: 103. https://doi.org/10.
1126/science.282.5386.103
33. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theo-
retic Approach (2nd ed). Ecological Modelling. 2002. https://doi.org/10.1016/j.ecolmodel.2003.11.004
34. Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, et al. Polyomavirus BK-specific cellular immune
response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant. 2007; 7: 1131–9.
https://doi.org/10.1111/j.1600-6143.2007.01754.x PMID: 17359507
35. Lamarche C, Orio J, Georges-Tobar V, Pincez T, Goupil M, Dahmani A, et al. Clinical-scale Rapid
Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Vire-
mia for Adoptive Immunotherapy. Transplantation. 2017. https://doi.org/10.1097/TP.
0000000000001698 PMID: 28230645
36. Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965; 7: 308–313.
37. Banks HT, Baraldi R, Cross K, Flores K, McChesney C, Poag L, et al. Uncertainty quantification in
modeling HIV viral mechanics. Math Biosci Eng. 2015; 12: 937–964. https://doi.org/10.3934/mbe.2015.
12.937 PMID: 26280189
Differential T cell response and BK virus dynamics in renal transplantation
PLOSComputational Biology | https://doi.org/10.1371/journal.pcbi.1005998 May 10, 2018 20 / 20
141
10.2 Supplementary materials 
10.2.1 Figure S1 
Comparison of anti-VP responses fittings for patient A 
Results of the fitting assuming only one activation event, compared to the fitting for two activation events. 
10.2.2 Figure S2 
Comparison of the fittings of the hypotheses to the best-performing hypothesis 
The hypotheses are shown in order of increasing fSUM 
10.2.2.1 Figure S2A 
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10.2.2.2 Figure S2B 
10.2.2.3 Figure S2C 
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10.2.3 Figure S3 
Plotting of the sensitivity analysis results for the extreme parameter values. 





















































10.2.3.5 Figure S3E  
  
Note that for k only k = 10.7 was plotted, as k = 0.107 is not biologically meaningful. 
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10.2.4 Table S1 







































































































































































































tst 3.19·102 1.85·102 - 57.0 28.0 0.00 
rst 1.34·10-1 8.36·10-1 - 1.25 1.06·10-1 6.16·10-1 
maxantist 2.01·102 1.66·102 - 1.29·102 2.95·102 4.19·102 




tLT 3.27·102 1.81·102 - 44.6 1.13 0.00 
rLT 1.66·10-1 1.18·10-1 - 1.17 9.63·10-2 1.66 
maxantiLT 1.70·102 2.02·102 - 1.55·102 4.30·102 1.69·102 
decLT 1.00·10-6 1.08·10-5 - 3.82·10-3 6.53·10-3 3.46·10-3 
f Obj. Function 4.16·10-2 3.99·10-1 8.21·10-1 3.84·10-2 8.30·10-3 3.70·10-3 
Results of the fitting for the immune response model in Eq. 1 for all six patients and 
five antigens. The last row indicates the achieved value of the objective function (Eq. 2). 
aFor Patient A, the response against the VP antigens was described using a second 
activation time ta2 with a second parameter set to achieve a better fit. 
 
10.2.5 Table S2 
Hypotheses on the dominant modes of action of the immune system as defined by the model. 
 
Hypothesis Definition Description 
VPε-sLTε 
maxμ = maxM = maxυ = maxN = 0 
0 < maxε < 1 
0 < maxE < 1 
Anti-VP response and anti-sLT response both trigger 
blockage of virus production 
VPε-sLTμ 
maxE = maxμ = maxυ = maxN = 0 
 
maxε = 1 
 
maxM = 1 
Anti-VP response triggers blockage of virus 
production 
Anti-sLT response triggers accelerated killing of 
infected cells 
VPε-sLTυ 
maxE = maxμ = maxM = maxυ = 0 
 
maxε = 1 
 
maxN = 1 
Anti-VP response triggers blockage of virus 
production 
Anti-sLT response triggers blockage of cell infection 
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VPμ-sLTε 
maxε = maxM = maxυ = maxN = 0 
 
maxμ = 1 
 
maxE = 1 
Anti-VP response triggers accelerated killing of 
infected cells 
Anti-sLT response triggers blockage of virus 
production 
VPμ-sLTμ 
maxε = maxE = maxυ = maxN = 0 
0 < maxμ < 1 
0 < maxM < 1 
Anti-VP response and anti-sLT response both trigger 
accelerated killing of infected cells 
VPμ-sLTυ 
maxε = maxE = maxM = maxυ = 0 
 
maxμ = 1 
 
maxN = 1 
Anti-VP response triggers accelerated killing of 
infected cells 
Anti-sLT response triggers blockage of cell infection 
VPυ-sLTε 
maxε = maxμ = maxM = maxN = 0 
 
maxυ = 1 
 
maxE = 1 
Anti-VP response triggers blockage of cell infection 
Anti-sLT response triggers blockage of virus 
production 
VPυ-sLTμ 
maxε = maxE = maxμ = maxN = 0 
 
maxυ = 1 
 
maxM = 1 
Anti-VP response triggers blockage of cell infection 
Anti-sLT response triggers accelerated killing of 
infected cells 
VPυ-sLTυ 
maxε = maxE = maxM = maxμ = 0 
 
0 < maxυ < 1 
 
0 < maxN < 1 
 
Anti-VP and anti-sLT response both trigger blockage 
of cell infection 
Description of the possible hypotheses on the dominant mechanisms of the immune response against 
VP and sLT antigens, as defined by the model (Eqs. 3-5). 
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10.2.6 Table S3 
Detailed results for the model comparison criteria of the fittings for the nine hypotheses. 
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The results for the residual sum of squares (RSS), the objective function f (Eq. 6), BIC, ΔBIC, AIC and 
ΔAIC (Eq. 8 and 9) are shown for each one of the hypotheses and patients; as well as for a special case 
of the VPε-sLTμ for patient F, assuming a saturating anti-sLT response. The sum of the objective 
functions over all patients is shown as fSUM. In bold are highlighted: The lowest per patient values for 
f, as well as the scores of ΔBIC and ΔAIC within the range of substantial empirical support (<2). The 
definitions of the hypotheses are shown in S2 Table. 
10.2.7 Table S4 
Results of the sensitivity analysis for the fixed parameters 
The results for the sensitivity analysis of the fixed parameters (d, p, g, ß, and k) are reproduced below. 
The results for the original values of the parameters are marked in red. The sensitivity analysis was on 
a one-factor-at-a-time principle, with the values shown on the first row of each table. f is the lowest 
value of the objective function (Eq. 6) achieved for each patient and value of the parameter, fSUM 
indicates the sum of the objective functions for all six patients. 
10.2.7.1 Table S4A 
Value g  1.00·10-1 1.58·10-1 2.51·10-1 3.98·10-1 6.31·10-1 1.00 1.58 2.51 3.98 6.31 10.0 
fA 3.12·10-2 3.40·10-2 3.40·10-2 2.99·10-2 3.40·10-2 3.09·10-2 3.00·10-2 3.12·10-2 3.22·10-2 3.40·10-2 3.19·10-2 
fB 1.64·10-2 1.56·10-2 1.64·10-2 1.64·10-2 1.64·10-2 1.12·10-2 1.12·10-2 1.64·10-2 1.64·10-2 1.64·10-2 1.58·10-2 
fC 1.03·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.03·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 
fD 5.40·10-3 5.40·10-3 5.40·10-3 5.40·10-3 5.40·10-3 4.30·10-3 4.30·10-3 5.40·10-3 5.40·10-3 5.40·10-3 5.40·10-3 
fE 5.77·10-2 5.77·10-2 5.77·10-2 5.77·10-2 5.77·10-2 5.59·10-2 5.59·10-2 5.77·10-2 5.77·10-2 5.77·10-2 5.77·10-2 
fF 2.04·10-1 1.75·10-1 2.12·10-1 2.12·10-1 1.84·10-1 1.56·10-1 1.56·10-1 2.12·10-1 1.75·10-1 2.12·10-1 1.56·10-1 
fSUM 3.25·10-1 3.01·10-1 3.38·10-1 3.34·10-1 3.11·10-1 2.69·10-1 2.70·10-1 3.36·10-1 2.99·10-1 3.38·10-1 2.80·10-1 
10.2.7.2 Table S4B 
Value d 1.00·10-3 1.58·10-3 2.51·10-3 3.98·10-3 6.31·10-3 1.00·10-2 1.58·10-2 2.51·10-2 3.98·10-2 6.31·10-2 1.00·10-1 
fA 4.21·10-2 6.16·10-2 4.16·10-2 5.76·10-2 4.30·10-2 3.09·10-2 2.93·10-2 4.29·10-2 4.19·10-2 3.55·10-2 4.17·10-2 
fB 1.60·10-2 1.31·10-2 1.22·10-2 1.58·10-2 1.47·10-2 1.12·10-2 1.16·10-2 2.92·10-2 2.64·10-2 3.85·10-2 3.84·10-2 
fC 2.55·10-2 2.12·10-2 1.57·10-2 3.46·10-2 1.27·10-2 1.03·10-2 1.11·10-2 1.27·10-2 1.28·10-2 1.29·10-2 1.30·10-2 
fD 5.50·10-3 5.70·10-3 5.90·10-3 6.20·10-3 5.50·10-3 4.30·10-3 4.70·10-3 5.60·10-3 9.00·10-3 7.40·10-3 1.54·10-2 
fE 5.52·10-2 5.58·10-2 5.61·10-2 5.69·10-2 5.67·10-2 5.59·10-2 5.86·10-2 6.02·10-2 6.07·10-2 6.48·10-2 5.42·10-2 
fF 2.03·10-1 1.98·10-1 1.65·10-1 1.99·10-1 2.00·10-1 1.56·10-1 1.56·10-1 2.01·10-1 1.97·10-1 2.15·10-1 1.64·10-1 
fSUM 3.47·10-1 3.55·10-1 2.97·10-1 3.70·10-1 3.32·10-1 2.69·10-1 2.72·10-1 3.52·10-1 3.47·10-1 3.74·10-1 3.27·10-1 
10.2.7.3 Table S4C 
Value p 1.50 2.38 3.77 5.97 9.46 15.0 23.8 37.7 59.7 94.6 1.50·102 
fA 3.47·10-2 3.47·10-2 3.57·10-2 3.22·10-2 3.46·10-2 3.09·10-2 3.39·10-2 3.12·10-2 3.55·10-2 2.90·10-2 3.42·10-2 
fB 1.48·10-2 1.48·10-2 2.00·10-2 1.55·10-2 1.51·10-2 1.12·10-2 1.12·10-2 2.58·10-2 1.56·10-2 1.60·10-2 1.69·10-2 
fC 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.03·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 1.27·10-2 
fD 5.10·10-3 5.10·10-3 5.30·10-3 5.40·10-3 5.20·10-3 4.40·10-3 4.90·10-3 5.20·10-3 5.20·10-3 5.40·10-3 5.40·10-3 
fE 5.82·10-2 5.82·10-2 5.80·10-2 5.84·10-2 5.73·10-2 5.59·10-2 5.61·10-2 5.80·10-2 5.72·10-2 5.80·10-2 5.73·10-2 
fF 1.56·10-1 1.56·10-1 2.03·10-1 1.60·10-1 2.08·10-1 1.56·10-1 1.56·10-1 2.08·10-1 2.06·10-1 1.83·10-1 1.83·10-1 




10.2.7.4 Table S4D 
Value ß 3.00·10-9 4.75·10-9 7.54·10-9 1.19·10-8 1.89·10-8 3.00·10-8 4.75·10-8 7.54·10-8 1.19·10-7 1.89·10-7 3.00·10-7 
fA 3.79·10-2 3.34·10-2 3.56·10-2 3.86·10-2 3.55·10-2 3.09·10-2 4.06·10-2 5.18·10-2 4.60·10-2 6.34·10-2 7.03·10-2 
fB 2.49·10-2 1.55·10-2 1.52·10-2 1.57·10-2 1.71·10-2 1.12·10-2 1.33·10-2 1.45·10-2 1.37·10-2 1.50·10-2 1.48·10-2 
fC 1.05·10-2 1.05·10-2 1.05·10-2 1.06·10-2 1.12·10-2 1.03·10-2 1.06·10-2 1.11·10-2 1.22·10-2 1.40·10-2 1.72·10-2 
fD 5.90·10-3 6.10·10-3 5.70·10-3 6.40·10-3 5.40·10-3 4.40·10-3 4.30·10-3 4.30·10-3 4.50·10-3 4.30·10-3 3.70·10-3 
fE 5.82·10-2 5.83·10-2 5.81·10-2 5.82·10-2 5.78·10-2 5.59·10-2 5.56·10-2 5.70·10-2 5.59·10-2 5.44·10-2 5.56·10-2 
fF 1.23·10-1 1.54·10-1 1.59·10-1 1.32·10-1 1.44·10-1 1.56·10-1 1.85·10-1 1.55·10-1 1.52·10-1 1.52·10-1 2.11·10-1 
fSUM 2.60·10-1 2.78·10-1 2.85·10-1 2.62·10-1 2.71·10-1 2.69·10-1 3.09·10-1 2.94·10-1 2.85·10-1 3.03·10-1 3.73·10-1 
10.2.7.5 Table S4E 
Value k 1.02·10-1 1.62·10-1 2.56·10-1 4.06·10-1 6.44·10-1 1.02 1.62 2.56 4.06 6.44 10.2 
fA 7.25·10-2 4.20·10-2 5.11·10-2 5.86·10-2 4.28·10-2 3.09·10-2 2.93·10-2 4.03·10-2 3.42·10-2 4.62·10-2 2.91·10-2 
fB 1.73·10-2 1.65·10-2 1.65·10-2 1.69·10-2 1.44·10-2 1.12·10-2 1.16·10-2 1.36·10-2 3.87·10-2 1.73·10-2 3.06·10-2 
fC 2.49·10-2 2.07·10-2 1.58·10-2 3.39·10-2 1.27·10-2 1.03·10-2 1.12·10-2 1.27·10-2 1.08·10-2 1.07·10-2 1.07·10-2 
fD 5.30·10-3 5.30·10-3 2.80·10-3 5.60·10-3 5.60·10-3 4.30·10-3 4.80·10-3 6.00·10-3 5.30·10-3 1.51·10-2 3.00·10-2 
fE 5.53·10-2 5.58·10-2 5.58·10-2 5.63·10-2 5.68·10-2 5.59·10-2 5.89·10-2 6.01·10-2 6.21·10-2 5.99·10-2 6.28·10-2 
fF 1.56·10-1 2.02·10-1 2.05·10-1 2.01·10-1 1.56·10-1 1.56·10-1 1.56·10-1 1.99·10-1 1.64·10-1 1.72·10-1 1.58·10-1 










11. Summary of the manuscripts in the context of personalized 
medicine 
The work in this thesis was performed as part of a study on personalized medicine for renal 
transplantation, the e:KID study.* The four manuscripts I present analyse the clinical evolution 
of patients after renal transplantation, with special emphasis on complications such as viral 
reactivations and acute rejections.130,211,213,237 Different analytical methods were applied in 
these works to achieve different goals: In the first manuscript (chapter 7) descriptive statistical 
analysis was applied to detect correlations suggestive for causal relationships between clinical 
outcome and viral reactivations.130 In the second manuscript (chapter  8) we utilized a mixture 
of descriptive bivariate statistical analysis and diagnostic multivariate analysis to tentatively 
determine the influence of anti-viral prevention strategies on patient outcome in a non-
randomised design.213 In our third manuscript (chapter 9), machine learning methods were 
used for the predictive analysis of biomarkers of acute cellular rejection.130 Lastly, in the fourth 
manuscript (chapter 10) we employed ordinary differential equation modelling for a 
diagnostic analysis of the immune modes of action against BK virus.237 
Together, these four manuscripts show how different analytical methods can be employed to 
generate complementary knowledge on personalized factors associated with transplantation 
outcome and how this knowledge can be employed to improve medical interventions for the 
benefit of the patient.130,211,213,237 In this chapter, a summary of the background, methods and 
results of these four works is provided, with special emphasis on their contributions to 
personalized medicine.  
11.1 Studying the prevalence, risk factors and consequences of combined viral 
reactivations: A thorough exploratory statistical analysis 
The use of modern immunosuppressive drugs in renal transplantation has led in the last 
decades to a dramatic increase of short term graft survival, but also to the emergence of viral 
infections.19,20,239,240 Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), together with BK 
virus (BKV), are major viral pathogens, increasing morbidity and mortality of the patients.241 
Due to their high prevalence, combined infections of two of these viruses (either 
simultaneously or subsequently) are expected to be a common event.242–244 Yet, it is unclear 
whether there is an association between the reactivations, and what the effects of such 
combined infections in transplantation outcome might be.242–244 Therefore, we decided to 
analyse the Harmony cohort for the prevalence, risk factors of viral reactivations and their 
association with transplantation outcome.211 
A thorough exploratory (not hypothesis-based) analysis of the data was performed employing 
conventional bivariate statistics. These methods were chosen due to their simplicity, as they 
best suited the goals of the analysis – finding associations between variables. They allow 
moreover for a fast evaluation of a large number of comparisons, as we performed a 
systematic evaluation over a large range of thresholds for each of the viral reactivations.  
Almost fifty thousand tests were performed for this publication. An example for an analysis 
requiring a large number of simple tests is the determination of the influence of 
immunosuppressant on viral reactivations. We compared the quantitative variable 
immunosuppressant usage for patients during viral reactivation with a cohort with no 
 
* For details on the e:KID study, see section 6.1. 
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reactivation. For patients with no reactivation, the time point of immunosuppressant usage 
was randomly selected, so that the final temporal distribution is similar to that of the viral 
reactivation group. This analysis was replicated a hundred times for each threshold and drug 
combination, in order to ensure the statistical significance of the results. An additional 
example of analyses requiring a high number of tests is the investigation of the influence of 
viral load thresholds on renal function (GFR). These were performed to ensure the robustness 
of our results on GFR, and account for 81% of the tests performed in this publication. 
Note that no multiple testing correction was necessary in spite of the large number of tests 
(see sub-section 5.4.1.2). The great majority of the tests were either performed for different 
thresholds or with replications, so that their results are not independent from each other and 
a correction of the significance values would not be appropriate.81 Furthermore, as the study 
had an exploratory character, our goal was maximising the output based on the precautionary 
principle. A correction of these data would have led to a discarding of potentially relevant 
clinical effects.81,82 
A total of 540 patients were analysed for BKV, CMV and EBV reactivations after renal 
transplantation during the eight study visits. Reactivations were extremely common, in spite 
of the Harmony cohort having a low immunological risk: Almost half of the patients suffered 
BKV reactivation and around one fifth CMV and EBV. BKV and CMV were significantly 
associated with a lower GFR at the end of the study; for the first time this was observed for 
patients with combined BKV-CMV infections, already at low viral load levels. This is especially 
relevant, as CMV was significantly associated with both BKV and EBV, thereby suggesting 
possible interactions between the viruses. Moreover, long cold ischaemia times were shown 
for the first time in a large study to be associated with very high viral loads of CMV, which in 
turn are associated with reduced GFR. 
This study is the most systematic analysis so far of viral reactivations in renal transplantation, 
due to the large number of samples obtained along the first post-transplantation year and the 
large number of associations tested. Our results reveal BKV as an emerging virus, 
demonstrating it is the most relevant viral reactivation from the epidemiological point of view. 
Moreover, our results have the potential of improving BKV and CMV management, appealing 
for a more frequent monitoring of these viruses and stricter intervention – especially for 
patients with a history of subclinical reactivations for one of the two viruses. These 
developments of personalized viral monitoring may eventually contribute to reverting the 
growing trend of viral reactivations after renal transplantation. 
11.2 Improving prevention of cytomegalovirus complications: A hypothesis-based 
assessment of sex-treatment interactions on transplantation outcomes by means of 
multivariate statistics 
Antiviral agents can be employed to prevent and treat cytomegalovirus (CMV) 
reactivations.245,246 Ganciclovir and its oral prodrug valganciclovir are routinely employed in 
the clinic after renal transplantation for this goal, following two main prevention strategies: 
prophylactic strategy, which comprises the universal administration of antiviral drugs (during 
the first 3-6 months after transplantation), and the pre-emptive strategy, in which patients 
are regularly monitored for CMV and antiviral drugs are employed only after a positive test.245–
247 While current guidelines accept both strategies for patients with a high or intermediate 
risk constellation, it is unclear which therapy is superior with respect to transplantation 
outcomes.246 Importantly, in spite of increasing evidence of the relevance of sex differences 
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in anti-CMV immunity and prevention, there are still no studies analysing the interactions of 
sex with these prevention strategies in a clinical context.248–251 Because of this, we decided to 
analyse the Harmony cohort to determine which prevention strategy is associated with a 
better patient outcome regarding renal function (GFR), acute rejection and viral reactivations, 
and identify potential sex-associated differences in these outcomes.213 
Our study was designed following the schema of a non-randomized controlled trial, in which 
patients are assigned to one of the two prevention strategies. The assignment was based on 
the VIPP study, the most relevant study on the matter: Patients receiving (val)ganciclovir 
during the first two post-transplantation weeks were assigned to the prophylactic group, the 
rest were assigned to the pre-emptive group.32,33 Comparisons between the two groups were 
initially performed using standard bivariate statistical tests, both for the whole cohort and 
stratifying according to risk factors; sex-associated differences were assessed both 
independently from and in interaction with prevention strategy. These methods are sensitive 
to potential bias in the sub-cohorts, due to the non-randomized character of the study.90 In 
fact, significant demographic differences between the sub-cohorts were observed, which 
constitute potential confounders.90 Because of this, multivariate analysis techniques were 
employed to control for potential confounders. Multi-parameter regression with backward 
elimination was the method of choice, as it is a standard and recommended approach for 
controlling confounders (see sub-section 5.4.1.2).93,96 Furthermore, to avoid P value inflation 
issues, Akaike’s information criterion was chosen as the basis for variable selection. 93,96 
A total of 540 patients – 194 (35.9%) female  – were analysed, of which 308 (57.0%) followed 
a prophylactic strategy and 232 (43.0%) a pre-emptive strategy. As expected, prophylactic 
strategy was associated with lower incidence of CMV syndrome and lower CMV viral loads. 
On the other hand, prophylaxis also was associated with higher acute rejection incidence, 
higher BK virus loads and lower GFR from the third post-transplantation month on, as 
confirmed by the multivariate analysis. There was a strong sex effect in the association of 
prevention strategy with GFR: while for male patients there was no difference between 
prevention strategies, female patients receiving prophylaxis suffered a severe impairment in 
the GFR.  Furthermore, a significant female-specific association of prophylaxis with lower 
incidence of Epstein-Barr virus reactivations was observed. 
This study provides the first evidence in the literature of a strong, clinically relevant sex effect 
in the outcomes of anti-CMV prevention strategies. Furthermore, it is the first study 
suggesting that the pre-emptive strategy might be superior for both male and female patients 
with respect to transplantation outcomes. While it is unclear what the explanation for this 
effect might be, our data suggest an effect of immunological nature where subclinical CMV 
reactivations and the immune reaction against them have a protective effect on the graft, as 
suggested by previous works.252,253 In spite of the difficulties associated with the 
interpretation of non-randomized analysis, our study has a number of advantages, including 
the closeness to clinical reality and the large number of participants.32,33,254  Therefore, our 
results support a broader use of the pre-emptive strategy, especially in female patients. This 
personalization of the prevention strategy would then lead to improved patient outcomes.  
11.3 Predicting acute cellular rejection employing pre-transplant antibody profiles: 
Identification of markers for risk assessment using a machine learning tool  
Acute cellular rejection (ACR) is a severe complication caused by a T cell cytotoxic immune 
response against the transplanted kidney, which is associated with graft dysfunction and 
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loss.255,256 Early treatment of ACR generally leads to a positive outcome; therefore much effort 
is dedicated to the development of non-invasive diagnostic and risk assessment methods.35,257 
Most early risk assessment methods are donor-dependent, as they either incorporate data on 
the donor or employ samples taken during the early post-transplantation period.224,225,262,263,226–
228,230,258–261 Until now, the characterization of anti-HLA antibodies in serum through single 
antigen bead assays has been employed as a means of detecting donor specific antibodies 
(DSA), which can cause antibody-mediated rejection.224–230 However, the potential of anti-HLA 
antibody profiles for the prediction of ACR has not been fully explored yet. Because of this, we 
analysed the antibody profile of a sub-group of 52 patients of the immunological low risk and 
DSA-free Harmony cohort, to determine whether these profiles can also be employed for the 
prediction of ACR.130 
Pre-transplantation anti-HLA 1 serum antibody profiles were analysed employing the method 
Potential Support Vector Machine (PSVM), an implementation of the support vector machine 
(see section 5.4.2.1).62  Due to the low number of patients with available data, a validation 
cohort could not be defined. Therefore, to avoid a bias in the prediction, the performance of 
the classifier was estimated employing leave-one-out cross validation, so that for each patient 
the predictor was optimized employing the rest of the cohort. Furthermore, a P value of the 
prediction was estimated employing a permutation test. 
Our antibody-based ACR risk assessment tool predicts this condition with a balanced accuracy 
of 82.7% (sensitivity=76.5%, specificity=88.9%), one of the best performances in the literature 
of pre-transplant ACR risk assessment.227,258,263–265 Therefore, our results demonstrate that 
antibody profiles can be employed for the prediction of ACR. Interestingly, this prediction was 
not achieved with the conventional pre-processing of antibody profiles used in the clinic, 
which transforms the quantitative profiles into categorical (presence/absence) data. This 
highlights the potential hidden in the raw single antigen bead data, which is lost with the 
conventional pre-processing method.  
As usual in association studies, the mechanism linking antibody profiles with ACR is not known. 
The prediction of our tool is based on a large number of features, thereby making its 
interpretation difficult.5,133,135 We hypothesize that the prediction is based on an 
immunosignature effect, as immunosignatures have already been shown to be useful in 
disease diagnosis.266–269 Further studies with a larger cohort are necessary to externally 
validate the predictor, as well as further investigate the mechanism of prediction. 
As profiling of anti-HLA antibodies is a standard clinical procedure for the detection of anti-
donor antigens, our tool can contribute to an improved risk assessment after 
transplantation.256,270 It allows for high-accuracy pre-transplantation prediction of ACR in a 
low-risk no-DSA cohort. Therefore, once validated, this tool could be employed in the clinic 
without additional cost, allowing for an improved and personalized prevention of ACR and 
thereby better long-term survival expectative. 
11.4 Inferring mechanisms of T cell response against BK virus: A mathematical model of 
viral dynamics  
Reactivations of BK virus (BKV) are a common adverse event after renal transplantation.271 
BKV is the cause of BK virus-associated nephropathy (BKVN), a major complication affecting 
1-10% of kidney transplantation recipients.271,272 It leads to graft failure in over half of the 
cases and currently there are no specific treatments against it.18,272 BKVN is treated by 
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reducing or changing the immunosuppression, fostering an antiviral immune response; 
simultaneously, progression of the disease can be monitored through screening of plasma BKV 
load.240,273,274 Cellular immune response has been shown to have a prognostic value for BKVN 
outcome.275 Five BKV proteins can elicit such a response: the structural antigens VP1, VP2 and 
VP3 and the regulatory antigens st and LT.276 However, immune response does not equal 
immune response: There is evidence that responses against these two classes of antigens 
might play different roles in BKV immunity, as only immune responses against regulatory 
antigens seem to be associated with BKV clearance.275  Because of this, we decided to analyse 
data of six patients with BKVN that had been closely monitored after immunosuppression 
reduction, to better understand which modes of action of the cellular immune system play a 
dominant role in BKV clearance and what the implications of differing modes of action are.237 
With this goal, we created an ordinary differential equation model of the BK virus life cycle 
and of the cellular immune response against it, based on a basic model of viral dynamics (see 
5.4.3.2).188 This method has been employed in the past to achieve insights in several viral 
infections, including BKV.70,164,165 The model allows for three different modes of action of the 
immune system: (i) blocking of BKV production by infected cells, (ii) killing of infected cells and 
(iii) blocking of new infection of cells. As the mathematical model describes three modes of 
action and there are two antigen classes, nine hypotheses on the dominant modes of action 
of each antigen type could be evaluated.  
The aforementioned hypotheses were evaluated individually for the six BKVN patients.275 Viral 
load and immune cellular response against BKV were monitored frequently during BKVN.275  
This frequent monitoring as well as the high degree of heterogeneity in their viral and immune 
dynamics made this small cohort ideal for the hypothesis testing using our model. The 
hypotheses were tested by individually fitting the model to the data of each patient and 
selecting the models with the higher empirical support, as assessed by the Bayesian 
information criterion (see sub-section 5.4.3.3). 
The results allowed for the rejection of the majority of hypotheses. The hypothesis linking 
immune response against structural antigens with the (i) mode of action and regulatory 
antigens with the (ii) mode of action achieved the highest degree of empirical support, in spite 
of the high degree of heterogeneity in the time courses. This is in agreement with biological 
evidence provided by flow cytometry analysis of immune cells specific for each antigen type, 
therefore supporting the validity of our approach.277 Following this hypothesis, regulatory 
antigens, as drivers of a cytotoxic response, would lead to a fast and continuous clearing of 
viral load.  
Interestingly, some hypotheses could also potentially explain the viral-immune dynamics of 
certain individual patients, opening the possibility that different modes of action are dominant 
for different patients. The results therefore highlight the individualised character of the 
immune response against BKV and the capacity of our model to detect different modes of 
action of the immune system. Our approach can therefore be employed for the determination 
of which modes of action are dominant for each BKVN patient, in order to accordingly tailor 
the immunotherapy for the patient.  As the generation of T cells specific against VP1 
(structural) and LT (regulatory) has been shown to be possible, a personalized adoptive 





12. Outlook: Personalized medicine and big data 
The four manuscripts included in this doctoral thesis offer a broad perspective on the 
methodological possibilities for addressing research questions and obtaining new results out 
of a large database with clinical and biological data. Bi- and multivariate statistical methods 
for the assessment of the consequences of viral infections and therapeutic strategies on the 
patient outcome; machine learning has been used to identify prediction models for 
complications from the very first day and modelling approaches have been employed for the 
analysis of mechanisms of the immune system. Taken together, these four studies have the 
potential of contributing to an improvement in patient care, influencing the establishment of 
new therapeutic approaches and better defining the individual risk profiles of each patient for 
a personalized health care, based on immunological, virological and demographic criteria.  
However, these four manuscripts have only scratched the surface of the data generated within 
the e:KID consortium. At the moment, at least three research sub-projects are ongoing: We 
have developed a biomarker-based prediction of 1-year renal transplant function (GFR), 
employing markers (e.g. metabolomics, expression and cytokine data) measured at the 
second week and the third month post-transplantation (publication pending); we are 
analysing the correlation networks of a cytokine central for GFR prediction to better 
understand its mechanistic role in the achievement of a high renal function; finally we are 
searching for biomarkers of viral reactivations during the first year post-transplantation. We 
expect these projects to improve individualized risk assessment for renal transplantation 
patients, as well as to contribute to a systemic understanding of the processes involved in a 
positive clinical outcome, which could in turn lead to new therapeutic approaches. Moreover, 
new data from newly performed measurements on the collected samples are still flowing into 
the database, and we expect to receive in short the first follow-up data on the patient cohort, 
so that the factors leading to a long-term positive outcome can also be investigated. Finally, a 
validation study has recently started and is currently recruiting patients, in order to obtain an 
independent validation of the biomarker signatures established in the first phase of the e:KID 
project. 
All results of the e:KID consortium, both present and future, are only possible by addressing 
data management, analysis, and interpretation – i.e. the real problem in systems medicine is 
not obtaining the data, but knowing what to do with them. As shown in the chapter reporting 
on data management experience at e:KID, data management cannot be easily automatized, 
as its success relies highly on the biological and clinical knowledge of the data scientist. Not 
every method is adequate for each data analysis, but it has to be tailored for the research 
goals and the characteristics of the employed data. This is critical when attempting to upscale 
the methods for the research on personalized systems medicine based on big data 
approaches, as the number of data-related problems will increase in orders of magnitude. 
Nevertheless, we have also shown the high hidden potential of our dataset to answer a wide 
range of research questions, even with just a few hundreds of patients. I thus expect that big 
data approaches can achieve much more: With large, dedicated, expert teams of data 
scientists, we will be able to truly obtain high-throughput results in personalized medicine, 
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